



TURKISH JOURNAL OF OBSTETRICS AND GYNECOLOGY

December 2017 Volume: 14 Issue: 4 www.tjoddergisi.org

Clinical Investigations

- ▶ **Activity of corifollitropin alpha in diminished ovarian reserve**
Corifollitropin alfanın azalmış yumurta rezervi hastalarında etkinliği
Süleyman Akarsu, Sibel Demir, Funda Gode, Ahmet Zeki Işık; İzmir, Turkey
- ▶ **Role of positron emission tomography-computed tomography in endometrial cancer**
Endometriyal kanserde pozitron emisyon tomografisi-bilgisayarlı tomografinin rolü
Evrım Erdemoğlu, Sevim Süreyya Çerçi, Ebru Erdemoğlu, Yakup Yalçın, Burak Tatar; Isparta, Turkey
- ▶ **Urodynamic parameters and overactive bladder**
Ürodinamik parametreler ve aşırı aktif mesane
Hediye Dağdeviren, Hüseyin Cengiz, Çağlar Helvacıoğlu, Ulkar Heydarova, Cihan Kaya, Murat Ekin; İstanbul, Turkey
- ▶ **Depression and anxiety disorder in hyperemesis gravidarum**
Hiperemesis gravidarumlu kadınlarda depresyon ve anksiyete bozukluğu
Yusuf Topalrahmetoğlu, Mehmet Metin Altay, Derya Akdağ Cirik, Yusuf Aytac Tohma, Eser Çolak, Bora Çoşkun, Orhan Gelişen; Ankara, Turkey
- ▶ **Leptin enhances interleukin-8**
Leptin interlökin-8'i artırır
Sefa Arlıer; Tampa, USA, Adana, Turkey
- ▶ **Sevoflurane and oxidative stress**
Sevofluran ve oksidatif stres
Hatice Yılmaz Doğru, İsmail Benli, Serkan Doğru; Tokat, Turkey
- ▶ **Donor candidates for uterus transplantation**
Uterus transplantasyonu için donör adayları
Murat Api, Ayşen Boza, Mehmet Ceyhan; İstanbul, Turkey
- ▶ **Laparoscopic presacral neurectomy**
Dismenorede laparoskopik presakral nörektomi
Murat Api, Ayşen Boza, Mehmet Ceyhan, Ecmel Kaygusuz, Hülya Yavuz, Olus Api; İstanbul, Turkey
- ▶ **Endometrium cancer and sleep disorder**
Endometrium kanseri ve uyku bozukluğu
Tolgay Tuyan İlhan, Mustafa Gazi Uçar, Ayhan Gül, Türkan Saymaz İlhan, Güler Yavaş, Çetin Çelik; Mersin, Konya, Turkey





TURKISH JOURNAL OF OBSTETRICS AND GYNECOLOGY

■ Owner on the behalf of Turkish Society of Obstetrics and Gynecology

Ateş Karateke

■ Editorial Manager

Eray Çalışkan

■ Past/Honorary Editor in Chief

Hulusi Bülent Zeyneloğlu

■ Editor in Chief

Eray Çalışkan

Bahçeşehir University Faculty of Medicine, Department of Obstetrics and Gynecology, İstanbul, Turkey

ORCID ID: orcid.org/0000-0002-6799-5909

■ Editors

Barış Ata

Koç University Faculty of Medicine, Department of Obstetrics and Gynecology, İstanbul, Turkey

ORCID ID: orcid.org/0000-0003-1106-3747

Evrin Erdemoğlu

Süleyman Demirel Faculty of Medicine, Department of Gynecologic Oncology, Isparta, Turkey

ORCID ID: orcid.org/0000-0002-5993-6968

Münire Erman Akar

Akdeniz University Faculty of Medicine, Department of Obstetrics and Gynecology, Antalya, Turkey

ORCID ID: orcid.org/0000-0002-3656-3787

Bülent Haydardedeoğlu

Başkent University Faculty of Medicine, Department of Obstetrics and Gynecology, Adana, Turkey

ORCID ID: orcid.org/0000-0001-9873-7454

Fatma Ferda Verit

İstanbul Süleymaniye Maternity Training and Research Hospital, Clinic of Obstetrics and Gynecology, İstanbul, Turkey

ORCID ID: orcid.org/0000-0002-7104-4532

Recep Yıldızhan

Yüzüncü Yıl University Faculty of Medicine, Department of Obstetrics and Gynecology and Perinatology, Van, Turkey

ORCID ID: orcid.org/0000-0002-2841-0453

■ Section Editors

Gürkan Bozdağ

Hacettepe University Faculty of Medicine, Department of Obstetrics and Gynecology, Ankara, Turkey

Cem Çelik

Bahçeci Umut IVF Center, İstanbul, Turkey

Emek Doğer

Kocaeli University Faculty of Medicine, Department of Obstetrics and Gynecology, Kocaeli, Turkey

Melih Atahan Güven

Acıbadem Hospital, Clinic of Obstetrics and Gynecology, İstanbul, Turkey

Hatice Banu Kumbak Aygün

Acıbadem University Faculty of Medicine, Department of Obstetrics and Gynecology, İstanbul, Turkey

Özlem Özdeğirmenci

Zekai Tahir Burak Women's Health Training and Research Hospital, Clinic of Obstetrics and Gynecology, Ankara, Turkey

Kemal Özerkan

Uludağ University Faculty of Medicine, Department of Obstetrics and Gynecology, Bursa, Turkey

■ English Language Editor

David Chapman, Winchester, England

■ Statistics Editors

Murat Api

Zeynep Kamil Training and Research Hospital, Clinic of Obstetrics and Gynecology, İstanbul, Turkey

Ayşen Telce Boza

Vehbi Koç Foundation American Hospital, Clinic of Obstetrics and Gynecology, İstanbul, Turkey

■ Managing Editors

Rahime Nida Bayık

Bahçeşehir University Faculty of Medicine, Department of Obstetrics and Gynecology, İstanbul, Turkey

Yiğit Çakıroğlu

Kocaeli University Faculty of Medicine, Department of Obstetrics and Gynecology, Kocaeli, Turkey

Kemal Güngördük

Muğla Sıtkı Koçman University Training and Research Hospital, Clinic of Gynecologic Oncology, Muğla, Turkey



TURKISH JOURNAL OF OBSTETRICS AND GYNECOLOGY

Editorial Board

Remzi Abalı

Namık Kemal University Faculty of Medicine, Department of Obstetrics and Gynecology, Tekirdağ, Turkey

Aris Antsaklis

University of Athens, Department of Obstetrics and Gynecology, Athens, Greece

Aydın Arıcı

Yale University, Obstetrics, Gynecology and Reproductive Sciences, Connecticut, USA

Tayfun Bağış

Acıbadem University Faculty of Medicine, Department of Obstetrics and Gynecology, İstanbul, Turkey

Başak Baksu

Şişli Etfal Training and Research Hospital, Clinic of Obstetrics and Gynecology, İstanbul, Turkey

Eralp Başer

Zekai Tahir Burak Women's Health Training and Research Hospital, Clinic of Gynecologic Oncology, Ankara, Turkey

Ercan Baştu

İstanbul University Faculty of Medicine, Department of Obstetrics and Gynecology, İstanbul, Turkey

Orhan Bükülmez

University of Texas Southwestern Medical Center, Reproductive Endocrinology and Infertility, Dallas, USA

Sabri Cavkaytar

Zekai Tahir Burak Women's Health Training and Research Hospital, Clinic of Gynecologic Oncology, Ankara, Turkey

Aylin Pelin Çil

Gazi Public Hospital, Clinic of Obstetrics and Gynecology, Ankara, Turkey

Cem Dane

Haseki Training and Research Hospital, Clinic of Gynecologic Oncology, İstanbul, Turkey

Berna Dilbaz

Etilik Zübeyde Hanım Women's Health Training and Research Hospital, Clinic of Infertility and Family Planning, Ankara, Turkey

Polat Dursun

Başkent University Faculty of Medicine, Department of Obstetrics and Gynecology, Ankara, Turkey

Mehmet Sıddık Evsen

Dicle University Faculty of Medicine, Department of Obstetrics and Gynecology, Diyarbakır, Turkey

Kazım Gezginç

Necmettin Erbakan University Meram Faculty of Medicine, Department of Obstetrics and Gynecology, Konya, Turkey

Çağrı Gülümser

Başkent University Faculty of Medicine, Department of Obstetrics and Gynecology, Ankara, Turkey

Haldun Güner

Gazi University Faculty of Medicine, Department of Obstetrics and Gynecology, Ankara, Turkey

Issam Lebbi

Obstetrics and Gynecology and Fertility Private Clinic; Dream Center, Belvedere, Tunisia

Giampaolo Mandruzzato

Istituto per l'Infanzia, Burlo Garofolo, Obstetrics and Gynecology, Trieste, Italy

Charles E. Miller

Edward-Elmhurst Health Hospital, Gynecology; Reproductive Endocrinology and Infertility, The Advanced IVF and Gynecologic Surgery Institute, Naperville, USA

Ceana H. Nezhat

Northside Hospital Director of Training and Education, Nezhat Medical Center, Endometriosis, Minimally Invasive Surgery, Atlanta, USA

Batuhan Özmen

Ankara University Faculty of Medicine, Cebece Training and Research Hospital, Clinic of Obstetrics and Gynecology, Ankara, Turkey

Abdullah Karaer

İnönü University Faculty of Medicine, Department of Obstetrics and Gynecology, Malatya, Turkey

Emre Karaşahin

Gülhane Training and Research Hospital, Clinic of Obstetrics and Gynecology, Ankara, Turkey

Taner Kasapoğlu

Etilik Zübeyde Hanım Women's Health Training and Research Hospital, Clinic of Perinatology, Ankara, Turkey

Esra Buldan Kılıçdağ

Başkent University Faculty of Medicine, Department of Obstetrics and Gynecology, Ankara, Turkey

Ali Kulusarı

Yüzüncü Yıl University Faculty of Medicine, Department of Obstetrics and Gynecology and Perinatology, Van, Turkey

Zehra Kurdoğlu

Yüzüncü Yıl University Faculty of Medicine, Department of Obstetrics and Gynecology and Perinatology, Van, Turkey

Mehmet Anıl Onan

Gazi University Faculty of Medicine, Department of Obstetrics and Gynecology, Ankara, Turkey

Halil Gürsoy Pala

University of Health Sciences, Tepecik Training and Research Hospital, Clinic of Obstetrics and Gynecology, Perinatology, İzmir, Turkey

Federico Prefumo

Local Health District of Garda, Obstetrics, Brescia, Italy

Walid Saghir

Clemenceau Medical Center and Trad Hospital, Clinic of Obstetrics and Gynecology, Lebanon, UAE



TURKISH JOURNAL OF OBSTETRICS AND GYNECOLOGY

Emre Seli

Yale University, Obstetrics, Gynecology and Reproductive Sciences,
Connecticut, USA

Silber Sherman

Infertility Center of St. Louis at St. Luke's Hospital; Public Health Service,
Alaska, USA

Akın Sivaslıođlu

Ankara Atatürk Training and Research Hospital, Clinic of Obstetrics and
Gynecology, Ankara, Turkey

Fatih Şendađ

Acıbadem University Faculty of Medicine, Department of Obstetrics and
Gynecology, İstanbul, Turkey

Alper Tanrıverdi

Adnan Menderes University Faculty of Medicine, Department of Obstetrics
and Gynecology, Aydın, Turkey

Ömer Lütfi Tapısız

Etlık Zübeyde Hanım Women's Health Training and Research Hospital,
Clinic of Obstetrics and Gynecology, Ankara, Turkey

Ebru Tarım

Başkent University Adana Application and Research Center,
Department of Obstetrics and Gynecology, Adana, Turkey

Abdülkadir Turgut

İstanbul Medeniyet University Faculty of Medicine,
Department of Obstetrics and Gynecology, İstanbul, Turkey

İlgın Türkçüođlu

İnönü University Faculty of Medicine, Department of Obstetrics and
Gynecology, Malatya, Turkey

Mete Gürol Uđur

Gaziantep University Faculty of Medicine, Department of Obstetrics and
Gynecology, Gaziantep, Turkey

Serdar Ural

Penn State Hershey Womens Health Obstetrics and Gynecology,
Maternal-Fetal Medicine, Pennsylvania, USA

Yaprak Üstün

Zekai Tahir Burak Women's Health Training and Research Hospital,
Clinic of Obstetrics and Gynecology, Ankara, Turkey

Yusuf Üstün

Medicana International Ankara Hospital, Clinic of Obstetrics and
Gynecology, Ankara, Turkey

Gazi Yıldırım

Yeditepe University Faculty of Medicine, Department of Obstetrics and
Gynecology, İstanbul, Turkey

Contact

Çetin Emeç Bulvarı Hürriyet Caddesi Harbiye Mahallesi 1/13 Öveçler, Ankara, Turkey
Phone: +90 312 481 06 06 Fax: +90 312 481 28 28 E-mail: editor@tjod.org

All rights are reserved. Rights to the use and reproduction, including in the electronic media, of all communications, papers, photographs and illustrations appearing in this journal belong to the Turkish Journal of Obstetrics and Gynecology. Reproduction without prior written permission of part or all of any material is forbidden. The journal complies with the Professional Principles of the Press.

⊗ The paper used to print this journal conforms to ISO 9706: 1994 standard (Requirements for Permanence). The National Library of Medicine suggests that biomedical publications be printed on acid-free paper (alkaline paper). Reviewing the articles' conformity to the publishing standards of the Journal, typesetting, reviewing and editing the manuscripts and abstracts in English and publishing process are realized by Galenos.



**Galenos Publishing House Owner
and Publisher**
Erkan Mor

Publication Director
Nesrin Çolak

Web Coordinators
Soner Yıldırım
Turgay Akpınar

Web Assistant
Büşra Başak Yılmaz

Graphics Department
Ayda Alaca
Çiğdem Birinci

Project Coordinators
Eda Kolküsa
Hatice Balta
Lütfiye Ayhan İrtem
Melis Kuru
Zeynep Altındađ

Project Assistants
Esra Semerci
Günay Selimođlu
Sedanur Sert

Finance Coordinator
Sevinç Çakmak

Research&Development
Deniz Sleptsov

Publisher Contact

Address: Molla Gürani Mah. Kaçamak Sk. No: 21/1
34093 İstanbul, Turkey
Phone: +90 (212) 621 99 25 Fax: +90 (212) 621 99 27
E-mail: info@galenos.com.tr/yayin@galenos.com.tr
Web: www.galenos.com.tr

Printing at: Creative Basım Ltd. Şti.
Litros Yolu 2. Matbaacılar Sitesi ZD1 Topkapı, İstanbul, Turkey
Phone: +90 (212) 709 75 25

Printing Date: December 2017
ISSN: 2149-9322 E-ISSN: 2149-9330

International scientific journal published quarterly.



TURKISH JOURNAL OF OBSTETRICS AND GYNECOLOGY

AIMS AND SCOPE

Turkish Journal of Obstetrics and Gynecology (formerly called Türk Jinekoloji ve Obstetrik Derneği Dergisi) is the official peer-reviewed publication of the Turkish Society of Obstetrics and Gynecology and is published quarterly on March, June, September and December.

It is an independent peer-reviewed international journal printed in English language since 2014 September. Manuscripts are reviewed in accordance with "double-blind peer review" process for both referees and authors.

The target audience of Turkish Journal of Obstetrics and Gynecology includes gynecologists, obstetricians, urogynecologists, reproductive medicine specialists, gynecological oncologists and primary care physicians interested in gynecology practice. It publishes original work on all aspects of obstetrics and gynecology. The aim of Turkish Journal of Obstetrics and Gynecology is to publish high quality original research articles. In addition to research articles, reviews, editorials, letters to the editor and case presentations are also published.

The General Guidelines for manuscript preparation specified below are based on "Recommendations for the Conduct, Reporting, Editing, & Publication of Scholarly Work in Medical Journals (ICMJE Recommendations)" by the International Committee of Medical Journal Editors (2016, archived at <http://www.icmje.org/>).

- Turkish Journal of Obstetrics and Gynecology is indexed in PubMed Central (PMC), Web of Science-Emerging Sources Citation Index (ESCI), EBSCO, DOAJ, Index Copernicus, Scopus, CINAHL, Google Scholar, Tübitak/Ulakbim Turkish Medical Database, Turk Medline and Türkiye Citation Index.

Open Access Policy

This journal provides immediate open access to its content on the principle that making research freely available to the public supporting a greater global exchange of knowledge.

Open Access Policy is based on rules of Budapest Open Access Initiative (BOAI) <http://www.budapestopenaccessinitiative.org/>. By "open access" to [peer-reviewed research literature], we mean its free availability on the public internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from gaining access to the internet itself. The only constraint on reproduction and distribution and the only role for copyright in this domain, is given to authors to retain control over the integrity of their work and the right to be properly acknowledged and cited.

This journal is licensed under a Creative Commons 3.0 International License.

Permission

Permission required for use any published under CC-BY-NC license with commercial purposes (selling, etc.) to protect copyright owner and author rights. Republication and reproduction of images

or tables in any published material should be done with proper citation of source providing author names; title of the article; journal's name, year (volume) and page numbers of publication; copyright year of the article.

Financial expenses of the journal are covered by Turkish Society of Obstetrics and Gynecology.

Subscription Information

Turkish Journal of Obstetrics and Gynecology is distributed free of charge to all physicians, specialists in obstetrics and gynecology field. The access to tables of contents, abstracts and full texts of all articles published since 2004 are free to all readers via the journal's webpage "<http://www.tjoddergisi.org>". Visit the journal's home pages for details of the aims and scope and instruction to authors. Manuscripts can only be submitted electronically through the Journal Agent website (<http://journalagent.com/tjo/>) after creating an account. This system allows online submission and review.

Instructions for Authors

Instructions for authors page of the journal is available in the journal content and at www.tjoddergisi.org

Disclaimer

The statements and opinions expressed contained in the articles of the Turkish Journal of Obstetrics and Gynecology are solely those of the individual authors and contributors not of the Turkish Society of Obstetrics and Gynecology or Galenos Yayınevi.

Advertising

Enquiries concerning advertisements should be addressed to Editorial Office or Publisher:

Editorial Office

Editor-in-Chief: Eray Çalıřkan, M.D.

Address : Çetin Emeç Bulvarı Hürriyet Caddesi Harbiye Mahallesi 1/13 Öveçler, Ankara - Turkey

Phone : +90 (312) 481 06 06

Fax : +90 (312) 481 28 28

E-mail : info@tjod.org

Publisher

Galenos Yayınevi Tic. Ltd. Şti.

Address : Molla Gürani Mah. Kaçamak Sk. No: 21/1 34093 Fındıkzade, İstanbul - Turkey

Phone : +90 212 621 99 25

Fax : +90 212 621 99 27

E-mail : info@galenos.com.tr

The journal is printed on acid-free paper.



TURKISH JOURNAL OF OBSTETRICS AND GYNECOLOGY

INSTRUCTIONS FOR AUTHORS

The "Turkish Journal of Obstetrics and Gynecology" is the official publication of the Turkish Society of Obstetricians and Gynecologists. The journal is published quarterly (March, June, September and December) in English and publishes original peer-reviewed articles, reviews, case reports and commentaries in the fields of gynecology, gynecologic oncology, endocrinology and reproductive medicine and obstetrics. The journal gives publication priority to original research articles over case reports. Reviews are considered for publication only if they are prepared by authors who have at least three published manuscripts in international peer-reviewed journals on the topic of the review and these studies should be cited in the review. Otherwise only invited reviews will be considered for peer-review from qualified experts in the area.

The "Turkish Journal of Obstetrics and Gynecology" is a peer-reviewed journal and adheres to the highest ethical and editorial standards. The editors also adhere to the Committee on Publications Ethics (COPE) recommendations (<http://publicationethics.org>).

The journal should be abbreviated as Turk J Obstet Gynecol when referenced.

Turkish Journal of Obstetrics and Gynecology does not charge any article submission or processing charges.

Turkish Journal of Obstetrics and Gynecology is indexed in PubMed Central (PMC), Web of Science-Emerging Sources Citation Index (ESCI), EBSCO, DOAJ, Index Copernicus, Scopus, CINAHL, Google Scholar, Tübitak/Ulakbim Turkish Medical Database, Turk Medline and Turkiye Citation Index.

Submission of Manuscripts

Turkish Journal of Obstetrics and Gynecology has specific instructions and guidelines for submitting articles. Those instructions and guidelines are readily available on the submission service site. Submit all manuscripts through the journal's web page at www.tjoddergisi.org. New users should first create an account. Once a user is logged onto the site, submissions should be made via the Author Centre. Download the Instructions to Authors for detailed notes on how to prepare your manuscript.

The ORCID (Open Researcher and Contributor ID) number of the correspondence author should be provided while sending the manuscript. A free registration can be done at <http://orcid.org>.

Manuscripts submitted via any other medium will not be evaluated. During the submission please make sure to provide all requested information to prevent any possible delays in the evaluation process. Only those submitted articles are not currently being considered by another journal, or have not been previously published, will be considered for publication in Turkish Journal of Obstetrics and Gynecology. The submitted articles are firstly evaluated over by the non-biased editors. The articles that meet the originality and other requirements of the journal are peer-reviewed by the national or international referees. Acceptance for publication is based on significance, novelty, and quality of the article.

Authors who have any queries regarding the submission process can contact the journal's editorial office:

Çetin Emeç Bulvarı Harbiye Mahallesi Hürriyet Caddesi 1/3 Öveçler/Ankara.

Phone number: +90 (312) 481 06 06

E-mail: editor@tjod.org

Editorial Policies

All manuscripts will be evaluated for their scientific contribution, originality and content by the editorial board. Only those submitted articles are not currently being considered by another journal, or have not been previously published, will be considered for publication in Turkish Journal of Obstetrics and Gynecology. Authors are responsible for the accuracy of the data presented in their manuscript. The journal retains the right to make appropriate changes on the grammar and language of the manuscript when needed. When suitable the manuscript will be sent to the corresponding author for revision. The manuscript, if accepted for publication, will become the property of the journal and copyright will be taken out in the name of the journal.

All manuscripts submitted to the journal for publication are checked by Crossref Smilarity Check powered by iThenticate software for plagiarism. If plagiarism is detected, relevant institutions may be notified. In this case, the authors might be asked to disclose their raw data to relevant institutions.

Peer-review

Turkish Journal of Obstetrics and Gynecology is an independent international journal based on double-blind peer-review principles. The manuscript is assigned to the Editor-in-Chief, who reviews the manuscript and makes an initial decision based on manuscript quality and editorial priorities. These manuscripts then sent for external peer-review, the Editor in Chief assigns Associate Editor. The Associate Editor sends the manuscript to the 3 internal and external reviewers. The reviewers must review the manuscript in 21 days. Associate Editor recommends decision based on the reviewers' recommendations and sends the manuscript to the Editor-in-Chief. The Editor-in-Chief makes a final decision based on editorial priorities, manuscript quality and reviewer recommendations. If there are any conflicting recommendation of reviewers, Editor-in-Chief can assign a new reviewer. The scientific board guiding the selection of the papers to be published in the journal consists of elected experts of the journal and if necessary, selected from national and international experts in the relevant field of research. All manuscripts are reviewed by the editor, section associate editors and at least three internal and external expert referees. All research articles undergo review by statistics editor as well.

Full text of all articles can be downloaded at the web site of the journal: www.tjoddergisi.org

Authorship

The role of authorship in Turkish Journal of Obstetrics and Gynecology is reserved for those individuals who meet the criteria recommended by the International Committee of Medical Journal Editors (ICMJE; <http://www.icmje.org>). Describe each authors' contribution by using ICMJE's criteria: substantial contributions to the conception or design; the acquisition, analysis, or interpretation of data; drafting the work or revising it critically for important intellectual content; final approval of the version to be published; agreement to be accountable for all aspects of the study in ensuring that questions related to the accuracy or integrity of any part of the work are



TURKISH JOURNAL OF OBSTETRICS AND GYNECOLOGY

INSTRUCTIONS FOR AUTHORS

appropriately investigated and resolved. The statement about the authors' contributions should be placed in the cover letter. All persons who contributed to the work, but not sufficiently to be authors, must be acknowledged.

Cover Letter

Cover letter to the editors addressing the following points:

- The authors' intent to submit solely to Turkish Journal of Obstetrics and Gynecology.
- Verification that the manuscript is not under consideration elsewhere, and indication from the authors that it will not be submitted elsewhere until a final decision is made by the editors of Turkish Journal of Obstetrics and Gynecology.
- The declaration of transparency from the corresponding author.
- Clinical trial registration, if applicable.
- Institutional review board (IRB) approval or exemption.
- Informed consent.
- Any explanations related to reporting guidelines.
- The statement about the authors' contributions.

Preparation of Manuscripts

The "Turkish Journal of Obstetrics and Gynecology" follows the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals" (International Committee of Medical Journal Editors - <http://www.icmje.org/>). Upon submission of the manuscript, authors are to indicate the type of trial/research and provide the checklist of the following guidelines when appropriate:

CONSORT statement for randomized controlled trials (Moher D, Schulz KF, Altman D, for the CONSORT Group. The CONSORT statement revised recommendations for improving the quality of reports of parallel group randomized trials. *JAMA* 2001; 285: 1987-91) (<http://www.consort-statement.org/>),

PRISMA for preferred reporting items for systematic reviews and meta-analyses (Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLoS Med* 2009; 6(7): e1000097.) (<http://www.prisma-statement.org/>),

STARD checklist for the reporting of studies of diagnostic accuracy (Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al, for the STARD Group. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. *Ann Intern Med* 2003;138:40-4.) (<http://www.stard-statement.org/>),

STROBE statement-checklist of items that should be included in reports of observational studies (<http://www.strobe-statement.org/>),

MOOSE guidelines for meta-analysis and systemic reviews of observational studies (Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting Meta-analysis of observational Studies in Epidemiology (MOOSE) group. *JAMA* 2000; 283: 2008-12).

CARE guidelines are designed to increase the accuracy, transparency, and usefulness of case reports. (Gagnier JJ, Kienle G, Altman DG, Moher

D, Sox H, Riley D; the CARE Group. The CARE Guidelines: Consensus-based Clinical Case Reporting Guideline Development.) (<http://www.care-statement.org/>)

Human and Animal Studies

Manuscripts submitted for publication must contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards described in an appropriate version of the 1964 Declaration of Helsinki, as revised in 2013 (<http://www.wma.net/en/30publications/10policies/b3/>). It should also be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted. In case of usage of any image media that potentially can expose patients' identity requires obtaining permission for publication from the patients or their parents/guardians. Experimental animal studies should be presented with the disclosure of the appropriateness to the institutional/national/international ethical guides on care and use of laboratory animals.

Reports of animal experiments must state that the "Principles of laboratory animal care" (NIH publication No. 86-23, revised 1985) were followed, as well as specific national laws where applicable.

The editors reserve the right to reject manuscripts that do not comply with the above mentioned requirements. The author will be held responsible for false statements or for failure to fulfill the above mentioned requirements.

Authors must provide statement on the absence of conflict of interests between authors and provide authorship contributions and declare if any financial/material support.

Copyright

The author(s) transfer(s) the copyright to his/their article to the Turkish Journal of Obstetrics and Gynecology effective if and when the article is accepted for publication. The copyright covers the exclusive and unlimited rights to reproduce and distribute the article in any form of reproduction (printing, electronic media or any other form); it also covers translation rights for all languages and countries. For U.S. authors the copyright is transferred to the extent transferable.

After receiving and accept decision for publication, submissions must be accompanied by the "Copyright Transfer Statement". The form is available for download on the journal's manuscript submission and evaluation site. The copyright transfer form should be signed by all contributing authors and a scanned version of the wet signed document should be submitted.

Manuscript Structure

All manuscripts must be submitted as Microsoft Word (.doc or .docx) files. All manuscript pages (including references, tables, and figure legends) must be double-spaced. Use a standard, 12-point typeface such as Times New Roman. Top, bottom, and side margins should be set at 1 inch. Authors must include the following in the manuscript file:

INSTRUCTIONS FOR AUTHORS

Title Page

A separate title page should list;

-The manuscript title, which should contain no more than a total of 100 characters (counting letters and spaces) and should not be declarative; do not use abbreviations or commercial names in the title.

- A short title of no more than 50 characters, including spaces, for use as a running foot.

- All author name(s), institutional, corporate, or commercial affiliations, and up to two major degree(s).

- Corresponding author's name, address, telephone (including the mobile phone number), fax numbers and e-mail address (the corresponding author will be responsible for all correspondence and other matters relating to the manuscript).

Precis

The precis is a one-sentence synopsis of no more than 30 words that describes the basic findings of the article. Precis sample can be seen below:

'Using a 45 point questionnaire, we have evaluated the trend of Robotic surgery training in the gynecologic surgery fellowship programs across the nation!'

Abstract

All manuscripts should be accompanied by an abstract. All information in the abstract should be consistent with the information in the text, tables, or figures. Avoid use of commercial names in the abstract. Original research reports should have a structured abstract of no more than 250 words, using the following headings:

- Objective: Main question, objective, or hypothesis (single phrase starting with, for example, "To evaluate..." or "To estimate." [never start with "To determine."]).
- Materials and Methods: Study design, participants, outcome measures, and in the case of a negative study, statistical power.
- Results: Measurements expressed in absolute numbers and percentages, and when appropriate indicate relative risks or odds ratios with confidence intervals and level of statistical significance; any results contained in the abstract should also be presented in the body of the manuscript, tables, or figures.
- Conclusion: Directly supported by data, along with clinical implications.

Authors from Turkey or Turkish speaking countries are expected to submit a Turkish abstract including subheadings such as "Amaç, Gereç ve Yöntemler, Bulgular, Sonuç". The abstract of Authors whose native language is not Turkish will be provided free of charge translation services into Turkish language.

A structured abstract is not required with review articles and case reports.

Keywords

Below the abstract provide 3 to 5 keywords. Abbreviations should not be used as keywords. Keywords should be picked from the Medical

Subject Headings (MeSH) list (www.nlm.nih.gov/mesh/MBrowser.html).

Turkish abstracts should have keywords "Anahtar Kelimeler" picked from www.atifdizini.com under "Türkiye Bilim Terimleri" link.

Several types of articles can be submitted for publication in Turkish Journal of Obstetrics and Gynecology: Original research, case reports, systematic reviews, current commentaries, procedures and instruments, and letters. Stated word counts and page limits were shown in Table 1. Copyright transfer forms, the cover letter, and figures do not contribute to the page limits.

Table 1. Manuscript length at a glance

Article type	Abstract Length	Manuscript Word Count*	Maximum Number of Authors	Maximum Number of References [®]
Original Research	250 words	5,500 words (~22 pages) [®]	NA	30
Case report	150 words	2,000 words (~8 pages)	4	8
Systematic review	300 words	6,250 words (~25 pages)	4	60
Current commentary	250 words	3,000 words (~12 pages)	4	12
Procedure and Instruments	200 words	2,000 words (~8 pages)	4	10
Letters	NA	350 words	4	5

*Manuscript length includes all pages in a manuscript (ie, title page, abstract, text, references, tables, boxes, figure legends, and appendixes). [®]Suggested limit. [®]The Introduction should not exceed 250 words. [®]approximately; NA, not applicable.

Original researches should have the following sections;

Introduction

State concisely the purpose and rationale for the study and cite only the most pertinent references as background. Avoid a detailed literature review in this section.

Materials and Methods

Describe the research methodology (the patients, experimental animals, material and controls, the methods and procedures utilized, and the statistical method(s) employed) in sufficient detail so that others could duplicate the work. Identify methods of statistical analysis and when appropriate, state the basis (including alpha and beta error estimates) for their selection. Cite any statistical software programs used in the text. Express p values to no more than two decimal places. Indicate your study's power to detect statistical difference.

Address "IRB" issues and participants informed consent as stated above, the complete name of the IRB should be provided in the manuscript. State the generic names of the drugs with the name and country of the manufactures.

Results

Present the detailed findings supported with statistical methods. Figures and tables should supplement, not duplicate the text; presentation of data in either one or the other will suffice. Authors should report



INSTRUCTIONS FOR AUTHORS

outcome data as both absolute and relative effects since information presented this way is much more useful for clinicians. Actual numbers and percentages should be given in addition to odds ratios or relative risk. When appropriate, number needed to treat for benefits (NNTb) or harm (NNT_h) should be supplied. Emphasize only your important observations; do not compare your observations with those of others. Such comparisons and comments are reserved for the discussion section.

Discussion

Begin with a description of what your study found in relation to the purpose or objectives as stated in the Introduction. State the importance and significance of your findings to clinicians and actual patient care but do not repeat the details given in the Results section. Limit your opinions to those strictly indicated by the facts in your report. Compare your finding with previous studies with explanations in cases where they differ, although a complete review of the literature is not necessary.

Study Limitations

Provide information on the limitations of the study. No new data are to be presented in this section. A final summary is not necessary, as this information should be provided in the abstract and the first paragraph of the Discussion. Although topics that require future research can be mentioned, it is unnecessary to state, "Further research is needed."

Conclusion

The conclusion of the study should be highlighted. The study's new and important findings should be highlighted and interpreted.

Conflict of Interest

Authors must indicate whether or not they have a financial relationship with the organization that sponsored the research.

The main text of case reports should be structured with the following subheadings:

Introduction, Case Report, Discussion and References.

References

References are numbered (Arabic numerals) consecutively in the order in which they appear in the text (note that references should not appear in the abstract) and listed double-spaced at the end of the manuscript. The preferred method for identifying citations in the text is using within parentheses. Use the form of the "Uniform Requirements for Manuscripts" (<http://www.icmje.org/about-icmje/faqs/icmje-recommendations/>). If number of authors exceeds seven, list first 6 authors followed by et al.

Use references found published in peer-reviewed publications that are generally accessible. Unpublished data, personal communications, statistical programs, papers presented at meetings and symposia, abstracts, letters, and manuscripts submitted for publication cannot be listed in the references. Papers accepted by peer-reviewed publications but not yet published ("in press") are not acceptable as references.

Journal titles should conform to the abbreviations used in "Cumulated Index Medicus".

Examples

Journals; Zeyneloglu HB, Onalan G. Remedies for recurrent implantation failure. *Semin Reprod Med* 2014;32:297-305.

Book chapter; Ayhan A, Yenen MC, Dede M, Dursun P, Gultekin M. How to Manage Pre-Invasive Cervical Diseases? An Overview. In: Ayhan A, Gultekin M, Dursun P, editors. *Textbook of Gynaecological Oncology*. Ankara, Turkey: Gunes Publishing; 2010. p. 28-32.

Book; Arici A, Seli E. Non-invasive Management of Gynecologic Disorders. In: Arici A, Seli E (eds). London: Informa Healthcare; 2008.

Tables and Figures

Tables should be included in the main document after the reference list. Color figures or gray-scale images must be at minimum 300 DPI resolutions. Figures should be submitted in ".tiff", ".jpg" or ".pdf" format and should not be embedded in the main document. Tables and figures consecutively in the order they are referred to within the main text. Each table must have a title indicating the purpose or content of the table. Do not use internal horizontal and vertical rules. Place explanatory matter in footnotes, not in the heading. Explain all abbreviations used in each table in footnotes. Each figure must have an accompanying descriptive legend defining abbreviations or symbols found in the figure. If photographs of people are used, the subjects must be unidentifiable and the subjects must have provided written permission to use the photograph. There is no charge for color illustrations.

Units of Measurement and Abbreviations

Units of measurement should be in Système International (SI) units. Abbreviations should be avoided in the title. Use only standard abbreviations. If abbreviations are used in the text, they should be defined in the text when first used.

Revisions

Revisions will be sent to the corresponding author. Revisions must be returned as quickly as possible in order not to delay publication. Deadline for the return of revisions is 30 days. The editorial board retains the right to decline manuscripts from review if authors' response delays beyond 30 days. All reviewers' comments should be addressed a revision note containing the author's responses to the reviewers' comments should be submitted with the revised manuscript. An annotated copy of the main document should be submitted with revisions. The Editors have the right to withdraw or retract the paper from the scientific literature in case of proven allegations of misconduct.

Accepted Articles

Accepted articles are provided with a DOI number and published as ahead of print articles before they are included in their scheduled issue.

Journal and Society Web sites:

www.tjod.org (Turkish Society of Obstetrics and Gynecology)

www.tjoddergisi.org (Turkish Journal of Obstetrics and Gynecology)



CONTENTS

Clinical Investigations

- 199** Comparison of corifollitropin alfa and daily recombinant follicle-stimulating hormone in poor responder patients undergoing *in vitro* fertilization cycles
Düşük over yanıtılı hasta grubunda corifollitropin alfa ve rekombinant folikül uyarıcı hormonun in vitro fertilizasyon sikluslarında karşılaştırılması
Süleyman Akarsu, Sibel Demir, Funda Gode, Ahmet Zeki Işık; İzmir, Turkey
- 203** Role of positron emission tomography-computed tomography in endometrial cancer
Endometriyal kanserde pozitron emisyon tomografisi-bilgisayarlı tomografinin rolü
Evrim Erdemoğlu, Sevim Süreyya Çerçi, Ebru Erdemoğlu, Yakup Yalçın, Burak Tatar; Isparta, Turkey
- 210** A comparison of normal and high post-void residual urine and urodynamic parameters in women with overactive bladder
Aşırı aktif mesanesi olan kadınlarda normal ve artmış işeme sonrası rezidüleri ve ürodinamik parametrelerin karşılaştırılması
Hediye Dağdeviren, Hüseyin Cengiz, Çağlar Helvacıoğlu, Ulkar Heydarova, Cihan Kaya, Murat Ekin; İstanbul, Turkey
- 214** Depression and anxiety disorder in hyperemesis gravidarum: A prospective case-control study
Hiperemesis gravidarumlu kadınlarda depresyon ve anksiyete bozukluğu: Prospektif olgu kontrol çalışması
Yusuf Topal Ahmetoğlu, Mehmet Metin Altay, Derya Akdağ Cırık, Yusuf Aytaç Tohma, Eser Çolak, Bora Çoşkun, Orhan Gelişen; Ankara, Turkey
- 220** Endothelial cell leptin receptors, leptin and interleukin-8 in the pathogenesis of preeclampsia: An *in-vitro* study
Preeklampsi patogeneğinde endotelial hücre leptin reseptörleri, leptin ve interlökin-8: İn-vitro çalışma
Sefa Arlier; Tampa, USA, Adana, Turkey
- 228** The oxidative/anti-oxidative effects of sevoflurane on reproductive system of females: An experimental study
Dişilerin üreme sistemleri üzerinde sevofluranın oksidatif/anti-oksidatif etkileri: Deneysel çalışma
Hatice Yılmaz Doğru, İsmail Benli, Serkan Doğru; Tokat, Turkey
- 233** Could the female-to-male transgender population be donor candidates for uterus transplantation?
Kadınlardan erkeğe cinsiyet değiştiren kişiler uterus transplantasyonu için donör olabilir mi?
Murat Api, Ayşen Boza, Mehmet Ceyhan; İstanbul, Turkey
- 238** The efficacy of laparoscopic presacral neurectomy in dysmenorrhea: is it related to the amount of excised neural tissue?
Laparoskopik presakral nörektominin etkinliği çıkartılan nöral doku miktarı ile ilişkili midir?
Murat Api, Ayşen Boza, Mehmet Ceyhan, Ecmel Kaygusuz, Hülya Yavuz, Olus Api; İstanbul, Turkey
- 243** Sleep quality of endometrial cancer survivors and the effect of treatments
Endometrium kanseri olan hastalarda uyku kalitesi ve tedavinin etkisi
Tolgay Tuyan İlhan, Mustafa Gazi Uçar, Ayhan Gül, Türkan Saymaz İlhan, Güler Yavaş, Çetin Çelik; Mersin, Konya, Turkey

Case Reports

- 249** Molar pregnancy in cesarean section scar: A case report
Sezaryen skarında molar gebelik: Olgu sunumu
Elif Gülşah Dağdeviren, Rıza Dur, Erdem Fadiloğlu, Erhan Demirdağ, Çağatayhan Öztürk, Metin Altay; Ankara, Kilis, Turkey



TURKISH JOURNAL OF OBSTETRICS AND GYNECOLOGY

CONTENTS

252 Uterine rupture in pregnancy subsequent to hysteroscopic surgery: A case series

Histeroskopi sonrası gebelikte uterin rüptür: Olgu serisi

Şahin Zeteroğlu, Melisa Aslan, Bertan Akar, Rukiye Ada Bender, Alper Başbuğ, Eray Çalışkan; Bursa, İstanbul, Düzce, Turkey

Technical Description

256 Fertility preservation in male patients subjected to chemotherapy; innovative approaches for further progress

Kemoterapiye maruz kalan erkek hastalarda üretkenliğin korunması ve yenilikçi yaklaşımlar

Mohamed Shehata; Cologne, Germany

Index

2017 Referee Index

2017 Author Index

2017 Subject Index



TURKISH JOURNAL OF OBSTETRICS AND GYNECOLOGY

LETTER FROM THE PRESIDENT

Dear Collagues,

I am glad that our journal to reach this satisfactory level with your great contributions. I am also aware of the fact that we have to move forward in order to further progress.

I herein thank in the first place to the editor of the journal and also those who work hard to make the journal worthy of the doctors countrywide.

I especially thank the obstetrics and gynecology community for your support for the TJOD congress which will be held between May 9-13, 2018. We are preparing for our congress with a great excitement and enthusiasm.

I will be pleased to meet and recognize a few new academican colleague as it occurs in every congress. I think this congress would be an unique opportunity for our young colleagues to express and show themselves, and to enhance their scientific knowledge as well.

In addition, there would be a marvellous ambiance for the young colleagues with the most experienced and knowledgeable colleagues of all the major branches of our specialty, to inform all the women about the reproductive health.

I look forward to seeing each and every one of our precious colleague in our congress which will be held between May 9-13, 2018.

Best regards,

Ateş Karateke, Prof. MD
President of TJOD



TURKISH JOURNAL OF OBSTETRICS AND GYNECOLOGY

EDITORIAL

Dear Colleagues,

After our inclusion in the Pubmed the manuscript submissions to our journal trippled. I would like to thank to all the scientists who gives us the oppurtunity to evaluate their work. The visibility and fulltext download of our articles exceeded 1500 during the first half of September 2017. This year our journal received second highest number of submissions in its history. In 2013 we have received 228 manuscripts and in 2017 we have received 200 manuscripts. The manuscripts submitted are mostly in the field of Perinatology followed by Reproductive Endocrinology and infertility, Gynecological Oncology and Urogynecology.

Our acceptance rate was 26% in 2017. We try to be constructive and provide feedback to the authors about possible sources of bias, methodological flaws, reporting errors and we encourage the authors to write the limitations of their studies. I think this provides an area of scientific discussion among colleagues and improve experience of every one of us even the manuscripts are not accepted. We would like to thank to our 228 reviewers and our Editorial board for donating their time to our journal just for improvement of science. In 2018 we are planning a series of Systematic Review and Metaanalysis courses for encouraging scientists to evaluate the literatüre and provide a highest level of scientific information for the readers of our journal. Please save the date of first course on 17-18 February 2018. Those who wants to join this team can mail to me.

I wish all the best in the new year.

Eray Çalışkan
Editor in Chief



Comparison of corifollitropin alfa and daily recombinant follicle-stimulating hormone in poor responder patients undergoing *in vitro* fertilization cycles

*Düşük over yanıtı hasta grubunda corifollitropin alfa ve rekombinant folikül uyarıcı hormonun *in vitro* fertilizasyon sikluslarında karşılaştırılması*

Süleyman Akarsu¹, Sibel Demir², Funda Gode¹, Ahmet Zeki Işık¹

¹Izmir Medical Park Hospital, Clinic of Obstetrics and Gynecology, In Vitro Fertilization Unit, Izmir, Turkey

²Izmir Başkent University Hospital, Clinic of Obstetrics and Gynecology, Izmir, Turkey

Abstract

Objective: The aim of this study was to compare the effect of corifollitropin alfa (CFA) and recombinant follicle-stimulating hormone (rFSH) in poor-responder patients undergoing antagonist cycles.

Materials and Methods: The study was a retrospective analysis of the treatment results of 214 poor responder patients who had been admitted to the *In Vitro* Fertilization Unit of Izmir Medical Park Hospital between November 2014 and November 2016. Intracytoplasmic sperm injections were performed in 38 patients (group 1) with CFA, and the remaining 176 (group 2) with rFSH for controlled ovarian hyperstimulation.

Results: The age, body mass index, anti-müllerian hormone level, duration of infertility, duration of induction and antral follicle number were similar in the two groups. There was no difference in the total aspirated oocyte counts, mature oocyte ratio, fertilization rate, implantation rate, and clinical pregnancy rates between the two groups. The implantation rate was 9/38 (23.6%) in group 1 and 42/176 (23.8%) in group 2, whereas the clinical pregnancy rates were 16.3% and 17.2%, respectively.

Conclusion: No difference was found in terms of oocyte count, fertilization rate, implantation rate, and clinical pregnancy rates of CFA or rFSH use in the antagonist cycles in poor-responder patients.

Keywords: Corifollitropin alfa, diminished ovarian reserve, gonadotropin-releasing hormone antagonist, *in vitro* fertilization, poor responder

Öz

Amaç: Bu çalışmanın amacı düşük over yanıtı hasta grubunda antagonist sikluslarda korifollitropin alfa (CFA) ve rekombinant folikül stimülant hormonun (rFSH) etkinliğini karşılaştırmaktır.

Gereç ve Yöntemler: Çalışma İzmir Medical Park Hastanesi *In Vitro* Fertilizasyonu Merkezi'nde Kasım 2014 ile Kasım 2016 tarihleri arasında düşük over yanıtı toplam 214 hastanın kayıtlarından retrospektif olarak yapıldı. Otuz sekiz hastaya CFA (grup 1), 176 hastaya (grup 2) rFSH kullanılarak kontrollü ovaryan stimülasyon yapıldı.

Bulgular: Yaş, vücut kitle indeksi, anti-müllerian hormon düzeyi, infertilite süresi, indüksiyon süresi ve antral follikül sayısı her iki grupta aynıydı. Aspire edilen toplam oosit sayısı, matür oosit oranı, fertilizasyon oranı, implantasyon oranı ve klinik gebelik oranı açısından her iki grup arasında fark gözlenmedi. İmplantasyon oranı grup 1'de 9/38 (%23,6) ve grup 2'de 42/176 (%23,8) iken; klinik gebelik oranı sırasıyla grup 1'de %16,3 ve grup 2'de %17,2 idi.

Sonuç: Düşük over yanıtı hasta gruplarında yapılan antagonist sikluslarda CFA ve rFSH kullanımının oosit sayısı, fertilizasyon oranı, implantasyon oranı ve klinik gebelik oranı arasında fark yoktur.

Anahtar Kelimeler: Korifollitropin alfa, yumurtalık rezervinin azalması, gonadotropin salgılatıcı hormon antagonisti, *in vitro* fertilizasyonu, düşük over yanıtı

PRECIS: No difference was found in terms of oocyte count, fertilization rate, implantation rate, and clinical pregnancy rates of CFA or rFSH use in the antagonist cycles in poor-responder patients.

Address for Correspondence/Yazışma Adresi: Süleyman Akarsu, MD,

Izmir Medical Park Hospital, Clinic of Obstetrics and Gynecology, In Vitro Fertilization Unit, Izmir, Turkey

Phone: +90 532 324 20 25 E-mail: suleymanakarsu@hotmail.com ORCID ID: orcid.org/0000-0001-6571-6403

Received/Geliş Tarihi: 28.07.2017 Accepted/Kabul Tarihi: 21.09.2017

©Copyright 2017 by Turkish Society of Obstetrics and Gynecology

Turkish Journal of Obstetrics and Gynecology published by Galenos Publishing House.

Introduction

Corifollitropin alfa (CFA) is a new gonadotropin analogue with follicle-stimulating hormone (FSH) activity, which is effective for 7 days at the beginning and continuation of multi-follicular development⁽¹⁾. This FSH analogue is a recombinant molecule that contains the carboxy terminal peptide structure of the human FSH beta subunit, but does not exhibit luteinizing hormone (LH) activity that affects only FSH receptors^(1,2). The greatest advantage of this molecule is the half-life of about 68 hours⁽³⁾. The pharmacodynamic properties of this molecule are that the serum concentration reaches the peak level (T_{max}) in a short time and reaches the maximum concentration (C_{max}) after 25-45 hours of injection⁽⁴⁾. There are no adverse effects or complications associated with this drug, which is well tolerated by patients⁽⁵⁾. The treatment of patients with low over-exposure has been the main topic of many randomized studies in past years. Different treatment regimens have been applied to increase over-response and pregnancy rates. Decreasing oocyte quality and decreasing over-reserve are closely related to female age⁽⁶⁻⁸⁾. The European Society of Human Reproduction and Embryology developed a new definition called Bologna criteria in 2011 for the poor-response patient group⁽⁹⁾. These criteria are: 1) older age of women (40 years) or other existing factors causing diminished ovarian reserve (DOR); 2) less oocyte counts in treatments taken in previous treatments (3 oocytes); 3) disorder in over reserve tests [antral follicles <5-7 or anti-müllerian hormone (AMH) <0.5-1.1 ng/mL]. Two of these criteria will cause the patient to have a diagnosis of DOR⁽⁹⁾.

Materials and Methods

This study was the result of a retrospective study of 214 patients who were diagnosed as having DOR according to the Bologna criteria at the *in vitro* fertilization (IVF) Unit of İzmir Medical Park Hospital between November 2014 and November 2016. Ethics committee approval was obtained from İzmir University Ethics Committee (approval number: 012742) before the study commencement. Informed consent was obtained from all of the study participants. The inclusion criteria were: being aged <45 years old, regular menstrual cycles (24-35 days), body mass index of 18-30 kg/m², absence of any endocrine pathology, no severe male factor (total progressive motile sperm count 1 million/mL (Table 1). Thirty-eight patients were treated with single-dose subcutaneous injection of 150 µg CFA (Elonva, NV Organon, Oss, Netherlands) on the second or third day of the cycle as the first day of controlled ovarian hyperstimulation (COH). On the seventh day of treatment, 300 IU of highly purified human menopausal gonadotrophin (Merional, IBSA, Switzerland or Menopur, Ferring, Turkey) were administered, similar to the protocol of Polyzos and Devroey⁽⁶⁾, subcutaneously per day to each patient (group 1). The remaining 176 patients were treated with 300 IU follitropin alpha (Gonal-f; Merck, Switzerland) or follitropin beta (Puregon; NV Organon, Oss, Netherlands) subcutaneously on the second or third day of

the cycle (group 2). In both groups, 0.25 mg gonadotropin-releasing hormone (GnRH) ganirelix (Orgalutran; NV Organon, Oss, Netherlands) or cetrorelix (Cetrotide; Merck, Switzerland) was given daily until the day of human chorionic gonadotropin (hCG) to prevent premature luteinization when the follicle diameter was 13 mm or more. When the leading follicle was 18 mm, 250 µg recombinant hCG (Ovitrelle; Merck, Switzerland) was administered subcutaneously for the final maturation of the oocyte. Thirty-five hours later, under general anesthesia, transvaginal ultrasound-guided oocyte pick-up was performed. Intracytoplasmic sperm injections was applied to all patients. All embryos were cultured for three days *in vitro* and then transferred in the presence of transabdominal ultrasonographic guidance. Four hundred milligrams per day of micronized progesterone (Progestin capsules 200 mg, Koçak Farma, İstanbul, Turkey) and 90 mg progesterone gel (Crinone gel, Merck, Switzerland) were applied vaginally for luteal phase support. On the second day of the cycle, serum estradiol, LH, and FSH, and on the day of hCG treatment, estradiol, LH, and progesterone values were recorded. On the second, seventh, and hCG days of the cycle, follicle evaluation was performed using transvaginal ultrasonography. Twelve days after the embryo transfer, a beta-hCG test was performed. Transvaginal ultrasonographic evaluation was performed for fetal heart beat two weeks after a finding a positive hCG test.

Statistical Analysis

The Statistical Package for the Social Sciences program (SPSS 20) [International Business Machines (IBM) Corp. released 2011. IBM SPSS Statistics for Windows, version 20.0, Armonk, NY: IBM Corp.] was used to evaluate the data. Variables mean + standard deviation and median (minimum-maximum) percentage and frequency values were used. The homogeneity of the variances from the preconditions of the parametric tests was checked using the Levene test. The assumption of normality was examined using the Shapiro-Wilk test. The differences between the two groups were evaluated using Student's t-test

Table 1. Demographic characteristics of patients

	Grup 1	Grup 2	p
Patient number	25	119	
Age (year)	39.2	38.1	0.954
BMI (kg/m ²)	26.1	25.4	0.687
Duration of infertility (year)	5.3	5.7	0.545
Duration of induction (day)	10.5	10.3	0.998
Number of antral follicle	5.1	5.2	0.997
Endometrial thickness (hCG day)	8.1	8.3	0.995
AMH (ng/dL)	0.81	0.69	0.412
Progesteron (hCG day µg/L)	1.32	1.45	0.124
BMI: Body mass index, AMH: Anti-müllerian hormone, hcG: Human chorionic gonadotropin			

when parametric test prerequisites were provided, and the Mann-Whitney U test was used when the conditions were not met. Categorical data were analyzed using the maximum likelihood and chi-square tests. In cases where the expected frequencies were less than 20%, the Monte Carlo Simulation Method was used including these frequencies in the analysis. For the significance level of the tests, $p < 0.01$ was accepted.

Results

CFA (group 1) was applied to 38 of 214 patients with DOR, as diagnosed according to the Bologna criteria, and recombinant FSH and antagonist protocol (group 2) treatment was applied to the remaining 176 patients. It was not possible to retrieve any oocytes in 13 (34.2%) patients in group 1 and 57 (32%) patients in group 2; therefore, these cycle were cancelled ($p=0.718$). The mean number of oocytes collected in group 1 with 25 patients with at least one oocyte was 3.2, and in group 2 with 119 patients it was 3.4 ($p=0.879$). The mean number of mature oocytes metaphase 2 was 1.8 in group 1 and 1.6 in group 2 ($p=0.745$). The duration of stimulation was 10.52 days in group 1 and 10.34 days in group 2 ($p=0.894$). The mean number of transferred embryos was 1.6 in group 1, whereas this value was 1.5 in group 2 ($p=0.478$). The implantation rate was 9/38 (23.6%) in group 1 and 42/176 (23.8%) in group 2 ($p=0.578$), and the clinical pregnancy rate was 16.3% and 17.2%, respectively ($p=0.622$). Multiple pregnancy and drug adverse effects were not observed in any patients (Table 2).

Discussion

Since 2008, there have been different results in a limited number of studies on single-dose CFA administration. In 2008, Devroey et al.⁽¹⁰⁾ wrote the first study about CFA. The authors suggested that a single injection of corifollitropin alfa induced a dose-related increase in multifollicular development and in

the number of retrieved oocytes⁽¹¹⁾. Devroey et al.⁽¹⁰⁾ postulated that CFA was a novel and effective treatment option for potential normal-responder patients undergoing ovarian stimulation with GnRH antagonist co-treatment for IVF resulting in ongoing pregnancy rates equal to that achieved with daily rFSH. Mahmoud Youssef et al.⁽¹²⁾ published a meta-analysis in 2012. They included four randomized trials involving 2326 women. There was no evidence of a statistically significant difference in ongoing pregnancy rates for CFA versus rFSH⁽¹²⁾. Boostanfar et al.⁽¹³⁾ designed a large comparative randomized double-blind trial that confirmed the non-inferiority of pregnancy rates for CFA compared with recombinant FSH in a GnRH antagonist COH protocol in advance-age patients undergoing IVF. CFA was proven noninferior to daily rFSH with respect to cardiopulmonary resuscitations, number of oocytes retrieved, and live birth rates, and the drug was generally well tolerated⁽¹³⁾. Another study was designed by Polyzos et al.⁽¹⁴⁾ with poor ovarian responders. In this study, the Bologna criteria were used to enroll the patients. The protocol with CFA in this group of patients resulted in low poor responder (PR) similar to the conventional short agonist protocol⁽¹⁴⁾. Revelli et al.⁽¹⁵⁾ demonstrated that starting CFA on day 4 of the cycle resulted in comparable PR with significantly less injections and a similar risk of Ovarian Hyperstimulation syndrome (OHSS)⁽¹⁵⁾. On the other hand Oehninger reported that, in women aged 35 to 42 years, the prediction of ovarian response to CFA treatment was related with AMH, AFC, and age at the start of stimulation for in both high and PR patients⁽¹⁶⁾. In addition, basal FSH values for high ovarian response and menstrual cycle length for poor ovarian response were prognostic. In a meta-analysis consisting of 2138 women who were randomized to receive corifollitropin alfa and 1788 who were randomized to receive daily rFSH, Fensore et al.⁽¹⁷⁾ emphasized that the risk of cycle cancellation due to overstimulation was significantly higher in the CFA group. On the other hand, the incidence of OHSS was comparable between patients receiving long-lasting or daily rFSH. Accordingly, they suggested that CFA resulted in a higher number of metaphase 2 oocytes collected and a higher number of cycles cancelled due to overstimulation; therefore, CFA should be cautiously considered in women with the potential of being hyper-responders. In view of this meta-analysis, one can consider using CFA more effectively for patients with DOR, but to date, the results have not been consistent. In a retrospective study, Polyzos et al.⁽¹⁴⁾ used HP-hMG as an additional gonadotropin in poor-responder patients according to the Bologna criteria. They achieved a very reasonable ongoing pregnancy rate (28%) in patients aged below 40 years, whereas no pregnancies occurred in patients aged over 40 years.

Study Limitations

The retrospective design is the major limitation of our study. Therefore, prospective randomized studies are also necessary about this subject.

Table 2. Over response, embryo results and pregnancy rates

	Grup 1	Grup 2	p
Patient Number	38	176	
Number of cycles cancelled	13 (34.2%)	57 (32%)	0.72
Number of taken oocytes	3.2	3.4	0.88
MII Number	1.8	1.6	0.75
2PN Number	1.5	1.4	0.99
Emb Grade			
Grade 1-2	11 (44%)	48 (40.3%)	0.74
Grade 3-4	14 (56%)	71 (59.7%)	0.74
Transferred embriyo number	1.6	1.5	0.48
Pozitive hCG	9 (23.6%)	42 (23%)	0.58
Clinical pregnancy	16.3%	17.2%	0.64
Emb: Endometrial biopsy, 2PN: Two-pro-nucleii, hcG: Human chorionic gonadotropin MII: Metaphase II			

Conclusion

CFA is a long-acting novel gonadotropin for COH. In our study, we used a similar protocol to Polyzos et al.⁽¹⁴⁾ who found considerably high PR in patients with DOR, particularly in the younger age group. Unfortunately, we could not show any difference between the two different COH modalities. Although the CFA treatment was well accepted by the patients, the high cost of the medication was a limiting concern. As far as we know, this is the first study to report the use of CFA in patients with DOR from our country.

Ethics

Ethics Committee Approval: Ethics committee approval was obtained from İzmir University Ethics Committee (approval number: 012742)

Informed Consent: This study was the result of a retrospective study of 214 patients who were diagnosed as having DOR according to the Bologna criteria at the *In Vitro* Fertilization Unit of İzmir Medical Park Hospital between November 2014 and November 2016.

Peer-review: Internally peer-reviewed.

Authorship Contributions

Surgical and Medical Practices: A.Z.I., S.A., F.G., Concept: A.Z.I., Design: S.A., F.G., Data Collection or Processing: S.A., Analysis or Interpretation: S.A., Literature Search: A.Z.I., S.D., Writing: S.A., F.G., S.D.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study received no financial support.

References

1. Fauser BC, Mannaerts BM, Devroey P, Leader A, Boime I, Baird DT. Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency. *Hum Reprod Update* 2009;15:309-21.
2. Fares FA, Sukanuma N, Nishimori K, LaPolt PS, Hsueh AJ, Boime I. Design of a long-acting follitropin agonist by fusing the C-terminal sequence of the chorionic gonadotropin beta subunit to the follitropin beta subunit. *Proc Natl Acad Sci U S A* 1992;89:4304-8.
3. Fauser BC, Alper MM, Ledger W, Schoolcraft WB, Zandvliet A, Mannaerts BM, et al. Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF. *Reprod Biomed Online* 2010;21:593-601.
4. Devroey P, Fauser BC, Platteau P, Beckers NG, Dhont M, Mannaerts BM. Induction of multiple follicular development by a single dose of long-acting recombinant follicle-stimulating hormone (FSH-CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization. *J Clin Endocrinol Metab* 2004;89:2062-70.
5. Bouloux PM, Handelsman DJ, Jockenhövel F, Nieschlag E, Rabinovici J, Frasa WL, et al. First human exposure to FSH-CTP in hypogonadotrophic hypogonadal males. *Hum Reprod* 2001;16:1592-7.
6. Polyzos NP, Devroey P. A systematic review of randomized trials for the treatment of poor ovarian responders: is there any light at the end of the tunnel? *Fertil Steril* 2011;96:1058-61.
7. Baird DT, Collins J, Egozcue J, Evers LH, Gianaroli L, Leridon H, et al. ESHRE Capri Workshop Group: Fertility and ageing. *Hum Reprod Update* 2005;11:261-76.
8. Younis JS. Ovarian aging: latest thoughts on assessment and management. *Curr Opin Obstet Gynecol* 2011;23:427-34.
9. Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L, et al. ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. *Hum Reprod* 2011;26:1616-24.
10. Devroey P, Boostanfar R, Koper NP, Mannaerts BM, Ijzerman-Boon PC, Fauser BC; ENGAGE Investigators. A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. *Hum Reprod* 2009;24:3063-72.
11. Abyholm T, Andersen AN, Balen AH, Braat DD, Devroey P, D'Hooghe TH, et al. Corifollitropin Alfa Dose-finding Study Group. A randomized dose-response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation. *Hum Reprod* 2008;23:2484-92.
12. Mahmoud Youssef MA, van Wely M, Aboulfoutouh I, El-Khyat W, van der Veen F, Al-Inany H. Is there a place for corifollitropin alfa in IVF/ICSI cycles? A systematic review and meta-analysis. *Fertil Steril* 2012;97:876-85.
13. Boostanfar R, Shapiro B, Levy M, Rosenwaks Z, Witjes H, Stegmann BJ, et al. Large, comparative, randomized double-blind trial confirming noninferiority of pregnancy rates for corifollitropin alfa compared with recombinant follicle-stimulating hormone in a gonadotropin-releasing hormone antagonist controlled ovarian stimulation protocol in older patients undergoing in vitro fertilization. *Fertil Steril* 2015;104:94-103.
14. Polyzos NP, De Vos M, Corona R, Vloeberghs V, Ortega-Hrepich C, Stoop D, et al. Addition of highly purified HMG after corifollitropin alfa in antagonist-treated poor ovarian responders: a pilot study. *Hum Reprod* 2013;28:1254-60.
15. Revelli A, Chiadò A, Dalmaso P, Stabile V, Evangelista F, Basso G, et al. "Mild" vs. "long" protocol for controlled ovarian hyperstimulation in patients with expected poor ovarian responsiveness undergoing in vitro fertilization (IVF): a large prospective randomized trial. *J Assist Reprod Genet* 2014;31:809-15.
16. Oehninger S. Poor responders in in vitro fertilization (IVF) therapy: the challenge continues. *Facts Views Vis Obgyn* 2011;3:101-8.
17. Fensore S, Di Marzio M, Tiboni GM. Corifollitropin alfa compared to daily FSH in controlled ovarian stimulation for in vitro fertilization: a meta-analysis. *J Ovarian Res* 2015;8:33.



Role of positron emission tomography-computed tomography in endometrial cancer

Endometriyal kanserde pozitron emisyon tomografisi-bilgisayarlı tomografinin rolü

Evrım Erdemođlu¹, Sevim Süreyya Çerçi², Ebru Erdemođlu³, Yakup Yalçın¹, Burak Tatar¹

¹Süleyman Demirel University Faculty of Medicine, Department of Gynecologic Oncology, Isparta, Turkey

²Süleyman Demirel University Faculty of Medicine, Department of Nuclear Medicine, Isparta, Turkey

³Maternity Hospital, Clinic of Obstetrics and Gynecology, Isparta, Turkey

Abstract

Objective: The efficacy of preoperative ¹⁸F-fluoro-D-glucose (¹⁸F-FDG) positron emission tomography-computed tomography (PET-CT) in endometrium cancer is controversial. We examined the efficacy of PET-CT and the association between maximum standardized uptake value (SUV_{max}) and prognostic factors in endometrial cancer.

Materials and Methods: Thirty patients with endometrial cancer underwent preoperative ¹⁸F-FDG/PET-CT. The patients were treated with abdominal hysterectomy with bilateral salpingo-oophorectomy, and bilateral systemic pelvic lymphadenectomy was planned for all patients; paraaortic lymphadenectomy was performed in patients with intermediate and high risk. Tumor histology, grade, depth of myometrial invasion, maximum tumor diameter, lymphovascular invasion, nodal status, and ovarian/adnexal metastases were recorded.

Results: The mean primary tumor diameter was reported smaller in PET-CT and the effect size of PET-CT was -0.60. The kappa value was 0.06 for myometrial invasion. Pelvic lymph node metastasis was reported in 22.2% of patients in PET-CT. However, 3.7% of patients had pelvic lymph node metastasis. The kappa value for pelvic lymph node metastasis was 0.23, and sensitivity, specificity, and positive and negative predictive values were 100%, 80.7%, 16.6%, and 100%, respectively. Paraaortic lymph node metastasis in PET-CT was suspected in 10%. However, paraaortic lymph node metastasis was found in 6.7% in histopathologic analyses. The kappa value was 0.15. The sensitivity, specificity, and positive and negative predictive values of PET-CT for detecting paraaortic lymph node metastases were 100%, 93.7%, 66.6%, and 100%, respectively. Myometrial invasion and tumor diameter were the only important prognostic factors affecting SUV_{max}.

Conclusion: According to our results, PET-CT has a limited role and diagnostic efficacy in endometrial cancer. The indications of FDG/PET-CT in endometrium cancer should be studied further and revised.

Keywords: Endometrial cancer, maximum standardized uptake value, positron emission tomography, diagnosis, prognostic factors

Öz

Amaç: Endometriyal kanserde preoperatif ¹⁸F-floro-D-glukoz (¹⁸F-FDG) pozitron emisyon tomografi-bilgisayarlı tomografinin (PET-BT) etkinliđi tartışmalıdır. Endometriyal kanserde PET-BT'nin etkinliđini ve maksimum standart uptake deđeri (SUV_{maks}) ile prognostik faktörler arasındaki iliřkiyi inceledik.

Gereç ve Yöntemler: Endometriyal kanserli otuz hastada preoperatif ¹⁸F-FDG/PET-BT vardı. Hastalar bilateral salpingo-oofrektomi ile abdominal histerektomi ile tedavi edildi ve her olguda bilateral sistemik pelvik lenfadenektomi planlandı, orta ve yüksek riskli hastalarda paraaortik lenfadenektomi yapıldı. Tümör histolojisi, grade, myometrial invazyon derinliđi, maksimum tümör çapı, lenfovasküler invazyon, nodal durum, over/adneksiyel metastaz kaydedildi.

Bulgular: Ortalama primer tümör çapının PET/BT'de daha küçük olduđu ve PET-BT'nin etki büyüklüđünün 0,60 olduđu rapor edildi. Myometrial invazyon için kappa deđeri 0,06 idi. Pelvik lenf nodu metastazı PET-BT'de %22,2 olarak bulundu. Bununla birlikte, hastaların %3,7'sinde pelvik lenf nodu metastazı vardı. Pelvik lenf nodu metastazı için kappa deđeri 0,23, duyarlılık, özgülük, pozitif prediktif deđeri ve negatif prediktif deđeri sırasıyla %100, %80,7, %16,6 ve %100 idi. PET-BT'de, paraaortik lenf nodu metastazı açısından %10'unda şüphelenildi. Bununla birlikte, histopatolojik analizlerde paraaortik lenf nodu metastazı %6,7'sinde bulundu. Kappa deđeri 0,15 idi. PET-BT'nin paraaortik lenf nodu metastazlarını saptamaya yönelik sensitivitesi, spesifitesi, pozitif prediktif deđeri ve negatif prediktif deđeri sırasıyla %100, %93,7, %66,6 ve %100 idi. SUV_{maks}'ı etkileyen tek önemli prognostik faktör, myometrial invazyon ve tümör çapı idi.

Address for Correspondence/Yazıřma Adresi: Evrim Erdemođlu, MD,

Süleyman Demirel University Faculty of Medicine, Department of Gynecologic Oncology, Isparta, Turkey

Phone: +90 505 272 43 44 E-mail: evrimmd@yahoo.com ORCID ID: orcid.org/0000-0002-5993-6968

Received/Geliř Tarihi: 11.08.2017 Accepted/Kabul Tarihi: 14.10.2017

©Copyright 2017 by Turkish Society of Obstetrics and Gynecology

Turkish Journal of Obstetrics and Gynecology published by Galenos Publishing House.

Öz

Sonuç: Sonuçlarımıza göre, PET-BT'nin endometriyum kanserinde sınırlı bir rolü ve tanısal etkinliği vardır. FDG/PET-BT'nin endometriyum kanseri endikasyonları daha fazla araştırılmalı ve gözden geçirilmelidir.

Anahtar Kelimeler: Endometriyal kanser, maksimum standart uptake değeri, pozitron emisyon tomografi, tanı, prognostik faktörler

PRECIS: Positron emission tomography-computed tomography has a limited role and diagnostic efficacy in endometrial cancer.

Introduction

Endometrial cancer is the most common gynecologic cancer; the estimated new cases and deaths in 2015 were 54.870 and 10.170, respectively⁽¹⁾. The majority of cases are confined to the uterus and diagnosed at an early stage⁽¹⁾. Endometrium cancer spreads primarily by direct extension, lymphatic channels, trans tubal migration, and blood vessels. The main lymphatic metastases involve pelvic lymph nodes, and less commonly presacral, paraaortic, and inguinal lymph nodes⁽²⁾. Until 1988, endometrium cancer was staged clinically⁽³⁾. After finding evidence that clinical staging was inaccurate, the International Federation of Gynaecology and Obstetrics (FIGO) staging of endometrium cancer changed to a surgical-pathologic-based system. Surgical staging of endometrium cancer provides prognostic factors that are not available before surgery, or which are not always in exact concordance before and after surgery. Prognostic factors are the stage, tumor histology, grade, depth of myometrial invasion, lymphovascular space invasion (LVSI), tumor diameter, extrauterine spread, and lymph node metastasis^(2,3).

Positron emission tomography (PET) uses the detection of enhanced glucose metabolism in malignant tumors based on the uptake of ¹⁸F-fluoro-D-glucose (¹⁸F-FDG) for functional diagnosis of malignant tumors. PET-computed tomography (CT) allows simultaneous imaging of anatomic and metabolic information. ¹⁸F-FDG/PET-CT has been widely used in clinical practice for tumor detection, staging, treatment monitoring and detection of disease recurrence. Preoperative PET-CT imaging is not universally accepted in endometrial cancer, and the efficacy and accuracy of ¹⁸F-FDG/PET-CT in endometrium cancer is controversial and may be overestimated. In this study, we examined the efficacy of PET-CT in a non-stratified patient group with endometrium cancer in a tertiary university setting over a 1-year period. We also analyzed the association between maximum standardized uptake values (SUV_{max}) and prognostic factors based on final pathology.

Materials and Methods

Subjects

Patients diagnosed as having endometrial cancer histopathologically who underwent PET-CT for treatment planning in our department between 2014 and 2015 were included in the study. Patients who did not undergo surgery or preoperative PET-CT imaging were not recruited. Patients who had neoadjuvant treatment before the operation, claustrophobia,

and uncontrolled diabetes mellitus (random blood sugar >200 mg/dL) were excluded. The standard preoperative procedures included clinical examination, chest X-ray, and abdominal and vaginal ultrasonography. Laboratory examinations including routine hematology, biochemistry, cancer antigen-125 (CA-125) were performed. Routine preoperative imaging for myometrial invasion was not performed because it was not found to be cost-effective. The study was approved by Süleyman Demirel University Ethics Committee (approval number: 54).

Surgery

All patients had a midline laparotomy and abdominal hysterectomy with bilateral salpingo-oophorectomy under general anesthesia. Panniculectomy was performed in two patients for staging purposes. Bilateral systemic pelvic lymphadenectomy was planned for all patients; paraaortic lymphadenectomy was performed in patients with intermediate and high risk. Lymph node dissection was performed en-bloc without dividing for separate regions for oncologic safety. Suspicious nodes on FDG/PET-CT were marked. Analysis of matching for the PET-CT and histopathology was made for the whole nodal chain including the marked lymph node(s).

Positron emission tomography-computed tomography protocol and image analysis

Whole-body ¹⁸F-FDG/PET-CT images were performed using a PET/CT scanner (Philips Gemini TF), consisting of dedicated lutetium yttrium oxyorthosilicate full-ring PET scanner and 64-slice CT. All patients were kept fasting for six hours before intravenous (i.v.) injection of 3.7 MBq/kg (0.1 mCi/kg) of ¹⁸F-FDG. During the 60 min. waiting period, all patients were orally hydrated with around 1.5 L of contrast. After 60 min., the combined examination was started by asking the patients to empty their bladder and injecting the i.v. contrast. The CT scan was acquired first, followed by the PET scan. PET and CT images (non-corrected and attenuation-corrected) were evaluated in the rotating maximum-intensity projection and in the cross-sectional planes view (transverse-sagittal-coronal). The ¹⁸F-FDG uptake in the primary tumor was quantified using SUV_{max} measurements.

Pathological evaluation

Tumor histology, grade, depth of myometrial invasion, maximum tumor diameter, lymphovascular invasion, nodal status, ovarian/adnexal metastases, and cytology were recorded. Each primary tumor and dissected lymph nodes were sliced and stained with hematoxylin and eosin (H&E) and examined

microscopically by at least one gynecologic pathologist. Pathologist(s) were blinded to the PET/CT results. Discordant results on lymph nodes were further evaluated by ultra-staging. Ultra-staging involved cutting an additional two adjacent 5- μ m sections at 2 levels 50- μ m apart from each paraffin block that lacked metastatic carcinoma on routine H&E staining. At each level, one slide was stained with H&E and with immunohistochemistry using anti-cytokeratin.

Prognostic factors

Prognostic factors evaluated were tumor histology, grade, depth of myometrial invasion, maximum tumor diameter, lymphovascular invasion, nodal status, elevated CA-125, and thrombocytosis. Grade 1 and 2 tumors were classified as low grade; grade 3 tumors were classified as high grade.

Statistical Analysis

Statistical analyses were performed using MedCalc for Windows, version 12.5 (MedCalc Software, Ostend, Belgium) and p values less than 0.05 were considered statistically significant.

Analyses of consistency and agreement between positron emission tomography-computed tomography and histopathology: Continuous variables

The mean and standard deviation of continuous variables were calculated using the t-test. The importance of the difference between means was evaluated through effect size. Effect size measures how much the mean in PET-CT exceeded the mean of the histopathologic measurement. Effect size <0.20 was considered small; 0.50 was moderate effect size, and >0.80 was large effect size. The consistency and agreement of the continuous variables (tumor diameter) were evaluated using the intraclass coefficient and concordance correlation coefficient. Concordance correlation coefficient <90 indicates poor correlation and agreement. Intraclass correlation coefficient (ICC) was analyzed for absolute agreement and consistency. ICC were calculated for each single measurement and also for average (mean) values; ICC >70 indicated poor agreement, >80 indicated moderate agreement, >90 good agreement, and 100 meant perfect agreement.

Analyses of consistency and agreement between positron emission tomography-computed tomography and histopathology: Ordinal and nominal variables

The frequency of variables was calculated, and kappa statistics was used to analyze agreement between PET-CT and histopathologic findings. Kappa value is 1 when there is perfect agreement between PET-CT findings and histopathologic findings. Kappa value is zero when there is no agreement better than chance. Kappa value is negative when the agreement is worse than chance. Kappa index (inter-rater agreement concordance, in ordinal or nominal scales) is usually interpreted according to qualifiers as "poor" (<0.20), "slight" ($0.20-0.40$), "fair" ($0.41-0.60$), "moderate" ($0.61-0.80$), and $0.81-1$ as almost perfect agreement.

Analyses of maximum standardized uptake value and high-risk prognostic indicators

Median and interquartile ranges SUV_{max} for each prognostic indicator such as histology, grade, myometrial invasion, lymphovascular invasion, and lymph node metastasis were calculated. The Mann-Whitney U test or Kruskal-Wallis test was used to analyze primary tumor SUV_{max} and prognostic indicators. Regression analyses were used to study the relation between tumor diameter in pathologic measurement and primary tumor SUV_{max} .

Results

A total of 30 patients were included in the study. The mean age of patients was 58.8 ± 9.3 years. Eighty-six percent of the women were postmenopausal. Endometrioid histology was reported in 90% of patients. Serous histology was reported in 10% of patients. Tumor was grade 1, 2, and 3 in 43.3%, 40%, and 16.7%, respectively. LVSI was observed in 6.7% of cases. Pelvic lymphadenectomy was planned for all patients. However, the procedure was abandoned during the operation in two patients because of co-morbidities and was not technically feasible and safe in one patient. Pelvic and paraaortic lymphadenectomy were performed in 27/30 and 18/30 of patients, respectively. The mean number of pelvic lymph nodes harvested was 18.6 ± 10.6 . The mean number of harvested paraaortic lymph nodes was 10.5 ± 5.4 . The mean blood glucose level was 110 ± 23.1 mg/dL. The mean CA-125 level was 25.5 ± 39.1 IU/mL. Thirteen percent of patients had CA-125 higher than the reference value of 35 IU/mL. Seven percent of patients had thrombocytosis. There was no positive cytology.

Agreement between positron emission tomography-computed tomography and pathologic findings

The mean primary tumor diameter was reported as 4.2 ± 1.8 cm in PET-CT. The mean primary tumor diameter was measured as 5.8 ± 3.2 cm in the specimen. The effect size was found to be -0.60 , indicating a modest change in diameter of tumor in PET-CT and histopathology. Tumor diameter was poorly correlated with measurements taken in PET-CT. Consistency and absolute agreement of PET-CT and histopathologic analyses are shown in Table 1 and Figure 1.

Thirty-three percent had myometrial invasion in PET-CT; however, 93.3% had myometrial invasion in the specimen. A kappa value of 0.06 [95% confidence interval (CI): $-0.0303-0.168$] was found for myometrial invasion in PET-CT and histopathology.

Pelvic lymph node metastasis was reported in 22.2% in the PET-CT reports. However, 3.7% of patients had pelvic lymph node metastasis. The kappa value for pelvic lymph node metastasis was 0.23 (95% CI: $-0.15-0.62$). There was fair consistency between PET-CT and histopathologic findings, and the sensitivity, specificity, and positive and negative predictive values were 100%, 80.7%, 16.6%, and 100%, respectively. Paraaortic lymph node metastasis in PET-CT was suspected in

10%. However, paraaortic lymph node metastasis was found in 6.7% in histopathologic analyses. The kappa value was 0.15 (95% CI: -0.0749-0.387). There was no agreement between PET-CT and histopathologic findings. The sensitivity, specificity, and positive and negative predictive values of PET-CT for detecting paraaortic lymph node metastases were 100%, 93.7%, 66.6%, and 100%, respectively.

Factors effecting primary tumor maximum standardized uptake value

Myometrial invasion and tumor diameter were the only significant factors affecting SUV_{max} (Tables 2, 3). The median SUV_{max} of tumors with no myometrial invasion was 5.2. However, the median SUV_{max} of tumors with myometrial invasion less than 50% and more than 50% were 10.6 and 18.4, respectively (Figure 2). Primary SUV_{max} was not statistically significantly higher in high grade, LVSI positive, and lymph node positive patients. Tumor size and SUV_{max} were correlated; as the tumor size enlarged, SUV_{max} values increased (Table 3). SUV_{max} was not affected by high CA-125 values or thrombocytosis.

Discussion

Pre-operative imaging in endometrium cancer may help to plan surgery by adding or omitting staging procedures. Secondly, imaging may help to identify candidates for fertility-sparing treatment. Another indication of pre-operative imaging could be in patients who cannot undergo surgery because of comorbidities⁽⁴⁾. We found the efficacy of ¹⁸F-FDG/PET-CT was low in endometrium cancer, and ¹⁸F-FDG/PET-CT was not in concordance with histopathologic findings. We also analyzed prognostic factors that affected SUV_{max} values. The number of studies in this regard is few and the results conflicting^(5,6); most detected only lymph node metastasis, rather than other clinicopathologic prognostic factors.

Women with endometrium cancer are stratified into risk groups for recurrence and treatment planning. The French Multicenter Collaboration study and others identified that tumor size larger than 2-3 cm was a poor prognostic factor⁽⁷⁻⁹⁾. Tumor size is correlated with myometrial invasion, nodal metastases, peritoneal cytology, CA-125 levels, advanced disease, and relapse^(8,9). The size of the primary tumor was moderately consistent with histopathologic tumor measurement, and tumor diameter was predicted smaller in PET-CT scans in our study.

Myometrial invasion is a part of staging in endometrium cancer, and PET-CT was not useful in predicting myometrial invasion; 33% of patients had myometrial invasion in PET-CT, whereas 93.3% had myometrial invasion in the specimen. The sensitivity and specificity of CT in detecting myometrial invasion range from 40% to 83% and 42% to 75%, respectively⁽¹⁰⁾. Sudo et al.⁽¹¹⁾ reported that patients with endometrium cancer should first be triaged by myometrial invasion in magnetic resonance imaging (MRI) before PET-CT. Their report on 37 patients with endometrium cancer showed that PET-CT could identify risk groups after MRI triage. FDG/PET-CT has limitations in the evaluation of the depth of myometrial invasion and in defining tumor borders⁽¹²⁾.

Lymphatic metastases are one of the most important prognostic factors in endometrium cancer. There are various imaging modalities to assess for lymph node metastasis before surgery. Park et al.⁽¹³⁾ compared PET-CT and MRI to detect lymph node metastases in patients with endometrial cancer, and reported that the sensitivity and specificity of FDG/PET-CT was better than MRI for detecting metastatic lymph nodes in patients with endometrial cancer. Pelvic and paraaortic lymph node metastases were over-estimated by FDG/PET-CT in our study. We found fair consistency for pelvic lymph nodes and no consistency for paraaortic lymph nodes. Our findings for




Figure 1. Tumor size estimate in positron emission tomography-computed tomography and histopathologic measurement
PET/CT: Positron emission tomography/Computed tomography

Table 1. Intraclass correlation coefficient analyses for tumor diameter

Consistency	Intraclass correlation ^a	95% Confidence interval
Single measures ^b	0.64	0.37 to 0.81
Average measures ^c	0.78	0.54 to 0.89
Absolute	Intraclass correlation ^a	95% Confidence interval
Single measures ^b	0.51	0.19 to 0.73
Average measures ^c	0.67	0.32 to 0.84

^aThe degree of absolute agreement among measurements, ^bEstimates the reliability of single ratings, ^cEstimates the reliability of averages of κ ratings

detecting lymph node metastases using FDG/PET-CT are in agreement with other studies. Gholkar et al.⁽¹⁴⁾ reported that FDG/PET-CT had a sensitivity of 100%, specificity of 61.11%, positive predictive value of 22.22%, negative predictive value of 100%, and accuracy of 65% for pelvic lymph node metastases; sensitivity of 100%, specificity of 66.67%, positive predictive

value of 20%, negative predictive value of 100%, and accuracy of 69.23%⁽¹⁵⁾. The high sensitivity and negative predictive value of FDG/PET-CT are important in the detection of patients who are truly lymph node-negative⁽¹⁵⁾. However, FDG/PET-CT has a high false positive rate for lymph nodes. Besides, FDG/PET-CT cannot detect metastatic lymph nodes smaller than 5 mm⁽¹⁵⁾.




Figure 2. A 60-year-old female with endometrial cancer. Fluoro-D-glucose/positron emission tomography-computed tomography images demonstrate increased fluoro-D-glucose uptake in the tumor (a,b) and metastatic inter aortocaval lymph node (c,d)

Table 2. Maximum standardized uptake value and histopathologic prognostic factors

		SUV _{max} median	SUV _{max} IQR	p
Histology	Endometroid	14.2	9.8	0.51
	Serous	15.8	7	
Grade	Low (grade1/2)	13.3	9.8	0.16
	High (grade 3)	15.8	7	
Myometrial invasion	No invasion	5.2	4.5	0.03
	Invasion	15.1	9.2	
LVSI	Negative	15.1	10	0.66
	Positive	11.7	3.7	
Myometrial invasion	(a) No	5.2	4.5	Different from c
	(b) <50%	10.6	8.2	Different from c
	(c) >50%	18.4	4	Different from a, b 0.004
Lymph node metastasis	Negative	15.1	9.5	NA
	Positive	16.2	-	
CA-125	Normal	13.6	10.1	0.37
	Elevated	15.5	8.4	
Thrombocyte	Normal	14.9	8.6	1
	Thrombocytosis	14.2	-	

p<0.05 statistically significant

NA: Non-applicable, statistical evaluation not appropriate, LVSI: Lymphovascular space invasion, CA-125: Cancer antigen-125, IQR: Interquartile range, SUV: Standardized uptake values

Table 3. Regression analyses between primary tumor maximum standardized uptake value and tumor diameter
primary tumor maximum standardized uptake value=8.03+1.06 diameter

Parameter	Coefficient	Standard error	95% CI	t	p
Intercept	8.03	2.10	3.69 to 12.38	3.81	0.0008
Slope	1.06	0.30	0.44 to 1.68	3.53	0.0017

CI: Confidence interval

Analyses of prognostic factors and SUV_{max} values showed that SUV_{max} was significantly higher in patients with deeper myometrial invasion and higher tumor diameter. However, we found no correlation between SUV_{max} and tumor histology, tumor grade, lymphovascular invasion, and lymph node metastases in contrast to other reports^(16,17). Kitajima et al.⁽¹⁸⁾ reported that SUV_{max} was not a good index for preoperative stratifying patients into high risk and low risk, and suggested the use of metabolic tumor volume and total lesion glycolysis instead of SUV_{max} .

Study Limitations

The limitations of our study were similar to other reports; its design was retrospective, and a relatively small number of patients were included in a single tertiary center. Another limitation of our study may be that paraaortic lymphadenectomy was not performed in all cases due to technical considerations or due to other pathologic findings indicating low risk.

There are also diagnostic limitations of FDG/PET-CT in endometrial cancer due to the natural slow progress of the disease. The majority of patients with endometrial cancer have the endometrioid type, are early stage and low risk without lymph node metastases. The low prevalence of poor prognostic factors may cause a bias towards a lower positive predictive value and higher negative predictive value. We did not stratify patients by preoperative histopathologic findings or other imaging techniques. We rather preferred to include a non-stratified population of patients who were referred to the gynecologic oncology department in one year.

Conclusion

Surgical staging and obtaining prognostic factors using the FIGO staging is the standard of treatment for endometrial cancer, although lymphadenectomy for early-stage low-risk patients is controversial. Although the pre-operative use of PET-CT in endometrium cancer is increasing, the results of our study and others cast doubt on the diagnostic efficacy of PET-CT in endometrium cancer⁽¹⁹⁾. The indications of FDG/PET-CT in endometrium cancer should be revised and studied further.

Ethics

Ethics Committee Approval: This study was approved by Ethical Committee of Süleyman Demirel University (approval number: 54).

Informed Consent: Consent form was obtained from all participants.

Peer-review: Internally peer-reviewed.

Authorship Contributions

Surgical and Medical Practices: E.E., S.S.Ç., Concept: E.E., E.E., Design: E.E., S.S.Ç., Data Collection or Processing: B.T., Y.Y., Analysis or Interpretation: E.E., Literature Search: E.E., Y.Y., Writing: E.E., E.E.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study received no financial support.

References

- SEER Stat Fact Sheets: Endometrial Cancer <http://seer.cancer.gov/statfacts/html/corp.html>
- Berretta R, Patrelli TS, Migliavacca C, Rolla M, Franchi L, Monica M, et al. Assessment of tumor size as a useful marker for the surgical staging of endometrial cancer. *Oncol Rep* 2014;31:2407-12.
- Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer: Gynecologic Oncology Group study. *Cancer* 1987;60(8 Suppl):2035-41.
- Iglesias DA, Huang M, Soliman PT, Djordjevic B, Lu KH. Endometrial hyperplasia and Cancer. In: Karlan B, Bristow R, Li Aw (eds). *Gynecologic Oncology: Clinical Practice and Surgical Atlas* (Kindle Location 4104). McGraw-Hill Education; 2012.
- Kitajima K, Murakami K, Kaji Y, Sakamoto S, Sugimura K. Established, emerging and future applications of FDG-PET/CT in the uterine cancer. *Clin Radiol* 2011;66:297-307.
- Chang MC, Chen JH, Liang JA, Yang KT, Cheng KY, Kao CH. 18F-FDG PET or PET/CT for detection of metastatic lymph nodes in patients with endometrial cancer: a systematic review and meta-analysis. *Eur J Radiol* 2012;81:3511-7.
- Mariani A, Webb MJ, Keeney GL, Haddock MG, Calori G, Podratz KC. Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary. *Am J Obstet Gynecol* 2000;182:1506-19.
- Bendifallah S, Canlorbe G, Huguet F, Coutant C, Hudry D, Graesslin O, et al. A risk scoring system to determine recurrence in early-stage type 1 endometrial cancer: a French multicentre study. *Ann Surg Oncol* 2014;21:4239-45.
- Tuomi T, Pasanen A, Luomaranta A, Leminen A, Bützow R, Loukovaara M. Risk-stratification of endometrial carcinomas revisited: a combined preoperative and intraoperative scoring system for a reliable prediction of an advanced disease. *Gynecol Oncol* 2015;137:23-7.
- Hardesty LA, Sumkin JH, Hakim C, Johns C, Nath M. The ability of helical CT to preoperatively stage endometrial carcinoma. *AJR Am J Roentgenol* 2001;176:603-6.
- Sudo S, Hattori N, Manabe O, Kato F, Mimura R, Magota K, et al. FDG PET/CT diagnostic criteria may need adjustment based on MRI to estimate the presurgical risk of extrapelvic infiltration in patients with uterine endometrial cancer. *Eur J Nucl Med Mol Imaging* 2015;42:676-84.
- Avril N, Gourtsoyianni S, Reznik R. Gynecological cancers. *Methods Mol Biol* 2011;727:171-89.
- Park JY, Kim EN, Kim DY, Suh DS, Kim JH, Kim YM, et al. Comparison of the validity of magnetic resonance imaging and positron emission tomography/computed tomography in the preoperative evaluation of patients with uterine corpus cancer. *Gynecol Oncol* 2008;108:486-92.
- Gholkar NS, Saha SC, Prasad G, Bhattacharya A, Srinivasan R, Suri V. The Accuracy of Integrated [(18)F] Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Detection of Pelvic and Para-aortic Nodal Metastasis in Patients with High Risk Endometrial Cancer. *World J Nucl Med* 2014;13:170-7.

15. Signorelli M, Guerra L, Buda A, Picchio M, Mangili G, Dell'Anna T, et al. Role of the integrated FDG PET/CT in the surgical management of patients with high risk clinically early stage endometrial cancer: detection of pelvic nodal metastases. *Gynecol Oncol* 2009;115:231-5.
16. Lee DW, Chong GO, Lee YH, Hong DG, Cho YL, Jeong SY, et al. Role of SUVmax and GLUT-1 Expression in Determining Tumor Aggressiveness in Patients With Clinical Stage I Endometrioid Endometrial Cancer. *Int J Gynecol Cancer* 2015;25:843-9.
17. Nakamura K, Kodama J, Okumura Y, Hongo A, Kanazawa S, Hiramatsu Y. The SUVmax of 18F-FDG PET correlates with histological grade in endometrial cancer. *Int J Gynecol Cancer* 2010;20:110-5.
18. Kitajima K, Suenaga Y, Ueno Y, Maeda T, Ebina Y, Yamada H, et al. Preoperative risk stratification using metabolic parameters of (18) F-FDG PET/CT in patients with endometrial cancer. *Eur J Nucl Med Mol Imaging* 2015;42:1268-75.
19. Nogami Y, Banno K, Irie H, Iida M, Kisu I, Masugi Y, et al. The efficacy of preoperative positron emission tomography-computed tomography (PET-CT) for detection of lymph node metastasis in cervical and endometrial cancer: clinical and pathological factors influencing it. *Jpn J Clin Oncol* 2015;45:26-34.



A comparison of normal and high post-void residual urine and urodynamic parameters in women with overactive bladder

Aşırı aktif mesanesi olan kadınlarda normal ve artmış işeme sonrası rezidülerin ve ürodinamik parametrelerin karşılaştırılması

Hediye Dağdeviren, Hüseyin Cengiz, Çağlar Helvacıoğlu, Ulkar Heydarova, Cihan Kaya, Murat Ekin

University of Health Sciences, Bakırköy Dr. Sadi Konuk Training and Research Hospital, Clinic of Obstetric and Gynecology, İstanbul, Turkey

Abstract

Objective: To investigate voiding functions and assess the relationships of voiding parameters to overactive bladder symptoms and postvoiding residue volumes.

Materials and Methods: This is a retrospective study analyzing urodynamic parameters in patients who were diagnosed as having overactive in our urogynecology clinic between April 2014 and April 2016. A total of 290 women who met the selection criteria were included in the study. The patients were divided into two groups according to postvoiding residue volumes: group 1, postvoiding residue volumes <100 mL (n=135); group 2, postvoiding residue volumes ≥100 mL (n=155).

Results: A total of 290 women were included in the study; the mean age was 71.4 years. A total of 158 (54.5%) patients had detrusor over-activity during urodynamic testing. The mean maximum bladder capacity in elevated group 2 (postvoiding residue volumes ≥100 mL) was significantly higher than in group 1 (postvoiding residue volumes <100 mL) (p<0.01). Additionally, there was a significant difference between detrusor pressure at Q_{max} in both study groups (p<0.05). There were no significant differences in the first-sensation volume between the normal and elevated postvoiding residue volumes groups.

Conclusion: In conclusion, patients with overactive with elevated postvoiding residue volumes showed increased maximum bladder capacity, but detrusor over-activity was not more prevalent in these women compared with women with normal postvoiding residue volumes.

Keywords: Residue urine, urodynamics, voiding, bladder pressure

Öz

Amaç: Çalışmanın amacı işeme fonksiyonlarını ve işeme fonksiyonları ile aşırı aktif mesane semptomları ve işeme sonrası rezidü idrar volümünü arasındaki ilişkiyi değerlendirmektir.

Gereç ve Yöntemler: Çalışmada 2014 Nisan ile 2016 Nisan arasında ürojinekoloji kliniğimizde aşırı aktif mesane tanısı alan hastaların ürodinamik parametrelerini geriye dönük olarak değerlendirdik. Çalışmaya seçilme kriterlerini karşılayan 290 hasta dahil edildi. Hastalar işeme sonrası rezidü miktarlarına göre 2 gruba bölündü: Grup 1, rezidü <100 mL (n=135); grup 2, rezidü ≥100 mL (n=155).

Bulgular: Toplam 290 hasta çalışmaya dahil edildi ve hastaların ortalama yaşları 71,4 idi. Ürodinamik testler sonucunda toplam 158 hastada (54,5%) detrusor aşırı aktivitesi saptandı. Grup 2'deki (rezidü ≥100 mL) hastaların ortalama mesane kapasitesi grup 1'deki (rezidü <100 mL) hastalardan belirgin olarak yüksekti (p<0,01). Ayrıca 2 grup arasındaki maksimum akış hızındaki detrusor basınçları belirgin olarak farklıydı (p<0,05). Ancak 2 grup arasında hastaların ilk idrar hissi miktarında belirgin fark yoktu.

Sonuç: Sonuç olarak; artmış rezidü idrar volümüne sahip aşırı aktif mesaneli hastalarda artmış maksimum mesane kapasitesi gözlenirken, bu grupta işeme sonrası normal rezidüye sahip olan gruba göre detrusor aşırı aktivitesi prevalansı daha fazla değildi.

Anahtar Kelimeler: Rezidü idrar, ürodinami, işeme, mesane basıncı

PRECIS: We studied urodynamic parameters and their clinical importance in patients with overactive bladders.

Address for Correspondence/Yazışma Adresi: Hediye Dağdeviren, MD,

University of Health Sciences, Bakırköy Dr. Sadi Konuk Training and Research Hospital, Clinic of Obstetric and Gynecology, İstanbul, Turkey

Phone: +90 553 616 13 85 E-mail: hedyedagdeviren@gmail.com ORCID ID: orcid.org/0000-0002-9384-4514

Received/Geliş Tarihi: 16.12.2016 Accepted/Kabul Tarihi: 18.10.2017

©Copyright 2017 by Turkish Society of Obstetrics and Gynecology

Turkish Journal of Obstetrics and Gynecology published by Galenos Publishing House.

Introduction

Urinary incontinence is defined as involuntary leakage of urine^(1,2). It is estimated that between 26 and 61% of women receive care for urinary incontinence in their lifetime^(3,4). Overactive bladder (OAB) is a term that describes a syndrome of urinary urgency with or without incontinence, often accompanied by nocturia and urinary frequency^(5,6).

Urodynamics comprises a group of tests used to evaluate urinary tract function. Urodynamic testing is a simple and non-invasive procedure for evaluating lower urinary tract symptoms. It is also a way of assessing maximum flow rate (Q_{maximum} ; Q_{max}), average flow rate (Q_{average} ; Q_{ave}), bladder capacity, and post-void residual (PVR) urine⁽⁷⁾.

Voiding dysfunction is a broad term. It is defined by the International Urogynecological Association/International Continence Society as “incomplete micturition or abnormally slow micturition⁽⁸⁾.” It is the cause of elevated PVR. Parameters for interpreting the results of PVR testing are neither standardized nor well evaluated. In general, a PVR of less than one-third of total voided volume is considered adequate emptying^(9,10). Additional parameters include designation of PVR greater than 100 mL as abnormal⁽¹¹⁾.

Urodynamic parameters and their clinical importance in patients with OAB have not been well studied. Therefore, we explored voiding functions and assessed the relationships of voiding parameters with OAB symptoms and PVR volumes.

Materials and Methods

The patients' data were retrospectively collected from the hospital medical records. We analyzed urodynamic parameters in patients who diagnosed as having OAB in our urogynecology clinic between April 2014 and April 2016. All patients signed informed consent forms. The same researchers (H.D. and C.H.) conducted retrospective chart reviews for all patients with OAB. A total of 290 women who met the selection criteria were included in the study. The patients were divided into two groups according to PVR: group 1, PVR <100 mL (n=135); group 2, PVR ≥100 mL (n=155).

OAB syndrome is defined as urinary urgency with or without urge incontinence, typically associated with increased daytime frequency and nocturia⁽¹²⁾. Detrusor over-activity (DO) is a urodynamic symptom characterized by involuntary detrusor contractions during the filling phase, which may be spontaneous or provoked⁽¹⁾.

Exclusion criteria were patients with pure stress incontinence, allergic diseases such as asthma, history of psychiatric disorders, urinary tract infection, urinary obstructive disease, metabolic diseases, neurologic disorders, and current use of diuretics.

All urodynamic tests were conducted by the same registered nurse and author (H.C.); the same instructions were used to prepare patients, and the same urodynamic machine was used for testing. Patients were evaluated using a multi-channel MMS® Solar (ADS, Ltd., Enschede, The Netherlands) urodynamic study

device. Filling cystometry and uroflowmetry were performed. Also residual urine was measured. Isotonic saline was infused at a rate of 50 mL/min at room temperature for the filling. The patients were in the semi-sitting position. After the urinary bladder was full, volumes at first sensation of urination (mL), feeling the need to urinate (mL), feeling the need to urinate immediately (mL), bladder capacity (mL), and compliance (mL/cm H₂O) were measured. Detrusor contractions present after 15 cm H₂O that could not be inhibited were recorded. During the procedure, maneuvers such as coughing and straining were performed to assess whether urinary leakage from the external meatus occurred. The results of urodynamic tests were interpreted and reported by a urogynecologist (H.C.) using an identical reporting form. Catheters for vesical and abdominal pressures were reset before placement of the catheters.

The filling sensations assessed as volumes at first sensation; first urge sensation; strong urge sensation; and bladder capacity. After reaching cystometric bladder capacity, all women were given permission to void. Each woman was repositioned to an upright position. In this position they could void without abdominal pressure. After the measurement of pressures, PVR volume was measured by a nurse who attached a urethral catheter. Bladder capacity was calculated. The values of Q_{max} and detrusor pressure at Q_{max} were calculated from the pressure-flow testing.

Statistical Analysis

Statistical analysis was performed using the Number Cruncher Statistical System 2007 statistical software. The mean differences between groups were compared using Student's t-test, and the Mann-Whitney U and independent-samples t-test were applied for comparisons of median values. Logistic regression analyses were conducted to determine the association between voiding parameters and PVR volume. A p value less than 0.05 was considered statistically significant.

Results

A total of 290 women were included in the study; the mean age was 71.4 years. Table 1 shows the characteristics of the women. A total of 158 (54.5%) patients had DO during urodynamic testing. The mean maximum bladder capacity in elevated group 2 (PVR ≥100 mL) was significantly higher than in group 1 (PVR <100 mL) (p<0.01). Additionally, there was a significant difference between detrusor pressure at Q_{max} in both study groups (p<0.05). There were no significant differences in first-sensation volume between the normal and elevated PVR groups. Women with elevated PVR had significantly higher voided volume and maximum flow rates than did women with normal PVR. Additionally, we found no significant difference in DO between the two groups (p=0.282). Table 2 shows a comparison of urodynamic parameters through PVR volumes. Table 3 shows the results of logistic regression analysis to determine the best predictor(s) to discriminate between the groups.

Discussion

Urodynamic evaluation is a non-invasive process that provides objective and subjective data about bladder functioning. Measurements of urine flow and PVR with uroflowmetry are important parameters. There are some parameters that affect the urine flow rate including voided volume, detrusor contractibility, and bladder outlet obstruction. The purpose of this study was to evaluate urodynamic parameters in women who had OAB symptoms and either normal or elevated PVR volumes. There were 290 medical records for the analyses in the clinical setting.

During urodynamic testing, 158 (54.8%) women showed DO. In this study we find that nearly 50% of patients with OAB had DO on urodynamics testing. Our results are compatible with previous studies^(11,13,14). Additionally, Futyma et al.⁽¹⁵⁾ observed DO in less than 20% of patients with OAB, which is much lower than the values in other studies where DO was found in more than 50% of patients. The authors believed that the difference in DO prevalence was associated with patients' performing maneuvers during the test that may have provoked urinary responses. The differences among studies may reflect differences in patient selection criteria before data analysis. Jeong et al.⁽¹⁶⁾

Table 1. Characteristics of the study groups

	Group 1		Group 2		p
	Normal PVR (<100 mL)		Elevated PVR (≥100 mL)		
	Mean ± SD/n-%	Median	Mean ± SD/n-%	Median	
Age	71.5±5.3	71	71.3±5.1	71	0.755
Vaginal parity (number)	2.5±1.3	2	2.4±1.5	2	0.271
Body mass index	31.0±5.0	31	30.4±4.8	30	0.302

PVR: Postvoiding residual urine, SD: Standart Deviation

Table 2. Comparison of urodynamic parameters through post-void residual volumes

	Group 1		Group 2		p
	Normal PVR (<100 mL)		Elevated PVR (≥100 mL)		
	Mean ± SD/n-%	Median	Mean ± SD/n-%	Median	
Max flow rate	26.7±12.7	24	30.3±11.8	28	0.002
Voiding volume	335.3±171.2	318	457.6±226.2	411	<0.001
Max bladder capacity	429±84.7	437	503.5±67	500	<0.001
Voiding efficiency vol/capacity*100	80.4±44.1	76	92.5±47.4	87	0.011

PVR: Postvoiding residual urine, SD: Standart Deviation

Table 3. Logistic regression analysis of voiding parameters though post-voidal residual urine in patients with overactive bladder

	OR	Univariate model	
		95% CI	p
Max flow rate	1.03	1.01-1.05	0.013
Voiding volume	1.00	1.00-1.00	<0.001
Max bladder capacity	1.01	1.01-1.02	<0.001
Voiding efficiency vol/capacity*100	1.01	1.00-1.01	0.030
First sensation volume	1.00	1.00-1.00	0.671
Detrusor overactivity	0.78	0.49-1.23	0.282
Valsalva leak point pressure	1.01	1.01-1.02	<0.001
Vesical pressure at Q _{max}	0.98	0.97-1.00	0.051
Abdominal pressure at Q _{max}	0.98	0.97-1.00	0.025
Detrusor pressure at Q _{max}	0.99	0.97-1.00	0.048

OR: Odds ratio, CI: Confidence interval

observed higher Q_{\max} detrusor pressures than were found in our study. We hypothesized that the difference might be explained by the age differences of the study samples. The mean age in the present study was 71 years, whereas in Jeong et al.⁽¹⁶⁾ the mean age was 58.9 years. It has been established that bladder and uretral profiles change with age. Women who had voided less than 100 mL (n=18) were excluded from the present study because the minimum voided volume for reliable urine flow rate in persons aged 56-80 years is 100 mL⁽¹⁷⁾.

PVR volume can be measured using uroflowmetry or pressure-flow studies. These tests are non-invasive. Previous reports reflected a debate regarding the measurement of residual urine volume. Specifically, when voided volume was greater than 300 mL, the mean PVR volumes were not significantly different between non-invasive uroflowmetries and pressure flow studies⁽¹⁸⁾. Therefore, further studies on the differences in PVR volume in relation to voided volume and type of testing are required. Other limitations of the current study are related to its retrospective design. We did not use a bladder diary data to examine the women's naturally voided volume.

Conclusion

Patients with OAB with elevated PVR volumes showed increased maximum bladder capacity, but DO was not more prevalent in these women compared with women with normal PVR volumes.

Ethics

Ethics Committee Approval: Retrospective study.

Informed Consent: Retrospective study.

Peer-review: Externally peer-reviewed.

Authorship Contributions

Surgical and Medical Practices: H.D., H.C., Concept: U.H., Design: M.E., Data Collection or Processing: Ç.H., Analysis or Interpretation: C.K., Literature Search: H.C., Writing: H.D.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study received no financial support.

References

- Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. *Neurourol Urodyn* 2002;21:167-78.
- Griffiths AN, Makam A, Edwards GJ. Should we actively screen for urinary and anal incontinence in the general gynaecology outpatients setting? A prospective observational study. *J Obstet Gynecol* 2006;26:442-4.
- Harris SS, Link CL, Tennstedt SL, Kusek JW, McKinlay JB. Care seeking and treatment for urinary incontinence in a diverse population. *J Urol* 2007;177:680-4.
- Morrill M, Lukacz ES, Lawrence JM, Nager CW, Contreras R, Lubner KM. Seeking healthcare for pelvic floor disorders: a population-based study. *Am J Obstet Gynecol* 2007;197:86.
- Nygaard I. Clinical practice. Idiopathic urgency urinary incontinence. *N Engl J Med* 2010;363:1156-62.
- Abrams P, Andersson KE, Birder L, Brubaker L, Cardozo L, Chapple C, et al. Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. *Neurourol Urodyn* 2010;29:213-40.
- Gupta NP, Kumar A, Kumar R. Does position affect uroflowmetry parameters in women? *Urol Int* 2008;80:37-40.
- Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J. An international Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. *Neurourol Urodyn* 2010;29:4-20.
- Al Afraa T, Mahfouz W, Campeau L, Corcos J. Normal lower urinary tract assessment in women: I. Uroflowmetry and post-void residual, pad tests, and bladder diaries. *Int Urogynecol J* 2012;23:681-5.
- Nager CW, Albo ME, Fitzgerald MP, McDermott S, Wruck L, Kraus S, et al. Reference urodynamic values for stress incontinent women. *Neurourol Urodyn* 2007;26:333-40.
- Park J, Lavelle JP, Palmer MH. Voiding dysfunction in older women with overactive bladder symptoms: a comparison of urodynamic parameters between women with normal and elevated post-void residual urine. *Neurourol Urodyn* 2016;35:95-9.
- Abrams P, Artibani W, Cardozo L, Dmochowski R, van Kerrebroeck P, Sand P, et al. Reviewing the ICS 2002 terminology report: the ongoing debate. *Neurourol Urodyn* 2009;28:287.
- Guralnick ML, Grimsby G, Liss M, Szabo A, O'Connor RC. Objective differences between overactive bladder patients with and without urodynamically proven detrusor overactivity. *Int Urogynecol J* 2010;21:325-9.
- Digesu GA, Khullar V, Cardozo L, Salvatore S. Overactive bladder symptoms: Do we need urodynamics? *Neurourol Urogyn* 2003;22:105-8.
- Futyma K, Nowakowski Ł, Bogusiewicz M, Ziętek A, Wiczorek AP, Rechberger T. Use of uroflow parameters in diagnosing an overactive bladder-Back to the drawing board. *Neurourol Urodyn* 2017;36:198-202.
- Jeong SJ, Lee SC, Jeongok CW, Hong SK, Byun SS, Lee SE. Clinical and urodynamic differences among women with overactive bladder according to the presence of detrusor overactivity. *Int Urogynecol J* 2013;2:255-61.
- Abrams P. The Practice of urodynamics. In: Mundy AR, Stephenson TP, Wein AJ (eds). *Urodynamic principles, practice and application*. Edinburgh: Churchill-Livingstone; 1984.
- Groutz A, Blaivas JG, Sassone AM. Detrusor pressure uroflowmetry studies in women: effect of a 7Fr transurethral catheter. *J Urol* 2000;164:109-14.



Depression and anxiety disorder in hyperemesis gravidarum: A prospective case-control study

Hiperemesis gravidarumlu kadınlarda depresyon ve anksiyete bozukluğu: Prospektif olgu kontrol çalışması

Yusuf Topal Ahmetoğlu, Mehmet Metin Altay, Derya Akdağ Cırık, Yusuf Aytaç Tohma, Eser Çolak, Bora Çoşkun, Orhan Gelişen

University of Health Sciences, Etlik Zübeyde Hanım Women's Health Training and Research Hospital, Clinic of Obstetrics and Gynecology, Ankara, Turkey

Abstract

Objective: To assess the anxiety and depression status of women with hyperemesis gravidarum (HG); the risk factors for developing both depression and anxiety in women with HG were evaluated.

Materials and Methods: A total of 200 women, 100 diagnosed as having HG before the 20th week of gestation at a tertiary referral center and 100 gestational-age-matched controls were enrolled. The socio-demographic data and the depression and anxiety scores, as assessed using the Beck depression and anxiety inventory were compared between the two groups.

Results: The median depression and anxiety scores were significantly higher in the HG group compared with controls (19.5 vs. 9.0 and 22.0 vs. 10.0). Women with HG have the highest relative risks for moderate depression and severe anxiety [relative risk (RR): 16.88 and RR: 20.50, respectively]. In the univariate analysis, having HG, low education level, low income and poor social relationships were significant predictors of depression and having HG. Moreover, poor social relationships significantly predicted the presence of anxiety disorder. However, having HG and poor social relationships were found as the only independent predictors of both depression and anxiety. Patients with HG were 5.5 and 6.7 times more prone to having depression and anxiety disorder compared with controls, respectively.

Conclusion: Both depression and anxiety disorder were more frequent in women with HG who have weak family and social relationships, lower education and income levels. Therefore, the determination of the psychological status of women with HG should be an integral part of the evaluation.

Keywords: Hyperemesis gravidarum, pregnancy, depression, anxiety disorder

Öz

Amaç: Araştırmanın birincil amacı, hiperemesis gravidarum (HG) olan kadınların anksiyete ve depresyon durumlarını değerlendirmektir. Ayrıca, tüm gruptaki depresyon ve anksiyete için risk faktörlerini de değerlendirdik.

Gereç ve Yöntemler: Gebeliğin 20. haftasından önce üçüncü basamak bir merkezde HG teşhisi konan 100 kadın ve gebelik haftası eşleştirilen 100 kontrol olmak üzere toplam 200 kadın çalışmaya dahil edildi. Sosyo-demografik veriler ve Beck depresyon ve anksiyete envanteri ile değerlendirilen depresyon ve anksiyete skorları iki grup arasında karşılaştırıldı.

Bulgular: Medyan depresyon ve anksiyete skorları HG grubunda kontrol grubuna göre anlamlı derecede yüksekti (sırasıyla 19,5 ve 9,0 ve 22,0 ve 10,0). Orta sınıf depresyon ve şiddetli kaygı açısından HG'li kadınlar en yüksek relatif riske sahipti [relatif risk (RR): 16,88 ve RR: 20,50]. Tek değişkenli analizde; düşük eğitim düzeyi, düşük gelir ve zayıf sosyal ilişkiler depresyon ve HG'ye sahip olma yönündeki prediktif belirteçlerdir, zayıf sosyal ilişkiler anksiyete bozukluğunu önemli ölçüde öngörmüştür. Bununla birlikte, çok değişkenli analiz sonrası depresyon ve anksiyete bozukluğunun bağımsız öngördürücüleri olarak sadece HG ve zayıf sosyal ilişkiler bulunmuştur. HG hastalarının, kontrol grubuna göre depresyon ve anksiyete bozukluklarına sırasıyla 5,5 ve 6,7 kat daha fazla eğilimli olduğu bulundu.

Sonuç: Depresyon ve anksiyete bozukluğunun her ikisi de HG'li, zayıf aile ve sosyal ilişki, düşük eğitim ve düşük gelirli kadınlarda görülmüştür. Bu nedenle, özellikle düşük sosyo-ekonomik popülasyonlar için, hastaların psikolojik durumu, HG değerlendirmesinin vazgeçilmez bir parçası olmalıdır.

Anahtar Kelimeler: Hiperemesis gravidarum, gebelik, depresyon, anksiyete bozukluğu

PRECIS: We showed that having weak family and social relationships, lower socio-economic status played an important role in the development of depression and anxiety in pregnant women.

Address for Correspondence/Yazışma Adresi: Derya Akdağ Cırık, MD,

University of Health Sciences, Etlik Zübeyde Hanım Women's Health Training and Research Hospital, Clinic of Obstetrics and Gynecology, Ankara, Turkey

Phone: +90 506 628 89 30 E-mail: deryaakdag@yahoo.com ORCID ID: orcid.org/0000-0003-0302-051X

Received/Geliş Tarihi: 19.06.2017 Accepted/Kabul Tarihi: 20.10.2017

©Copyright 2017 by Turkish Society of Obstetrics and Gynecology

Turkish Journal of Obstetrics and Gynecology published by Galenos Publishing House.

Introduction

Nausea and vomiting during early pregnancy is very common and generally accepted as a part of normal physiology^(1,2). Hyperemesis gravidarum (HG) is a pregnancy condition characterized by severe nausea and vomiting starting before the 22nd week of gestation. Although it generally ends before the 16th week, HG may be severe in 2% of pregnant women, who require hospitalization^(1,2). Although there is no universally accepted criteria for the diagnosis, HG is characterized by persistent vomiting and nausea, weight loss of more than 5% of pre-pregnancy body weight, ketonuria, electrolyte abnormalities (hypokalemia), and dehydration (high urine specific gravity), resulting in the diminishment of the woman's quality of life and a significant contribution to health care costs and time lost from work due to persistent vomiting⁽³⁾. Despite its frequency, the etiopathogenesis of HG has not yet been clearly elucidated. Many theories based on endocrinologic and metabolic factors, gastrointestinal dysfunction, and immunologic, genetic, and psychological factors have been proposed⁽²⁻⁴⁾. Besides its physical symptoms such as dehydration and electrolyte imbalance, HG can also affect quality of life and the psychological state of pregnant women^(5,6).

Depression is the most common psychological disease seen in women, and encountered in 14% to 48% of pregnant women⁽⁷⁻¹⁰⁾. Although recent studies demonstrated higher rates of depression and anxiety in pregnant women with HG, few studies have evaluated the predictive factors or cause-and-effect relation of these psychological disorders and pregnancy⁽¹¹⁻¹⁵⁾.

In this case-control study, the anxiety and depression disorder of pregnant women with HG was assessed, and we aimed to determine the risk factors for developing both depression and anxiety in pregnant women.

Materials and Methods

The study was conducted in a tertiary care center, Etlik Zübeyde Hanım Women's Health Training and Research Hospital from June 2013 to October 2013. The local ethics committee approved the study (approval number: 2013-165) and all participants gave written informed consent. The trial was performed in accordance with the Declaration of Helsinki. Pregnant women diagnosed as having HG before the 20th week of the current viable pregnancy and required hospitalization for intravenous fluid replacement were included in the study group. Persistent vomiting accompanied by weight loss exceeding 5% of pre-pregnancy body weight, an objective measure of acute starvation (usually large ketonuria on urine analysis), electrolyte abnormalities and acid-base disturbances, was diagnosed as HG. Gestational-age-matched controls were recruited from patients who came for routine antenatal care follow-ups. Patients who had multiple pregnancies, thyroid disease, prior psychiatric disease or conditions with elevated serum human chorionic gonadotropin levels such as gestational trophoblastic diseases and chromosomally abnormal fetus were excluded.

All participants were asked to complete a demographic and socioeconomic data collection form. In this form, patients assessed and rated their relations with other family members and society as strong or weak.

Anxiety and depression scores

The status of depression and anxiety was evaluated using the Beck Depression Inventory (BDI)-II and Beck Anxiety Inventory (BAI). The BDI includes a 21-question self-assessment scale and answers were scored from 0 to 3. BDI scores were grouped as follows: 0-9 as no depression, 10-16 as mild depression, 17-23 as moderate depression, and 24-63 as severe depression. Answers to each question in the BAI were scored from 0 to 3. The BAI scores were classified as follows: 0-7 as no anxiety, 8-15 as mild anxiety, 16-25 as moderate anxiety, and 24-63 as severe anxiety.

Statistical Analysis

Statistical analysis was performed using SPSS 21.0 (IBM Corp. Released 2012. IBM SPSS Statistics for Windows, Version 21.0. Armonk, NY). Univariate analyses to identify variables associated with anxiety and depression were investigated using appropriate statistical tests such as Student's t-test, the chi-square test and Mann-Whitney U tests. The Kruskal-Wallis test was used to compare the anxiety and depression scores between the two groups in terms of different variables. Bonferroni correction was used to test the significance with pairwise differences to adjust multiple comparisons. The association between ordinal variables was investigated, and correlation significance was calculated using the Spearman test. For multivariate analyses, possible factors identified were further entered into the logistic regression analysis to determine the independent predictors of anxiety and depression. A 5% type 1 error was used for the statistical significance.

Results

A total of 100 pregnant women with HG and 100 gestational-age-matched controls were included in the study. The socio-demographic data of all participants are listed in Table 1.

Using BDI, the median depression scores were significantly higher in the HG group compared with controls (19.5 vs. 9.0; $p < 0.001$). Similarly, using BAI, the median anxiety scores were also higher in the HG group compared with controls (22.0 vs. 10.0; $p < 0.001$). The percentage of pregnant women living on minimum wage was nearly double in the HG group compared with controls (61.9% vs. 38.0%; $p = 0.01$). The education level was also significantly lower in the HG group compared with controls such that the percentage of women who graduated from at least high school among the HG and control groups were 40.4% and 59.6%, respectively ($p = 0.005$). Pregnant women who defined their relationship with their families as "weak" had a higher percentage of HG than those who defined them as "strong" (69% vs. 31.0%; $p = 0.027$). Similarly, women who had weak social relations

were also more prone to having HG (63.6% vs. 36.4% $p=0.041$).

When all other possible contributing factors were matched, patients in the HG group had a higher risk of having depression or anxiety (mild, moderate or severe) compared with controls (Table 2). The relative risk of women with HG was highest for moderate depression and severe anxiety (16.88 vs. 20.50).

Data of all participants were analyzed to determine the risk factors for depression and anxiety. HG, lower educational status, lower income, and poor social relationships were the significant risk factors for depression and HG, and poor social relationships was a significant risk factor for anxiety in the entire pregnant population (Table 3). Additionally, HG and poor social relationships were independent risk factors for both depression and anxiety in the entire cohort. Patients with HG

were 5.5 times more prone to having depression and 6.7 times more prone to having anxiety compared with the matched controls. Additionally, risks of having depression and anxiety in pregnant women with poor social relationships were 2.8 and 5.6 times higher, respectively, when compared with controls (Table 4).

Discussion

The psychological theory for describing the pathogenesis of HG suggests that either the presence of conversion or somatization disorder, or the exaggerated response of a patient to stress may cause HG⁽¹⁶⁾. Although nausea and vomiting during pregnancy were more commonly seen in dependent, hysterical, depressive, and anxious women, severe and persistent vomiting itself might also cause the psychological problems in patients⁽¹⁷⁻²²⁾.

Table 1. Socio-demographic characteristics of the hyperemesis and control group

	HG ¹ (n=100)	Control (n=100)	p value
Age (years)	26.0 (9.0)	25.0 (6.0)	0.254
Age at marriage (years)	21.0 (4.0)	20.0 (4.0)	0.741
Gravidity	2.0 (2.0)	2.0 (2.0)	0.859
Parity	1.0 (1.0)	1.0 (1.0)	0.775
Paid employment	21 (21%)	16 (16%)	0.363
Low income ²	60 (60%)	37 (37%)	0.001
High school graduate	42 (42%)	62 (62%)	0.005
Poor relationships	20 (20%)	9 (9%)	0.027
Poor social relationships	28 (28%)	16 (16%)	0.041
Depression score	19.5 (11.0)	9.0 (8.8)	<0.001
Anxiety score	22.0 (14.5)	10.0 (11.8)	<0.001

Data presented as median (interquartile) and number (percentage)
¹HG: Hyperemesis gravidarum
²Monthly income of less than 1070 Turkish Liras (approximately USD 480)

Table 2a. The relative risk of depression (a) or anxiety (b) in the hyperemesis and control groups

HG control ¹	Odds ratio	95% CI ² Min; Max	p value
Mild depression	2.53	1.14; 5.60	0.022
Moderate depression	16.88	7.18; 39.66	<0.001
Severe depression	3.86	1.21; 12.28	0.022

¹Hyperemesis gravidarum group compared to controls, ²Confidence interval
HG: Hyperemesis gravidarum, Min-Max: Minimum-Maximum, CI: Confidence interval

Table 2b. The relative risk of anxiety (b) in the hyperemesis and control groups

HG ¹ control	Odds ratio	95% CI ² Min; Max	p value
Mild anxiety	2.62	1.05; 6.56	0.039
Moderate anxiety	9.11	3.64; 22.79	<0.001
Severe anxiety	20.50	7.16; 58.72	<0.001

¹Hyperemesis gravidarum group compared to controls, ²Confidence interval
HG: Hyperemesis gravidarum, Min-Max: Minimum-Maximum, CI: Confidence interval

In this study, we investigated the possible effects of many socio-demographic parameters on HG. Among these parameters, some (age, parity, previous miscarriage, age of marriage and working status) were found not to be related, whereas others (income

level, education level, social and family relations) were found related. Anxiety and depression were significantly more common and more severe in the HG group than in the controls. Similar to Hizli et al.⁽¹⁵⁾, we also found the incidence of depression as

Table 3. Parameters tested to be risk factors for depression or anxiety in early pregnancy: univariate analysis

Parameters		Incidence of depression	p value	Incidence of anxiety	p value
Age	Adolescent ¹	33.3%	0.999	33.3%	0.499
	Adult	35.1%		24.5%	
Parity	Nulliparous	38.9%	0.387	29.2%	0.307
	Multiparous	32.8%		22.7%	
Previous miscarriage	Yes	36.3%	0.459	27.9%	0.619
	No	30.2%		24.2%	
Age at marriage	Child marriage ²	41.2%	0.577	35.3%	0.378
	Adult marriage	34.4%		24.0%	
Status of employment	Housewife	36.2%	0.457	25.2%	0.916
	Employee	29.7%		24.3%	
Income level	Lower than MW ³	44.7%	0.003	22.7%	0.462
	Higher than MW	24.7%		27.2%	
Education level	Elementary school	43.3%	0.011	26.9%	0.513
	High school	26.0%		22.9%	
Family relationship	Poor	36.3%	0.365	26.9%	0.132
	Good	27.6%		13.8%	
Social relationship	Poor	39.7%	0.008	30.1%	0.002
	Good	18.2%		6.8%	
Hyperemesis gravidarum	Not present	16.0%	<0.001	9.0%	<0.001
	Present	54.0%		41.0%	

¹Patient ≥19 years of age, ²Formal marriage or informal union before age 18 years
MW³: Minimal wage

Table 4. Relative risk ratios of various parameters for depression and anxiety: multivariate analysis

	¹ RR	² 95% CI (upper-lower)	p value
Risk factors for depression			
Low income	1.615	0.800-3.258	0.181
Lower education	1.361	0.673-2.752	0.390
Poor family relationship	1.934	0.637-5.869	0.244
Poor social relationship	2.842	1.037-7.791	0.042
HG	5.505	2.755-10.998	<0.001
Risk factors for anxiety disorder			
Poor social relationship	5.689	1.449-22.340	0.013
Poor family relationship	1.351	0.354-5.164	0.660
HG	6.704	2.974-15.111	<0.001

¹Predictive relative risk calculated with odds ratio, ²95% CI: Confidence interval, RR: Relative risk, HG: Hyperemesis gravidarum

84% in the HG group. This high incidence of depression might be attributed to the completion of questionnaires on the first day of hospitalization and high percentage of patients with low income. In the univariate analysis, patients with low income, low educational status, and poor social relationships had increased risk for having depression in the current study. An alternative view is that HG is an independent variable that increases the relative risk of all stages of anxiety and depression. The most dramatic effect of HG was seen on the development of severe anxiety. A woman with HG was 20.5 times more prone to having severe anxiety compared with healthy pregnant woman in the present study. These findings are consistent with some previous studies; however, some other studies could not demonstrate an association between severity of HG and depression⁽¹⁹⁻²¹⁾.

Predictive factors for developing anxiety disorder and depression in pregnant women with HG were also investigated in a few studies^(11,14,17). Tan et al.⁽¹⁴⁾ investigated the incidence and risk factors for developing anxiety and depression in a cohort of 209 women with HG in early pregnancy. HG was found to be the only independent risk factor for developing anxiety, and the only independent protective factor for developing depression was the history of miscarriage. In 2012, Hizli et al.⁽¹⁵⁾ evaluated the impact of HG and socio-demographic variables on depression in Turkish patients during pregnancy. They used the BDI-II and reported the incidence of depression as 80% in the HG group and 5% in the control group. They also stated that the presence of HG was the most important predictor of depression, and additionally, young maternal age and poor family interaction were other weaker contributors. Recently, Annagür et al.⁽¹¹⁾ investigated the association between HG and eating attitudes on anxiety and depression symptoms in 48 women with HG and 44 controls. The authors concluded that HG was associated with symptoms of anxiety and depression but not with eating attitudes.

Study Limitations

The strengths of the study are the use of objective inclusion criteria and a relatively high number of patients, and the limitations are the use of psychiatric test for depression instead of examinations by a psychiatrist, and the matching process between the study and control group was insufficient.

Conclusion

In this study, we showed that both depression and anxiety disorders were more common and severe in patients with HG compared with controls. In addition, having weak family and social relationships and lower socioeconomic status also played an important role in developing depression and anxiety in pregnant women. Therefore, the psychological state of patients should also be noticed during the evaluation for physical health of women with HG.

Ethics

Ethics Committee Approval: The study was approved by Etik Zübeyde Hanım Women's Health Teaching and Research

Hospital Ethics Committee (approval number and date: 2013-165/27.05.2013).

Informed Consent: A consent form was completed by all participants.

Peer-review: External and internal peer-reviewed.

Authorship Contributions

Surgical and Medical Practices: Y.T., B.Ç., E.Ç., Concept: M.M.A., Y.A.T., Design: Y.T., D.A.C., O.G., Data Collection or Processing: Y.T., E.Ç., Y.A.T., Analysis or Interpretation: D.A.C., M.M.A., O.G., Literature Search: B.Ç., E.Ç., Writing: Y.T., D.A.C., Y.A.T.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study received no financial support.

References

1. Gazmararian JA, Petersen R, Jamieson DJ, Schild L, Adams MM, Deshpande AD, et al. Hospitalizations during pregnancy among managed care enrollees. *Obstet Gynecol* 2002;100:94-100.
2. London V, Grube S, Sherer DM, Abulafia O. Hyperemesis Gravidarum: A Review of Recent Literature. *Pharmacology* 2017;100:161-71.
3. Yeh CC, Tsui KH, Wang PH. Hyperemesis Gravidarum. *J Chin Med Assoc* 2017.
4. Munch S, Korst LM, Hernandez GD, Romero R, Goodwin TM. Health-related quality of life in women with nausea and vomiting of pregnancy: the importance of psychosocial context. *J Perinatol* 2011;31:10-20.
5. Masson GM, Anthony F, Chau E. Serum chorionic gonadotrophin, schwangerschafts protein 1, progesterone and estradiol levels in patients with nausea and vomiting in early pregnancy. *Br J Obstet Gynaecol* 1985;92:211-5.
6. Walsh JW, Hasler WL, Nugent CE, Owyang C. Progesterone and estrogen are potential mediators of gastric slow-wave dysrhythmias in nausea of pregnancy. *Am J Physiol* 1996;270:506-14.
7. Shiah YJ, Chang F, Chiang SK, Lin IM, Tam WC. Religion and health: anxiety, religiosity, meaning of life and mental health. *J Relig Health* 2015;54:35-45.
8. Koch KL, Stern RM, Vasey M, Botti JJ, Creasy GW, Dwyer A. Gastric dysrhythmias and nausea of pregnancy. *Dig Dis Sci* 1990;35:961-8.
9. Deal LW, Holt VL. Young maternal age and depressive symptoms: results from the 1988 National Maternal and Infant Health Survey. *Am J Public Health* 1998;88:266-70.
10. Orr ST, James SA, Blackmore Prince C. Maternal prenatal depressive symptoms and spontaneous preterm births among African-American women in Baltimore, Maryland. *Am J Epidemiol* 2002;156:797-802.
11. Annagür BB, Kerimoğlu ÖS, Gündüz Ş, Tazegül A. Are there any differences in psychiatric symptoms and eating attitudes between pregnant women with hyperemesis gravidarum and healthy pregnant women? *J Obstet Gynaecol Res* 2014;40:1009-14.
12. Uguz F, Gezginc K, Kayhan F, Cicek E, Kantarci AH. Is hyperemesis gravidarum associated with mood, anxiety and personality disorders: a case-control study. *Gen Hosp Psychiatry* 2012;34:398-402.
13. Tan PC, Zaidi SN, Azmi N, Omar SZ, Khong SY. Depression, anxiety, stress and hyperemesis gravidarum: temporal and case controlled correlates. *PLoS One* 2014;17;9:e92036.
14. Tan PC, Vani S, Lim BK, Omar SZ. Anxiety and depression in hyperemesis gravidarum: prevalence, risk factors and correlation with clinical severity. *Eur J Obstet Gynecol Reprod Biol* 2010;149:153-8.

15. Hizli D, Kamalak Z, Kosus A, Kosus N, Akkurt G. Hyperemesis gravidarum and depression in pregnancy: is there an association? *J Psychosom Obstetr Gynaecol* 2012;33:171-5.
16. Buckwalter JG, Simpson SW. Psychological factors in the etiology and treatment of severe nausea and vomiting in pregnancy. *Am J Obstet Gynecol* 2002;186(Suppl 5):210-4.
17. Iancu I, Kotler M, Spivak B, Radwan M, Weizman A. Psychiatric aspects of hyperemesis gravidarum. *Psychother Psychosom* 1994;61:143-9.
18. Simpson SW, Goodwin TM, Robins SB, Rizzo AA, Howes RA, Buckwalter DK, et al. (2001) Psychologic factors and hyperemesis gravidarum. *J Womens Health Gend Based Med* 2001;10:471-7.
19. Köken G, Yilmazer M, Cosar E, Sahin FK, Cevrioglu S, Gecici O. Nausea and vomiting in early pregnancy: relationship with anxiety and depression. *J Psychosom Obstetr Gynaecol* 2008;29:91-5.
20. Kjeldgaard HK, Eberhard-Gran M, Benth JŠ, Vikanes ÅV. Hyperemesis gravidarum and the risk of emotional distress during and after pregnancy. *Arch Womens Ment Health* 2017;20:747-56.
21. Bozzo P, Einarson TR, Koren G, Einarson A. Nausea and vomiting of pregnancy (NVP) and depression: cause or effect? *Clin Invest Med* 2011;34:245.
22. Gadsby R. Pregnancy nausea and vomiting-the role of the midwife. *Pract Midwife* 2012;15:17-9.



Endothelial cell leptin receptors, leptin and interleukin-8 in the pathogenesis of preeclampsia: An *in-vitro* study

Preeklampsi patogenezinde endotelial hücre leptin reseptörleri, leptin ve interlökin-8: İn-vitro çalışma

Sefa Arlier^{1,2}

¹South Florida University Faculty of Medicine, Department of Obstetrics and Gynecology, Tampa, USA

²University of Health Sciences, Adana Numune Training and Research Hospital, Clinic of Obstetrics and Gynecology, Adana, Turkey

Abstract

Objective: Increased leptin hormone and leptin receptor may enhance the generation of proinflammatory cytokines by endothelial cells and lead to endothelial dysfunction. This study assessed the umbilical cord endothelial leptin receptor levels in preeclampsia and investigated the effect of leptin on endothelial interleukin-8 (IL-8) production.

Materials and Methods: The association between IL-8 levels with leptin stimulation was investigated in leptin-treated human endothelial cells. Endothelial cell leptin receptor levels were evaluated using immunohistochemistry staining, and endothelial IL-8 protein expression by Western blot analysis. Data are presented as mean \pm standard error of the mean (SEM). Statistical significance was analyzed using Student's t-test or Mann-Whitney U test and one-way analysis of variance.

Results: Leptin receptor immunoreactivity increased significantly in umbilical cord venous and arterial endothelial cells in normal pregnancy (n=12) compared with preeclampsia (n=7) endothelial cells. The corresponding preeclampsia versus control histologic scores (mean \pm SEM) were 67.9 \pm 8.8 vs. 127.6 \pm 23.1, (p=0.011) for the leptin receptor and 55.4 \pm 8.0 vs. 93.7 \pm 17.1 (p=0.035), respectively, for the vein endothelial cells. Leptin treatment significantly increased IL-8 protein levels (control vs. 100 and 1000 ng/mL, p=0.003).

Conclusion: The findings of increased umbilical cord endothelial leptin receptor levels in preeclampsia and increased endothelial IL-8 expression with exposure to higher leptin concentrations may indicate the contribution of leptin to endothelial dysfunction and increased neutrophil-endothelial interaction, which are significant pathophysiologic features of preeclampsia.

Keywords: Preeclampsia, endothelial cell, umbilical cord, leptin, leptin receptor, interleukin-8

Öz

Amaç: Dolayışında artan leptin ve leptin reseptörü, endotel hücrelerinde proenflamatuvar sitokinlerin üretimini artırabilir ve endotel disfonksiyonuna neden olabilir. Bu çalışmada, preeklampside umbilikal kord endotelial leptin reseptör düzeyleri değerlendirildi. Ayrıca leptinin endotelial interlökin-8 (IL-8) üretimi üzerindeki etkisi araştırıldı.

Gereç ve Yöntemler: Endotel hücre leptin reseptör seviyesi immünohistokimyasal boyama ve endotelial IL-8 protein ekspresyonu Western blot analizi yöntemleri kullanılarak değerlendirildi. Veriler ortalama \pm standart hata (SEM) olarak sunuldu. İstatistiksel fark Student t-testi veya Mann-Whitney U testi ve tek yönlü varyans analizi kullanılarak analiz edildi.

Bulgular: Normal gebeliğe kıyasla (n=12), preeklampside (n=7), umbilikal kord venöz ve arteriyal endotel hücre leptin reseptör immünoaktivitesi, anlamlı olarak artmış bulundu. Kontrollerde ve preeklampsi leptin reseptörleri için histolojik skorlar (ortalama \pm SEM); umbilikal arter endotel hücrelerinde sırasıyla 67,9 \pm 8,8 ve 127,6 \pm 23,1 (p=0,011) iken, umbilikal ven endotel hücrelerinde sırasıyla 55,4 \pm 8,0 ve 93,7 \pm 17,1 (p=0,035) olarak saptandı. Yüksek leptin seviyelerine (100 ve 1000 ng/mL) maruz kalan endotel hücrelerinde, kontrole kıyasla, IL-8 düzeylerinin anlamlı olarak arttığı gözlemlendi (p=0,003).

Sonuç: Preeklampside umbilikal kord endotelial leptin reseptör düzeylerinin artmış olması ve yüksek leptin konsantrasyonlarının endotelial IL-8 ekspresyonunu uyarması; leptinin, preeklampsinin belirgin patofizyolojik özellikleri olan endotel disfonksiyonu ile artmış nötrofil-endotel etkileşimine katkısı olabileceğini göstermektedir.

Anahtar Kelimeler: Preeklampsi, endotelial hücre, umbilikal kord, leptin, leptin reseptörü, interlökin-8

PRECIS: This study identifies, higher levels of leptin expressions in umbilical cord from preeclampsia placenta, suggesting that provocation of interleukin-8 secretion by leptin in endothelial cells may contribute to preeclampsia-related inflammation.

Address for Correspondence/Yazışma Adresi: Sefa Arlier, MD,

South Florida University Faculty of Medicine, Department of Obstetrics and Gynecology, Tampa, USA

University of Health Sciences, Adana Numune Training and Research Hospital, Clinic of Obstetrics and Gynecology, Adana, Turkey

Phone: +90 532 486 16 68 **E-mail:** sefaarlier@gmail.com **ORCID ID:** orcid.org/0000-0002-0019-84039

Received/Geliş Tarihi: 17.08.2017 **Accepted/Kabul Tarihi:** 23.10.2017

©Copyright 2017 by Turkish Society of Obstetrics and Gynecology

Turkish Journal of Obstetrics and Gynecology published by Galenos Publishing House.

Introduction

Preeclampsia (PE) is a multisystem disorder. Hypertension, proteinuria, and pathologic edema in pregnancy are the classic clinical manifestations. Worldwide, approximately 5-7% of primigravid women develop PE in pregnancy⁽¹⁾. Many studies implied that the fundamental pathophysiologic abnormality is endothelial dysfunction associated with exaggerated inflammation and immunologic reaction⁽²⁻⁴⁾. In the pathogenesis of PE, activation of neutrophils, monocytes, and natural killer cells initiate inflammation, resulting in endothelial destruction in the pathogenesis of PE⁽⁴⁾. The damaged endothelium produces various chemokines, one of which is interleukin (IL)-8⁽⁵⁾.

Leptin was initially defined as an adipocyte hormone that controls energy balance, reproductive functions, and immune reactions in the body⁽⁶⁾. Mounting data imply that leptin is a novel proinflammatory adipocyte-originated element that manages the cytokine pathway by connecting the immune and inflammatory system^(7,8). The plasma leptin concentrations in patients with PE are considerably higher than those in normal patients⁽⁹⁾. Moreover, recent reports revealed that leptin showed vital roles in diverse physiologic processes including angiogenesis and arterial blood pressure regulation⁽⁹⁾.

IL-8 has been reported to activate chemotactic migration, proliferation, and survival of vascular endothelial cells; induce the expressions of vascular endothelial growth factor (VEGF) and VEGF receptor⁽¹⁰⁾, and regulate pathologic angiogenesis⁽¹¹⁾. Was first purified as a potent neutrophil chemotactic factor⁽¹²⁾. IL-8 is also characterized as a proinflammatory cytokine. Increased IL-8 levels have been described in various inflammatory diseases⁽¹³⁾. Many inflammatory cells, such as monocytes, lymphocytes, and mast cells, release IL-8 that is accumulated inside endothelial cells. IL-8 and its receptors C-X-C chemokine receptor 1-2 have been detected in endothelial cells⁽¹⁴⁾. Moreover, human placental tissue produces IL-8 during pregnancy. Previous studies showed a robust correlation between IL-8 levels and the severity of PE^(5,15). Neutrophil activation results in progressive damage to endothelial cells⁽¹⁶⁾. The present study aimed to investigate umbilical cord (UC) leptin receptor (LEPR) levels in PE and to examine the direct effect of leptin on IL-8 production by human endometrial endothelial cells (HEECs) and human umbilical vein endothelial cells (HUVECs), thus to describe the function of leptin in PE.

Materials and Methods

Tissue collection

Serial paraffin sections of human placental UC specimens were obtained from the University of South Florida under the protocol approved by the Ethics and Human Investigation Committees of the University of South Florida (approval number: 00015578). Written and verbal informed consents were obtained from each patient. All of the samples were grouped according to clinical diagnosis: UC control (n=12) or PE (n=7). For *in vitro* studies,

previously frozen HEECs (n=2) and HUVEC (n=1) from normal women undergoing hysterectomy (laparoscopy or laparotomy) or normal delivery were thawed and grown to confluence, as previously described⁽¹⁷⁾.

Immunohistochemistry

Collected PE and normal patient UC paraffin blocks were cut into 5 µm sections that were then put into a heater to incubate overnight at 56 °C. The slides were deparaffinized in xylene (x3) for 20 min., followed by 100, 90, 80, and 70% alcohol x1 for 10 min. per gradient. Following deparaffinization, the slides were heated in 10 mM citrate buffer (pH 6.0) for 3x5 min in a microwave oven for antigen retrieval. The slides were then immersed in 3% hydrogen peroxide (in 1:1 v/v methanol/distilled water) for 12 min. to quench endogenous peroxidase activity. After washing with tris-buffered saline (TBS); (pH: 7.4) (x3) for 5 min., the slides were incubated in a humidified chamber with 5% blocking normal goat serum (Vector Labs, Burlingame, CA) for 30 min at room temperature (RT) in TBS. Excess serum was emptied, and then the slides were incubated overnight with a primary rabbit polyclonal anti-LEPR antibody (1:60; Santa Cruz Biotechnology, Dallas, TX) in 1% normal goat serum at 4 °C. Normal rabbit immunoglobulin G (IgG) (Vector Labs) isotypes were used for negative controls at the equal primary antibody concentrations. The slides were rinsed (x3) for 5 min. with TBS, and then biotinylated anti-rabbit IgG (Vector Labs) was used at a 1:400 dilution for 30 min. at RT. The antigen-antibody complex was identified using an avidin-biotin-peroxidase kit (Vector Labs) for 30 min. at RT. 3,3'-Diaminobenzidine tetrahydrochloride dihydrate (Vector Labs) was added as the chromogen to visualize immunoreactivity for 90 seconds. The slides were then counterstained with hematoxylin and mounted. Immunoreactive LEPR levels were semi-quantitatively assessed using the subsequent intensity categories: 0, no staining; 1⁺, weak but visible staining; 2⁺, moderate or distinct staining; and 3⁺, strong staining. As described previously⁽¹⁸⁾, for each tissue, a histologic score (HSCORE) was derived by adding the percentages of cells that were stained at each intensity category and then multiplying that value by the weighted intensity of the staining using the formula $HSCORE = \sum P_i (i + 1)$, where *i* represents the intensity scores, and *P_i* is the corresponding percentage of the cells. In each slide, three randomly selected areas were assessed under a light microscope (x40 magnification), and the percentage of the cells at each intensity within these regions was evaluated at different times by two blinded researchers. The average HSCORE of the two examiners was used. Human endometrial endothelial cell and human umbilical vein endothelial cell isolation and experimental treatment with leptin. Frozen primary HEECs (n=2) and HUVECs (n=1) were derived from banked samples. The samples had been isolated and categorized as previously described⁽¹⁷⁾ from endometrial specimens obtained from reproductive-age women undergoing hysterectomy

(laparoscopy or laparotomy) and UC vein specimens obtained from the delivery of a normal pregnant woman. Written informed consent for sample retrieval was obtained from Yale University Faculty of Medicine, Human Investigation Committee and approved by the University of South Florida. Aliquots of frozen primary HEECs and HUVECs were thawed and grown to confluence in basal medium (BM), and a phenol red-free 1:1 v/v Dulbecco's Modified Eagle Medium/Ham's F-12 (Gibco, Grand Island, NY) mixture, containing 100 U/mL penicillin, 100 µg/mL streptomycin, and 0.25 µg/mL Fungizone complex (Gibco) supplemented with 10% charcoal-stripped calf serum (Gibco). At ~80% confluence, HEECs and HUVECs were transferred to 6-well plates at a density of 150×10^3 cells/well, for the corresponding treatments, as designated by each experimental condition. Confluent HEECs and HUVECs were incubated in parallel in BM with 0.1% ethanol (vehicle control) or leptin (0.1, 1.0, 10, 100 and 1000 ng/mL leptin, respectively). After incubation for 24 h, HEECs and HUVECs were rinsed with ice-cold 1x phosphate buffered saline and stored at -80 °C until used for immunoblotting analysis to measure IL-8 total protein levels.

Immunoblot analysis

Total protein was extracted using a cell extraction buffer (BioSource International, Camarillo, CA) containing 3 mM phenylmethylsulfonyl fluoride and a protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO). The protein level was determined using a detergent-compatible protein assay (Bio-Rad, Hercules, CA). Samples (40 µg) were loaded on 10% Tris-hydrochloric acid-ready gels (Bio-Rad), electrophoretically separated, and electroblotted onto a nitrocellulose membrane (Bio-Rad). The membrane was blocked with 5% non-fat milk powder in TBS containing 0.1% Tween 20 (TBS-T) for 1 h to reduce any non-specific antibody binding. Subsequently, the membrane was incubated overnight with a monoclonal mouse IgG1 clone primary antibody against IL-8 (1:800 R&D Systems, Inc., Minneapolis, MN) in 5% non-fat milk powder in TBS-T. The membrane was then rinsed several times with 1x TBS-T for 1 h and incubated with horseradish peroxidase-conjugated anti-rabbit IgG (Vector Labs) in TBS-T. Following several washes, IL-8 was visualized through light emission from the film (Denville Scientific, Holliston, MA) with enhanced chemiluminescence substrate (Thermo Scientific, Rockford, IL). Band intensities were quantified using computer

densitometry analysis (Image J, National Institutes of Health, Bethesda, MD).

Statistical Analysis

Data from immunohistochemistry and Western blot analysis that were normally distributed, according to the Kolmogorov-Smirnov test, were compared using Student's t-test or one-way analysis of variance, followed by the post hoc Holm-Sidak test. Immunohistochemistry and Western blot analysis data that were not normally distributed were analyzed using the Kruskal-Wallis nonparametric ANOVA-by-Ranks test, followed by the post hoc Student-Newman-Keuls test. Statistical calculations were performed using Sigmaplot 13 for Windows (Jandel Scientific Corp., San Rafael, CA). Statistical significance was considered as $p < 0.05$.

Results

Immunohistochemistry of human placental umbilical cord specimens evaluating leptin receptor immunostaining in the control vs. preeclamptic groups

LEPR immunostaining was detected in the cytoplasm and nucleus of the UC artery and vein endothelial cells. LEPR HSCOREs were significantly different between the control vs. PE specimens in the sectioned UC arterial endothelial cells [mean \pm standard error of the mean (SEM): 67.9 ± 8.868 vs. 127.6 ± 23.1 ; $p = 0.011$, respectively] (Figure 1) and UC vein endothelial cells (mean \pm SEM: 55.4 ± 8.043 vs. 93.7 ± 17.15 ; $p = 0.035$, respectively). LEPR immunostaining was moderate in the PE specimens ($n = 7$) (Figure 1a-d), whereas the control UC endothelial cells ($n = 12$) displayed weak immunostaining (Figure 1e-h). There were no statistically significant differences in maternal age, gestational age (GA), body mass index (BMI) at delivery, and baby weight between the control and PE groups (Table 1).

Effect of leptin on interleukin-8 protein expression in cultured human endometrial endothelial cells and human umbilical vein endothelial cells

Experimental incubations were followed by immunoblotting of the cell extracts to establish the functional regulation of leptin on IL-8 protein expression in the primary cultures of HEECs and HUVECs. Representative immunoblotting (Figure 2a) and the accompanying graphs (Figure 2b) indicated that IL-8 protein level was significantly increased by 1000 ng/mL leptin and 100

Table 1. Demographic data of the control and preeclamptic groups from which umbilical cord specimens were obtained

	Control (n=12)	Preeclampsia (n=7)	p value
Maternal age (years \pm SD)	32.7 \pm 2.265	28.625 \pm 1.625	0.247
Gestational age (weeks \pm SD)	37.50 \pm 0.44	37.14 \pm 0.36	0.152
BMI at delivery (kg/m ² \pm SD)	30.50 \pm 2.72	34.00 \pm 4.14	1.62
Birth weight of the baby (gr \pm SD)	3534.16 \pm 408.41	2670.62 \pm 621.43	0.056

SD: Standart deviation, BMI: Body mass index




Figure 1. Leptin receptor immunoreactivity in umbilical cord arterial and venous sections from gestational age-matched preeclamptic and normal pregnancies. Representative micrographs of immunohistochemical staining for leptin receptor in preeclampsia (n=7) (A, B, C, D) and normal pregnancy (n=12) (E, F, G, H). Graphs represent the histologic score analysis of leptin receptor immunostaining in umbilical cord vein (I) and umbilical cord artery (J) endothelial cells expressed as mean ± standard error of the mean

*p=0.035; endothelial cells of the umbilical vein, preeclampsia vs. normal pregnancy

**p=0.011; endothelial cells of the umbilical artery, preeclampsia vs. normal pregnancy

PE: Preeclampsia




Figure 2. Leptin stimulates interleukin-8 expression in endothelial cells. Representative immunoblotting in human endometrial endothelial cells (n=2) and human umbilical vein endothelial cells (n=1) cultures treated with leptin for 24 hours. Western blot analysis demonstrating the effect of leptin on interleukin-8 levels in human endometrial endothelial cells and human umbilical vein endothelial cells. Confluent human endometrial endothelial cells and human umbilical vein endothelial cells cultures were treated with vehicle (control), 0.1, 1, 10, 100 and 1000 ng/mL leptin, respectively, for 24 hours, to evaluate the effect of leptin. Immunoblot bands for interleukin-8 were quantified using Image J. Bars represent mean ± standard error of the mean (n=3)

*p<0.05; both for 100 and 1000 ng/mL leptin vs. control.

Data are representative of three independent experiments

IL: Interleukin

ng/mL compared with the control ($p=0.003$). Conversely, 0.1, 1, and 10.0 ng/mL leptin had not statistically significant effect on IL-8 levels when added to the culture medium ($p>0.05$) (Figure 2a, b). Incubation with 100 and 1000 ng/mL leptin induced greater IL-8 protein level vs. the control, 0.1 and 1 ng/mL leptin (Figure 2a). Compared with the control, 0.1, 1, and 10 ng/mL leptin showed no significant change in the basal IL-8 protein expression in HUVECs and HEECs.

Discussion

Several studies illustrated the potential role of cytokines, chemokines, and their receptors in the development and progression of PE⁽¹⁹⁻²¹⁾. Pregnancy complications associated with PE are major causes of materno-fetal morbidity and mortality, but their pathogenesis remains unclear⁽²²⁾. Despite significant development in the management of PE, it still constitutes an unsolved health problem in pregnancy⁽²³⁾. The current study examined the molecular mechanism of leptin-mediated inflammation in PE. The data in this study imply that leptin/LEPR interaction stimulated IL-8 production in endothelial cells, consequently promoting neutrophil chemotaxis and PE progression. Therefore, a view was instigated to connect leptin concentrations and IL-8 level in endothelial cells. The structure and function of endothelial cells are crucial to the preservation of arterial and vein vessel wall homeostasis, as well as immune cells migration⁽²⁴⁾. Damaged endothelial cells, increasing inflammatory cell recruitment, and high concentrations of inflammatory agents in the plasma of pregnant patients are responsible for the pathogenesis of PE^(13,24). Impaired placental function and placental vascular disorders result in the occurrence of poor perinatal outcome⁽²⁵⁾. Leptin is produced by cytotrophoblasts and syncytiotrophoblasts in the human placenta and adipose tissue, which is then secreted into the circulation, where it exerts its effects via interaction with the LEPR. The effect of leptin on endothelial cells has attracted particular attention^(20,26). LEPRs are expressed in many normal tissues, but also in pathologic tissues generally associated with obesity and abnormal energy balance⁽²⁷⁾. Immunohistochemically, endothelial cells, syncytiotrophoblasts, and cytotrophoblasts were stained with leptin⁽²⁸⁾. The present study demonstrated that the LEPR expression in UC artery and vein endothelial cells was augmented in PE and localized to the cytoplasm and nuclei of endothelial cells. Significant increases in the concentration and amounts of LEPR-positive endothelial cells, as implied by HSCORES in PE vs. normal pregnancy suggests a function for LEPR in the inflammatory pathway of PE. A previous study demonstrated a high level of the leptin gene expression in microarray investigations in PE⁽²⁹⁾. In this regard, the current study was designed to elucidate the possible correlation between UC artery and vein LEPR levels and PE and its functional effects on endothelial cells. The study data can also be considered as indirect evidence for

LEPR and its contribution to PE, and the functional results of leptin on endothelial cells. The data of the study can also be considered as indirect evidence for the contribution of LEPR to PE. Leptin possibly has an effect on the regulation of arterial blood pressure in pregnant women, as indicated by the direct relationship between plasma leptin concentrations and mean arterial blood pressure⁽³⁰⁾. Furthermore, dysfunctions of leptin metabolism or regulation in the placental unit and plasma are enhanced in pregnancies complicated with various abnormalities such as intrauterine growth restriction, gestational diabetes mellitus, and PE. Leptin synthesis and secretion have been shown as positively correlated with BMI and GA⁽³¹⁻³³⁾. In contrast, in this study, BMI, GA, maternal age, and birth weight of the baby were not significantly different between the control and PE groups. Mise et al.⁽³⁴⁾ stated that leptin messenger RNA (mRNA) levels in severe PE were significantly higher than in those with mild PE, also that placental leptin mRNA levels were generally similar to plasma leptin concentrations in women with PE compared with GA-matched healthy pregnant women. Higher concentrations of UC plasma leptin have been revealed in infants of mothers with PE than in a GA-, sex-, and infant ponderal index-matched control group⁽³⁵⁾. Compromised placental blood distribution causes chronic disturbance of nutrient resource and ultimately results in intrauterine growth restriction⁽³⁶⁾. Impaired placental perfusion also creates a depressed oxygen source at the placental level, which subsequently enhances leptin gene expression in the placental unit⁽²¹⁾. It is likely that the high leptin concentrations in maternal plasma may augment hypertension because leptin provokes endothelial dysfunction and hypertension via aldosterone-related mechanisms and milieu in gestations complicated by intrauterine growth restriction⁽³⁷⁾. PE is concomitant with shallow trophoblastic invasion into the endometrial layer, which leads to poor placental perfusion and augmented fetal and maternal plasma leptin levels that are considerably increased over the concentration of leptin specific to human gestation⁽³⁸⁾. This exaggerated hyperleptinemia may be linked to a compensatory response to augment nutrient supply to the growing fetus⁽³⁹⁾. The present study showed that although not significant, the LEPR level was slightly higher in the UC artery than the paired UC vein, especially in the preeclamptic group, suggesting that UC artery LEPR may be more functional than UC vein LEPR in PE. In a previous report, leptin levels were found to be higher in the UC vein than the UC artery⁽⁴⁰⁾. One other study showed that the leptin concentrations were considerably higher in UC artery and UC vein than those in paired maternal plasma, implying that leptin is produced in placental trophoblastic cells and is secreted into the maternal blood circulation. Furthermore, plasma leptin concentrations in the UC vein were notably higher than those in the paired UC artery, suggesting that leptin is released from placental trophoblastic cells into the fetal blood circulation⁽⁴¹⁾.

The increase in the proinflammatory chemoattractant cytokine levels in PE suggests an inflammatory basis for this disease. The proinflammatory and regulatory cytokine IL-8 has been discovered in endothelial cells. Prior studies demonstrated upregulation of IL-8 protein levels in PE. IL-8 is regulated by neutrophil and monocyte chemotaxis regarding the inflammation site and stimulated inflammatory response⁽⁴²⁾. IL-8 is secreted by some cell types, including endothelial cells, monocytes, macrophages, Neutrophils, and fibroblasts. This study investigated UC LEPR levels in PE and the relationship of IL-8 expression in HEECs and HUVECs with leptin at different concentrations in an attempt to explain the significant association between leptin and IL-8 in patients with PE. Increasing placental endothelial IL-8 production may contribute to the improvement of placental endothelial pathology in PE. There was a dose-dependent progressive connection between increasing leptin level and endothelial IL-8 protein expression. Exposing endothelial cells to a high leptin concentration plays a role in leukocyte migration into the placental area and in the management of the tissue-specific modifications related with the leukocyte extravasation. A prior study showed that circulating plasma IL-8 concentrations were elevated in women with PE compared with normal pregnant women^(5,15). These data indicate that IL-8 may have a critical role in endothelial cell proliferation and differentiation and regulating endothelial function. Human placental tissues constitutively produce IL-8 in pregnancy, and IL-8 secretion increases with progressing GA. IL-8 is critical for leukocyte recruitment⁽⁴³⁾. Namely, the vascular endothelial cell layer acts as the gatekeeper for maternal immune rejection and immune cells. Similarly, increased IL-8 plasma levels in PE have been documented^(15,44). Moreover, leptin induced the production of IL-8 in human cartilage, fibroblasts, and M2 macrophages^(45,46). These previous data also support the role of leptin-induced IL-8 secretion in endothelial cells⁽⁴⁶⁾. Additionally, the current study is the first to describe the association between leptin and IL-8 in HUVECs and HEECs. IL-8 influences early vascular remodeling by recruiting circulating neutrophil cells to the endothelial cells⁽²⁴⁾. Understanding the mechanism for the increased IL-8 expression in HEECs and HUVECs of women in pregnancy may contribute to explaining the pathophysiology and development of PE. Speculatively, increased leptin production may exaggerate cytokine-induced destruction of endothelial cells in PE or overweight patients. Neutrophil-endothelial contact is a hallmark of vascular inflammation that results in endothelial injury/dysfunction⁽⁴⁷⁾. Increasing IL-8 levels in endothelial cells probably contribute to enhanced neutrophil recruitment and cytokine production. Furthermore, neutrophil stimulation is amplified in inflammatory reactions in the maternal artery and vein blood circulation in PE. These observations reveal that there is a high rate of IL-8 production in PE, consistent with other studies⁽⁴⁴⁾. However, further studies are required to investigate the role of leptin and LEPR in other inflammatory-related cellular mechanisms.

Collectively, these *in vivo* and *in vitro* results indicate that endothelial cells contribute to increased IL-8 concentrations in maternal and fetal circulation, as well as neutrophil recruitment. Leptin-associated augmented IL-8 secretion in endothelial cells is probably related with the development of PE. Thus, the increase in IL-8 level may potentiate leukocyte activation into the placental tissue under the effects of leptin. Consequently, the source and physiologic importance of IL-8 in the maternal and fetal circulation are noteworthy objectives of potential investigation. However, whether this phenomenon is a compensatory effect or amplified reaction to the severity of the PE remains enigmatic⁽⁴⁸⁾.

Conclusion

These observations provide direct evidence of the stimulation of IL-8 gene expression in endothelial cells *in vitro* by high leptin concentrations. In this manner, the increased leptin and LEPR may cause or contribute to increased IL-8 production, leading to increased neutrophil recruitment and endothelial destruction and consequently, increase cytokine expression in PE. This study may provide an *in vivo* basis for the application of an anti-human IL-8 antibody for the treatment of PE. Further studies researching the possible role of LEPR in normal and PE UC endothelial cells are needed to explore these possibilities and to support new insight into our understanding of the pathogenesis of PE.

Acknowledgments

The authors would like to thank the lab members, Lockwood C.J. and Magnes R., Ümit A Kayışlı, and Dr. John Tsibris for their assistance.

Ethics

Ethics Committee Approval: Serial paraffin sections of human placental UC specimens were obtained from the University of South Florida under the protocol approved by the Ethics and Human Investigation Committees of the University of South Florida (approval number: 00015578).

Informed Consent: Written and verbal informed consents were obtained from each patient.

Peer-review: External and internal peer-reviewed.

Conflict of Interest: No conflict of interest was declared by the author.

Financial Disclosure: The author declared that this study received no financial support.

References

1. Dekker GA. Management of preeclampsia. *Pregnancy Hypertens* 2014;4:246-7.
2. Tomimatsu T, Mimura K, Endo M, Kumasawa K, Kimura T. Pathophysiology of preeclampsia: an angiogenic imbalance and long-lasting systemic vascular dysfunction. *Hypertens Res* 2017;40:305-10.
3. Boeldt DS, Bird IM. Vascular adaptation in pregnancy and endothelial dysfunction in preeclampsia. *J Endocrinol* 2017;232:27-44.
4. Harmon AC, Cornelius DC, Amaral LM, Faulkner JL, Cunningham MW Jr, Wallace K, et al. The role of inflammation in the pathology of preeclampsia. *Clin Sci (Lond)* 2016;130:409-19.

5. Sun L, Mao D, Cai Y, Tan W, Hao Y, Li L, et al. Association between higher expression of interleukin-8 (IL-8) and haplotype -353A/-251A/+678T of IL-8 gene with preeclampsia: A case-control study. *Medicine (Baltimore)* 2016;95:e5537.
6. Pandit R, Beerens S, Adan RAH. Role of leptin in energy expenditure: the hypothalamic perspective. *Am J Physiol Regul Integr Comp Physiol* 2017;312:938-47.
7. Doster Y, Cetinkaya Demir B, Atalay MA, Durusoy EE, Kucukkomurcu S. The possible role of serum leptin in preeclampsia. *Clin Exp Obstet Gynecol* 2016;43:98-102.
8. Lord GM, Matarese G, Howard JK, Baker RJ, Bloom SR, Lechler RI. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. *Nature* 1998;394:897-901.
9. Kalinderis M, Papanikolaou A, Kalinderi K, Vyzantiadis TA, Ioakimidou A, Tarlatzis BC. Serum levels of leptin and IP-10 in preeclampsia compared to controls. *Arch Gynecol Obstet* 2015;292:343-7.
10. Martin D, Galisteo R, Gutkind JS. CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex. *J Biol Chem* 2009;284:6038-42.
11. Wu S, Singh S, Varney ML, Kindle S, Singh RK. Modulation of CXCL-8 expression in human melanoma cells regulates tumor growth, angiogenesis, invasion, and metastasis. *Cancer Med* 2012;1:306-17.
12. Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elnor VM, et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. *Science* 1992;258:1798-801.
13. Sahin S, Ozakpinar OB, Eroglu M, Tulunay A, Ciraci E, Uras F, et al. The impact of platelet functions and inflammatory status on the severity of preeclampsia. *J Matern Fetal Neonatal Med* 2015;28:643-8.
14. Li A, Dubey S, Varney ML, Dave BJ, Singh RK. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. *J Immunol* 2003;170:3369-76.
15. Tosun M, Celik H, Avci B, Yavuz E, Alper T, Malatyalioglu E. Maternal and umbilical serum levels of interleukin-6, interleukin-8, and tumor necrosis factor-alpha in normal pregnancies and in pregnancies complicated by preeclampsia. *J Matern Fetal Neonatal Med* 2010;23:880-6.
16. Tsukimori K, Fukushima K, Tsushima A, Nakano H. Generation of reactive oxygen species by neutrophils and endothelial cell injury in normal and preeclamptic pregnancies. *Hypertension* 2005;46:696-700.
17. Shapiro JP, Guzeloglu-Kayisli O, Kayisli UA, Semerci N, Huang SJ, Arlier S, et al. Thrombin impairs human endometrial endothelial angiogenesis; implications for progestin-only contraceptive-induced abnormal uterine bleeding. *Contraception* 2017;95:592-601.
18. Yen CF, Kim SH, Liao SK, Atabekoglu C, Uckac S, Arici A, et al. Increased expression of integrin-linked kinase during decidualization regulates the morphological transformation of endometrial stromal cells. *Fertil Steril* 2017;107:803-12.
19. Stepanova OI, Safronova NU, Furaeva KN, Lvova TU, Sokolov DI, Selkov SA. Effects of placental secretory factors on cytokine production by endothelial cells. *Bull Exp Biol Med* 2013;154:375-8.
20. Güngör ZB, Ekmekçi H, Tüten A, Toprak S, Ayaz G, Çaliskan O, et al. Is there any relationship between adipocytokines and angiogenesis factors to address endothelial dysfunction and platelet aggregation in untreated patients with preeclampsia? *Arch Gynecol Obstet* 2017.
21. Hartley JD, Ferguson BJ, Moffett A. The role of shed placental DNA in the systemic inflammatory syndrome of preeclampsia. *Am J Obstet Gynecol* 2015;213:268-77.
22. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Preeclampsia. *Lancet* 2010;376:631-44.
23. Iciek R, Wender-Ozegowska E, Zawiejska A, Mikolajczak P, Mrozikiewicz PM, Pietryga M, et al. Placental leptin and its receptor genes expression in pregnancies complicated by type 1 diabetes. *J Physiol Pharmacol* 2013;64:579-85.
24. Walsh SW. Plasma from preeclamptic women stimulates transendothelial migration of neutrophils. *Reprod Sci* 2009;16:320-5.
25. Monari F, Pedrielli G, Vergani P, Pozzi E, Mecacci F, Serena C, et al. Adverse Perinatal Outcome in Subsequent Pregnancy after Stillbirth by Placental Vascular Disorders. *PLoS One* 2016;11:e0155761.
26. Vargas VE, Landeros RV, Lopez GE, Zheng J, Magness RR. Uterine artery leptin receptors during the ovarian cycle and pregnancy regulate angiogenesis in ovine uterine artery endothelial cells. *Reprod* 2017;96:866-76.
27. Tsai PJ, Davis J, Bryant-Greenwood G. Systemic and placental leptin and its receptors in pregnancies associated with obesity. *Reprod Sci* 2015;22:189-97.
28. Maymo JL, Perez Perez A, Gambino Y, Calvo JC, Sanchez-Margalet V, Varone CL. Review: Leptin gene expression in the placenta-regulation of a key hormone in trophoblast proliferation and survival. *Placenta* 2011;32(Suppl 2):146-53.
29. Nishizawa H, Pryor-Koishi K, Kato T, Kowa H, Kurahashi H, Udagawa Y. Microarray analysis of differentially expressed fetal genes in placental tissue derived from early and late onset severe pre-eclampsia. *Placenta* 2007;28:487-97.
30. Prior LJ, Davern PJ, Burke SL, Lim K, Armitage JA, Head GA. Exposure to a high-fat diet during development alters leptin and ghrelin sensitivity and elevates renal sympathetic nerve activity and arterial pressure in rabbits. *Hypertension* 2014;63:338-45.
31. Giudici KV, Martini LA. Comparison between body mass index and a body shape index with adiponectin/leptin ratio and markers of glucose metabolism among adolescents. *Ann Hum Biol* 2017;44:489-94.
32. Farias DR, Poston L, Franco-Sena AB, Moura da Silva AA, Pinto T, de Oliveira LC, et al. Maternal lipids and leptin concentrations are associated with large-for-gestational-age births: a prospective cohort study. *Sci Rep* 2017;7:804.
33. Ferrero S, Mazarico E, Valls C, Di Gregorio S, Montejó R, Ibanez L, et al. Relationship between Foetal Growth Restriction and Maternal Nutrition Status Measured by Dual-Energy X-Ray Absorptiometry, Leptin, and Insulin-Like Growth Factor. *Gynecol Obstet Invest* 2015;80:54-9.
34. Mise H, Sagawa N, Matsumoto T, Yura S, Nanno H, Itoh H, et al. Augmented placental production of leptin in preeclampsia: possible involvement of placental hypoxia. *J Clin Endocrinol Metab* 1998;83:3225-9.
35. Odegard RA, Vatten LJ, Nilsen ST, Salvesen KA, Austgulen R. Umbilical cord plasma leptin is increased in preeclampsia. *Am J Obstet Gynecol* 2002;186:427-32.
36. Semczuk M, Borczynska A, Bialas M, Rozwadowska N, Semczuk-Sikora A, Malcher A, et al. Expression of genes coding for proangiogenic factors and their receptors in human placenta complicated by preeclampsia and intrauterine growth restriction. *Reprod Biol* 2013;13:133-8.
37. Huby AC, Otvos L Jr, Belin de Chantemele EJ. Leptin Induces Hypertension and Endothelial Dysfunction via Aldosterone-Dependent Mechanisms in Obese Female Mice. *Hypertension* 2016;67:1020-8.

38. Linnemann K, Malek A, Schneider H, Fusch C. Physiological and pathological regulation of feto/placento/maternal leptin expression. *Biochem Soc Trans* 2001;29:86-90.
39. Valleau JC, Sullivan EL. The impact of leptin on perinatal development and psychopathology. *J Chem Neuroanat* 2014;61:221-32.
40. Yoshimitsu N, Douchi T, Kamio M, Nagata Y. Differences in umbilical venous and arterial leptin levels by mode of delivery. *Obstet Gynecol* 2000;96:342-5.
41. Yura S, Sagawa N, Mise H, Mori T, Masuzaki H, Ogawa Y, et al. A positive umbilical venous-arterial difference of leptin level and its rapid decline after birth. *Am J Obstet Gynecol* 1998;178:926-30.
42. Chu CQ, Lu XJ, Li CH, Chen J. Molecular characterization of a CXCL8-like protein from ayu and its effect on chemotaxis of neutrophils and monocytes/macrophages. *Gene* 2014;548:48-55.
43. Kobayashi Y. The role of chemokines in neutrophil biology. *Front Biosci* 2008;13:2400-7.
44. Laskowska M, Laskowska K, Leszczynska-Gorzalak B, Oleszczuk J. Comparative analysis of the maternal and umbilical interleukin-8 levels in normal pregnancies and in pregnancies complicated by preeclampsia with intrauterine normal growth and intrauterine growth retardation. *J Matern Fetal Neonatal Med* 2007;20:527-32.
45. Cao H, Huang Y, Wang L, Wang H, Pang X, Li K, et al. Leptin promotes migration and invasion of breast cancer cells by stimulating IL-8 production in M2 macrophages. *Oncotarget* 2016;7:65441-53.
46. Vuolteenaho K, Koskinen A, Kukkonen M, Nieminen R, Paivarinta U, Moilanen T, et al. Leptin enhances synthesis of proinflammatory mediators in human osteoarthritic cartilage--mediator role of NO in leptin-induced PGE2, IL-6, and IL-8 production. *Mediators Inflamm* 2009;2009:345838.
47. Granger DN, Senchenkova E. *Inflammation and the Microcirculation*. San Rafael (CA) 2010.
48. Canzonieri BJ, Lewis DF, Groome L, Wang Y. Increased neutrophil numbers account for leukocytosis in women with preeclampsia. *Am J Perinatol* 2009;26:729-32.



The oxidative/anti-oxidative effects of sevoflurane on reproductive system of females: An experimental study

Dişilerin üreme sistemleri üzerinde sevofluranın oksidatif/anti-oksidatif etkileri: Deneysel çalışma

Hatice Yılmaz Doğru¹, İsmail Benli², Serkan Doğru³

¹Gaziosmanpaşa University Faculty of Medicine, Department of Obstetrics and Gynecology, Tokat, Turkey

²Gaziosmanpaşa University Faculty of Medicine, Department of Biochemistry, Tokat, Turkey

³Gaziosmanpaşa University Faculty of Medicine, Department of Anesthesiology and Reanimation, Tokat, Turkey

Abstract

Objective: A permanent balance exists between the production and elimination of reactive oxygen species in all living organisms. The aim of this study was to evaluate the effects of sevoflurane possibly causing an imbalance in the equation of reactive oxygen species on the female rat reproductive system.

Materials and Methods: A total of 30 adult female Wistar-albino rats were placed into an anesthesia chamber to administer sevoflurane. Rats were randomly divided into six groups, each group consisting of five rats: the control group received 2 L/min O₂ 18 min/day for seven days; the first group received 1 minimum alveolar concentration (MAC) of sevoflurane and 2 L/min O₂ 18 min/day for seven days; the second group received 1 MAC of sevoflurane and 2 L/min O₂ 18 min/day for seven days with no treatment for the next seven days; the third group received 1 MAC of sevoflurane and 2 L/min O₂ 18 min/day for 14 days; the fourth group received 1 MAC of sevoflurane and 2 L/min O₂ 18 min/day for 14 days with no treatment for the next seven days; and the fifth group received 1 MAC of sevoflurane and 2 L/min O₂ 18 min/day for 14 days with no treatment for the next 14 days. Bilateral ovaries were subsequently removed for biochemical analysis of tissue anti-oxidative enzyme levels.

Results: Slight fluctuations were detected in mean nitric oxide, prostaglandin E₂, prostaglandin F₂-alpha, superoxide dismutase, glutathione peroxidase, malondialdehyde, alginat dialdehyde, and xanthine oxidase levels between the groups; however, the differences were not significant (p>0.05).

Conclusion: Sevoflurane has no effect on the activity of anti-oxidant systems in the rat ovary.

Keywords: Oxidative stress, nitric oxide, malondialdehyde, reproductive system

Öz

Amaç: Tüm yaşayan organizmalarda reaktif oksijen radikallerinin üretimi ve yıkımı arasında kalıcı bir denge mevcuttur. Bu çalışmanın amacı, dişi rat üreme sistemindeki dengenin bozulması üzerine sevofluranın olası etkilerini değerlendirmektir.

Gereç ve Yöntemler: Toplam 30 adet Wistar-albino rat sevofluran uygulamak için bir anestezi odasına yerleştirildi. Ratlar randomize olarak her biri beş rat içeren altı gruba bölündü: Kontrol grubu yedi gün boyunca 18 dakikada 2 L/dk O₂; birinci grup yedi gün boyunca 18 dakikada 1 minimum alveolar konsantrasyon (MAK) sevofluran ve 2 L/dk O₂; ikinci grup yedi gün boyunca 18 dakikada 1 MAK sevofluran ve 2 L/dk O₂ ve takip eden yedi gün boyunca herhangi bir tedavi almadı; üçüncü grup on dört gün boyunca 18 dakikada 1 MAK sevofluran ve 2 L/dk O₂; dördüncü grup on dört gün boyunca 18 dakikada 1 MAK sevofluran ve 2 L/dk O₂ ve takip eden yedi gün boyunca herhangi bir tedavi almadı; beşinci grup on dört gün boyunca 18 dakikada 1 MAK sevofluran ve 2 L/dk O₂ ve takip eden on dört gün boyunca herhangi bir tedavi almadı. İki taraflı overler doku anti-oksidatif enzim seviyelerinin biyokimyasal analizi için hızlı bir şekilde çıkarıldı.

Bulgular: Grupların ortalama nitrik oksit, prostaglandin E₂, prostaglandin F₂-alfa, süperoksit dismutaz, glutatyon peroksidaz, malondialdehit, aljinat dialdehit ve ksantin oksidaz seviyeleri arasında hafif dalgalanmalar tespit edildi ancak bu değişiklikler anlamlı değildi (p>0,05).

Sonuç: Rat overlerinde sevofluranın anti-oksidatif sistemlerin aktivitesi üzerine herhangi bir etkisi yoktur.

Anahtar Kelimeler: Oksidatif stres, nitrik oksit, malondialdehit, üreme sistemi

PRECIS: Sevoflurane did not show any effect on the activity of anti-oxidant systems in the rat ovary.

Address for Correspondence/Yazışma Adresi: Hatice Yılmaz Doğru, MD,

Gaziosmanpaşa University Faculty of Medicine, Department of Obstetrics and Gynecology, Tokat, Turkey

Phone: +90 505 832 21 34 E-mail: hatice_yilmaz47@hotmail.com ORCID ID: orcid.org/0000-0003-3431-2072

Received/Geliş Tarihi: 12.07.2017 Accepted/Kabul Tarihi: 02.11.2017

©Copyright 2017 by Turkish Society of Obstetrics and Gynecology

Turkish Journal of Obstetrics and Gynecology published by Galenos Publishing House.

Introduction

Sevoflurane [2,2,2-trifluoro-1-(trifluoromethyl) ethyl fluoromethyl ether], which has a boiling point of 58.6 °C, a vapor pressure of 160 mm hemoglobin at 20 °C, and a blood-gas partition coefficient of 0.69 (approximately half of isoflurane), is pleasant-smelling and relatively non-irritating to the airways providing a high inhaled concentration without any adverse effects or irritation⁽¹⁾.

Oxidative stress is a condition as a consequence of an irregularity between the production and elimination of reactive oxygen species that are spontaneously generated during aerobic respiration and consumed endogenously. The tendency of the balance through free oxygen radicals can be deleterious for the sustainability of the life of a cell. Nitric oxide, one of the free radicals, plays a crucial role in the female reproduction system and manages the endometrial, myometrial, and microvasculatory tasks by paracrine functions.

Superoxide dismutase activity has been shown in the granulosa and theca cells of the follicle, where glutathione peroxidase enzyme is localized in follicular fluid⁽²⁾. In contrast, with alginate dialdehyde, the oxidized form of alginate, there has been no study investigating the possible effects on female reproduction⁽³⁾.

Furthermore, prostaglandin E2 and F2-alpha are autocrine and paracrine lipid mediators that are increased during the late secretory phase in which reactive oxygen species trigger the production of prostaglandin F2-alpha^(2,3). A study conducted by Yalçınkaya et al.⁽⁴⁾ on the effects of follicular fluid nitric oxide, malondialdehyde, and reduced glutathione on *in vitro* fertilization outcomes demonstrated that malondialdehyde level was high in the follicular fluid of women with pregnancy, whereas nitric oxide was low. They also found that a positive correlation existed between malondialdehyde levels and the number of grade 1 embryos, and fertilization rates⁽⁴⁾. In this context, several drugs have been investigated for the production or the effects on the anti-oxidative enzyme systems of the body. The role of anesthetic agents is a very popular topic for researchers. Various studies conducted on the impacts of volatile anesthetics on the anti-oxidant system of different tissues showed controversial results. Sevoflurane decreases the intensity of oxidative stress and induced the activity of antioxidant defense mechanisms in erythrocytes⁽⁵⁻¹⁰⁾. Limited studies have been performed on the impacts of sevoflurane on reproductive tissues^(8,9). Therefore, the present study aimed to evaluate the impact of sevoflurane on the oxidant/anti-oxidant systems in the female reproductive tissue of rats.

Materials and Methods

After approval of the Animal Experiments Local Ethics Committee (2016-HADYEK-12), a total of 30 adult female Wistar-albino rats (90 days-old, 250-300 grams, all selected in the same period of estrus cycle as estrus by assessing vaginal smears) were obtained from the experimental medicine unit.

Rats were housed in a room sustained at 20-24 °C with a 12-h light-dark cycle (lights on at 06:00 to 18:00) and constant humidity of 40-50%. All animals were kept in polycarbonate cages and given tap water ad libitum.

For sevoflurane exposure, rats were moved to a 40x50x60 cm anesthesia chamber, which had a connection with an anesthesia system (Prima SP Alpha, Penlon Limited, Oxon, UK). As previously described by Ceyhan et al.⁽¹¹⁾, two holes, one at the top left side of the chamber and the other at the upper right side of the chamber, were opened for anesthetic gas inlet and outlet. Animals were randomly separated into six groups, each group included five rats: the control group (C) was administered 2 L/min O₂ 18 min/day for seven days; the first group (S1) was administered 1 minimum alveolar concentration (MAC) of sevoflurane and 2 L/min O₂ 18 min/day for seven days; the second group (S2) was administered 1 MAC of sevoflurane and 2 L/min O₂ 18 min/day for seven days with no treatment for the next seven days; the third group (S3) was administered 1 MAC of sevoflurane and 2 L/min O₂ 18 min/day for 14 days; the fourth group (S4) was administered 1 MAC of sevoflurane and 2 L/min O₂ in 18 min/day for 14 days with no treatment for the next seven days; and the fifth group (S5) was administered 1 MAC of sevoflurane and 2 L/min O₂ 18 min/day for 14 days with no treatment for the next 14 days. Animals were anesthetized by intraperitoneal injection of ketamine 90 mg/kg (Alfasan International B.V., Woerden, NL) with xylazine 10 mg/kg (Alfasan International B.V., Woerden, NL), and were killed by performing a cervical dislocation at the end of the 7th day in C and S1, the 14th day in S2 and S3, the 2nd day in S4, and the 28th day in S5. Bilateral ovaries were subsequently removed. The ovaries of each animal were placed on ice and then transferred to a -70 °C freezer where they remained frozen until biochemical analysis of tissue anti-oxidative enzyme levels.

Tissue nitric oxide level detection

Nitric oxide is a fast-eliminated molecule that is oxidized to nitrite and subsequently nitrate, which are used as the index parameters of nitric oxide production. The Griess reaction was performed for the detection of plasma nitrite and nitrate levels⁽¹²⁾. First, the protein fraction of the samples was removed using Somogyi reagent. After the total transformation of nitrite to nitrate using coppered cadmium granules, nitrite levels were calculated using spectrophotometry at 545 nm. A reaction curve was constructed with a pack of serial dilutions (10⁻⁸-10⁻³ mol/L) of sodium nitrate. Outcomes were calculated as micromole per liter (micromol/L).

Tissue superoxide dismutase activity detection

Total (copper-zinc, manganese) superoxide dismutase activity was defined using the method previously described by Sun et al.⁽¹³⁾ In brief, the method depends on the formation of nitro blue tetrazolium chloride reduction through the xanthine-xanthine oxidase system. After adding 1 mL ethanol/chloroform mixture (5/3, v/v) to the sample and centrifugation, superoxide

dismutase activity was evaluated in the ethanol phase of the sample. One unit of superoxide dismutase was determined as the enzyme intensity providing 50% inhibition in the nitro blue tetrazolium chloride reduction ratio. Superoxide dismutase activity was displayed as units per liter (U/L).

Tissue glutathione peroxidase activity detection

Glutathione peroxidase activity was calculated using the technique of Paglia and Valentine⁽¹⁴⁾. A chemical reaction was triggered by adding hydrogen peroxide in the mixture of sodium azide, nicotinamide adenine dinucleotide phosphate, glutathione reductase, and reduced glutathione. Thereafter, the absorbance of this solution was calculated using a spectrophotometer at 340 nm. Activity is presented as units per milliliter (U/mL).

Tissue xanthine oxidase activity determination

The measurement was performed using the method reported by Prajda and Weber⁽¹⁵⁾. The activity of xanthine oxidase was calculated using the production of uric acid via xanthine through a spectrophotometry elevation at 293 nm. A functional curve was established using 10-50 mL concentrations of standard xanthine oxidase solutions (Sigma X-1875). One unit of activity was determined as one micromol of uric acid produced per minute (37 °C, pH 7.5), and presented as U/mL.

Tissue alginate dialdehyde activity detection

Tissue protein concentrations were measured using the technique previously described by Lowry et al.⁽¹⁶⁾.

Prostaglandin E2 concentration

Prostaglandin E2 levels were measured using a prostaglandin E2 (514010) enzyme-linked immunosorbent assay (ELISA) (Cayman Chemical Company, Ann Arbor, MI, USA) kit as described in the manufacturer's instructions and presented as pg/mL.

Prostaglandin F2-alpha concentration

Prostaglandin F2-alpha levels were calculated using a prostaglandin F2-alpha (516011) ELISA (Cayman Chemical

Company, Ann Arbor, MI, USA) kit as described in the manufacturer's instructions and presented as pg/mL.

Statistical Analysis

Normality and variance were analyzed using the One-Sample Kolmogorov-Smirnov test. Numeric data are presented as means and standard deviation, and categorical data as frequency and percentage. Oxidative stress marker levels were analyzed using the One-Way ANOVA test, and post-hoc comparisons were conducted using Tukey's honest significant difference test. The Statistical Package for Social Sciences (SPSS Inc., Chicago, IL) version 20.0 program was used to complete all analyses. P values <0.05 were accepted as statistically significant in all analyses.

Results

All animals completed the experiment. No death or any complications occurred during the experimental exposure period. Slight fluctuations were detected in mean nitric oxide, prostaglandin E2, prostaglandin F2-alpha, superoxide dismutase, glutathione peroxidase, malondialdehyde, alginate dialdehyde, and xanthine oxidase levels; however, the differences were not significant ($p>0.05$, Table 1). The minimum levels of nitric oxide, prostaglandin E2, prostaglandin F2-alpha, superoxide dismutase, glutathione peroxidase, malondialdehyde, alginate dialdehyde, and xanthine oxidase were 0.75 ± 0.07 micromol/L in S4, 501.63 ± 149.29 pg/mL in S2, 0.11 ± 0.01 U/mg in S4, 2.51 ± 0.26 U/g in S1, 1.85 ± 0.83 nmol/g in C, 55.38 ± 29.09 nmol/g in S4, and 0.78 ± 0.23 U/g in S5, respectively.

Discussion

The effect of reactive oxygen species appears to be a double-edged sword, they are used as signaling factors in physiologic conditions but also have additional roles in pathologic conditions including in the female reproductive system. There is continuous stability between oxidants and antioxidants. Superoxide dismutase, copper-zinc superoxide dismutase, and manganese superoxide dismutase are located in the

Table 1. Oxidative stress marker levels in rats exposed to sevoflurane

	C	S1	S2	S3	S4	S5	p
NO	1.07±0.30	0.77±0.06	0.96±0.09	0.98±0.49	0.75±0.07	0.91±0.17	0.344
PGE2	521.01±198.09	663.88±285.62	501.63±149.29	688.08±127.66	698.23±183.93	582.64±123.67	0.401
PGF2-alpha	138.09±56.77	111.12±13.99	89.25±29.07	110.09±40.69	136.64±77.55	145.89±27.94	0.376
SOD	0.16±0.04	0.12±0.01	0.14±0.01	0.15±0.07	0.11±0.01	0.14±0.02	0.337
GPX	3.29±1.64	2.51±0.26	3.03±0.59	4.24±1.96	2.58±0.24	3.20±0.32	0.187
MDA	1.85±0.83	2.14±1.00	2.04±0.40	2.44±1.07	2.30±0.23	2.07±0.91	0.892
ADA	71.90±15.91	77.74±18.95	101.79±72.92	76.82±10.27	55.38±29.09	74.23±32.62	0.534
XO	1.08±0.20	1.21±0.50	0.91±0.19	0.81±0.31	1.04±0.44	0.78±0.23	0.351

One-Way ANOVA test. Post-hoc comparisons were conducted by Tukey's HSD. No significant differences were detected in intra-group comparisons

NO: Nitric oxide; PGE2: Prostaglandin E2, PGF2-alpha: Prostaglandin F2-alpha, SOD: Superoxide dismutase, GPX: Glutathione peroxidase, MDA: Malondialdehyde, ADA: Alginate dialdehyde; XO: Xanthine oxidase

granulosa and theca cells of developing follicles⁽¹⁷⁾. In addition, glutathione peroxidase activity can be seen in follicular fluid⁽¹⁸⁾. In contrast to the detrimental effects, oxidative stress may be one of the main factors that can manage ovarian germ and stromal cell physiology. Vascular changes and proteolytic cascades are the major factors regulating ovulation. The signaling between these two processes are established by vascular endothelial growth factor, reactive oxygen, reactive nitrogen species, and cytokines^(17,18). Ben-Shlomo et al.⁽¹⁸⁾ showed that interleukin 1-alpha caused nitric oxide accumulation in rat ovaries, suggesting a possible interaction between cytokines and reactive nitric oxide species. Oxidative stress and cytokines are demonstrated as intercellular and intracellular messengers in rat ovarian tissues^(19,20). There is an evident balance between antioxidant enzymes and reactive oxygen species in the ovaries. Superoxide dismutase, one of the antioxidant enzymes, is intensely present in the theca interna cells of antral follicles. An experimental study revealed that luteal cells reduced the expression of estradiol and progesterone hormones after adding hydrogen peroxide (reactive oxygen species) to the cell culture environment⁽²¹⁾. The preovulatory follicle is heavily guarded against oxidative stress in which glutathione peroxidase is the major enzyme maintaining its lower hydroperoxide levels thus holds a crucial role in gametogenesis and fertilization⁽²²⁾. In this context, the reactive oxygen scavenging system has an important role in all organ systems and the reproductive system. Environmental factors such as anesthetic agents may alter the fine balance of this regulatory mechanism.

The present study showed that acute exposure to sevoflurane by inhalation did not demonstrate any evident differences on oxidative stress markers of reproductive tissues in female rats. Various oxidative enzymes including copper-zinc superoxide dismutase, manganese superoxide dismutase, glutathione peroxidase, gamma-glutamyl-cysteine synthase, and catalase have an important role to protect the oocyte against the effects of oxidative damage during maturation and early preimplantation embryo development. Studies showed that codes for superoxide dismutase were ready to transcript in oocytes at all stages of maturation⁽²³⁾. Oxidative damage may occur with several drugs and diseases, and shows a similar route associated with their development⁽²⁴⁾. Various studies have been conducted on oxidative stress and inflammation, mainly focusing on isoflurane and sevoflurane⁽²⁵⁾. Despite the limited data about the effects of sevoflurane on female ovary tissues, a study by Türkan et al.⁽²⁶⁾ on liver, kidney, brain, and lung of rats demonstrated that sevoflurane caused an increase only in the activity of anti-oxidative enzyme, malondialdehyde in lungs. Allaouchiche et al.⁽⁸⁾ evaluated the impacts of sevoflurane and desflurane on lungs in mechanically-ventilated swine. Thereafter, they analyzed bronchoalveolar lavage fluid specimens and blood samples for levels of superoxide dismutase, glutathione peroxidase,

and malondialdehyde. They found that sevoflurane led to an evident raise in malondialdehyde levels in both bronchoalveolar lavage fluid and plasma.

Free oxygen radicals have crucial roles in the normal immune defense system and metabolic activity. In contrast, the overproduction or disrupted elimination of these radicals may cause mild-to-severe cellular damage and DNA mutations by chemical modifications of cellular protein, carbohydrate, lipid, and nucleotides. Oxidative stress is described as the incline in enzymes of the anti-oxidant defense system⁽²⁷⁾. Anesthetic agents may have a direct effect on the anti-oxidant system causing a decrease in the blood flow of the liver, thus leading to a relative increase in the magnitude of free oxygen radical production⁽²⁸⁾. In contrast, with minor fluctuations detected in oxidative stress markers in the present study, sevoflurane showed no apparent disturbances in the anti-oxidative system of testicular tissue.

Study Limitation

Due to the financial aspects of experimental studies, we could not enhance the design of the study by including neither ovarian cell DNA nor immunohistochemical analysis. These kind of techniques could have provided detailed information about the effects of sevoflurane on the ovarian cell.

Conclusion

This is the first study to define the impacts of sevoflurane on the female rat reproductive system using oxidative system biomarkers. Our findings revealed that sevoflurane has no effect on the activity of anti-oxidant systems in the rat ovary. This result suggests that sevoflurane is a safe anesthetic agent in reproduction-aged females. Comprehensive studies are needed to confirm this outcome.

Ethics

Ethics Committee Approval: This study was approved by Animal Experiments Local Ethics Committee (2016-HADYEK-12).

Peer-review: External and internal peer reviewed.

Author Contributions

Concept: H.Y.D., S.D., Design: H.Y.D., İ.B., Data Collection or Processing: H.Y.D., İ.B., Analysis or Interpretation: H.Y.D., S.D., Literature Search: S.D., Writing: H.Y.D., S.D., İ.B.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study received no financial support.

References

1. Behne M, Wilke HJ, Harder S. Clinical pharmacokinetics of sevoflurane. *Clin Pharmacokinet* 1999;36:13-26.
2. Agarwal A, Gupta S, Sharma RK. Role of oxidative stress in female reproduction. *Reprod Biol Endocrinol* 2005;3:28.
3. Zhu S, Yu X, Xiong S, Liu R, Gu Z, You J, et al. Insights into the rheological behaviors evolution of alginate dialdehyd-crosslinked collagen solutions evaluated by numerical models. *Mater Sci Eng C Mater Biol Appl* 2017;78:727-37.

4. Yalçinkaya E, Cakıroğlu Y, Doğer E, Budak O, Cekmen M, Çalışkan E. Effect of follicular fluid NO, MDA and GSH levels on in vitro fertilization outcomes. *J Turk Ger Gynecol Assoc* 2013;14:136-41.
5. Durak I, Güven T, Birey M, Oztürk HS, Kurtipek O, Yel M, et al. Halothane hepatotoxicity and hepatic free radical metabolism in guinea pigs; the effects of vitamin E. *Can J Anesth* 1996;43:741-8.
6. Durak I, Kurtipek O, Oztürk HS, Birey M, Güven T, Kavutcu M, et al. Impaired antioxidant defense in guinea pig heart tissues treated with halothane. *Can J Anesth* 1997;44:1014-20.
7. Durak I, Oztürk HS, Dikmen B, Güven C, Cimen MY, Büyükoçak S, et al. Isoflurane impairs antioxidant defense system in guinea pig kidney. *Can J Anesth* 1999;46:797-802.
8. Allaouchiche B, Debon R, Goudable J, Chassard D, Dufflo F. Oxidative stress status during exposure to propofol, sevoflurane and desflurane. *Anesth Analg* 2001;93:981-5.
9. Wilson JX, Gelb AW. Free radicals, antioxidants and neurologic injury: Possible relationship to cerebral protection by anesthetics. *J Neurosurg Anesthesiol* 2002;14:66-79.
10. Schneemich CE, Hachenberg T, Ansoorge S, Ittersson A, Bank U. Effects of different anesthetic agents on immune cell function in vitro. *Eur J Anesthesiol* 2005;22:616-23.
11. Ceyhan A, Cincik M, Bedir S, Ustun H, Dagli G, Kalender H. Effects of exposure to new inhalational anesthetics on spermatogenesis and sperm morphology in rabbits. *Arch Androl* 2005;51:305-15.
12. Cortas NK, Wakid NW. Determination of inorganic nitrate in serum and urine by a kinetic cadmium-reduction method. *Clin Chem* 1990;36:1440-3.
13. Sun Y, Oberley LW, Li Y. A simple method for clinical assay of superoxide dismutase. *Clin Chem* 1988;34:497-500.
14. Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. *J Lab Clin Med* 1967;70:158-69.
15. Prajda N, Weber G. Malignant transformation-linked imbalance: decreased xanthine oxidase activity in hepatomas. *FEBS Lett* 1975;59:245-9.
16. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. *J Biol Chem* 1951;193:265-75.
17. Seleem AK, Rafeey AA, Shaalan D, Sherbiny Y, Badawy A. Superoxide dismutase in polycystic ovary syndrome patients undergoing intracytoplasmic sperm injection. *J Assist Reprod Genet* 2014;31:499-504.
18. Ben-Shlomo I, Kokia E, Jackson MJ, Adashi EY, Payne DW. Interleukin-1 beta stimulates nitrite production in the rat ovary: evidence for heterologous cell-cell interaction and for insulin-mediated regulation of the inducible isoform of nitric oxide synthase. *Biol Reprod* 1994;51:310-8.
19. Rosselli M, Keller PJ, Dubey RK. Role of nitric oxide in the biology, physiology and pathophysiology of reproduction. *Hum Reprod Update* 1998;4:3-24.
20. Sugino N, Takiguchi S, Ono M, Tamura H, Shimamura K, Nakamura Y, et al. Nitric oxide concentrations in the follicular fluid and apoptosis of granulosa cells in human follicles. *Hum Reprod* 1996;11:2484-7.
21. Behrman HR, Kodaman PH, Preston SL, Gao S. Oxidative stress and the ovary. *J Soc Gynecol Investig* 2001;8(1 Suppl Precedings):40-2.
22. Paszkowski T, Traub AI, Robinson SY, McMaster D. Selenium dependent glutathione peroxidase activity in human follicular fluid. *Clin Chim Acta* 1995;236:173-80.
23. El Mouatassim S, Guérin P, Ménéz Y. Expression of genes encoding antioxidant enzymes in human and mouse oocytes during the final stages of maturation. *Mol Hum Reprod* 1999;5:720-5.
24. Chi CH, Shiesh SC, Lin XZ. Total antioxidant capacity and malondialdehyde in acute abdominal pain. *Am J Emerg Med* 2002;20:79-82.
25. Lee YM, Song BC, Yeum KJ. Impact of Volatile Anesthetics on Oxidative Stress and Inflammation. *Biomed Res Int* 2015;2015:242709.
26. Türkan H, Aydin A, Sayal A, Eken A, Akay C, Karahalil B. Oxidative and antioxidative effects of desflurane and sevoflurane on rat tissue in vivo. *Arh Hig Rada Toksikol* 2011;62:113-9.
27. Dalle-Donne I, Rossi R, Giustarini D, Milzani A, Colombo R. Protein carbonyl groups as biomarkers of oxidative stress. *Clin Chim Acta* 2003;329:23-38.
28. Lind RC, Gandolfi AJ, Hall PD. The role of oxidative biotransformation of halothane in the guinea pig model of halothane-associated hepatotoxicity. *Anesthesiology* 1989;70:649-53.



Could the female-to-male transgender population be donor candidates for uterus transplantation?

Kadından erkeğe cinsiyet değiştiren kişiler uterus transplantasyonu için donör olabilir mi?

Murat Api¹, Ayşen Boza², Mehmet Ceyhan³

¹Istanbul Medipol University Faculty of Medicine, Department of Obstetrics and Gynecology, İstanbul, Turkey

²American Hospital, Women's Health Centre Assisted Reproduction Unit, İstanbul, Turkey

³University of Health Sciences, Zeynep Kamil Women and Children's Health Training and Research Hospital, Clinic of Obstetrics and Gynecology, İstanbul, Turkey

Abstract

Objective: To evaluate the eligibility of female-to-male (FtM) transgender people as donor candidates with regard to histologic, surgical, and social aspects. **Materials and Methods:** In this prospective cohort study, 31 FtM transgender people underwent standard hysterectomy and bilateral salpingo-oophorectomy for gender reassignment upon their request. The pelvic viscera of the transgender people was intraoperatively observed and the histology of the removed uteri were evaluated for fertility capacity and procurement surgery. A questionnaire was administered to explore their attitude towards uterus donation.

Results: The mean \pm standard deviation age was 28.5 \pm 5 years. The median duration of testosterone supplementation was 2.4 years; therefore, they all had irregular menstrual periods during this therapy. None had any previous abdominal surgery or additional morbidity. The mean uterine volume was 138 \pm 48 cm³. No adenomyosis, endometriosis, polyps, adhesions or uterine anomalies were either observed or reported. Endometrial histology was reported as proliferative (58%), atrophic (29%), and secretory (13%) pattern. Of the 31 transgender people, 30 (96.7%) had a positive attitude; only one had no opinion at the beginning. After detailed information about the procedure was given, 26 (84%) still wanted to volunteer for donation, but 4 (12%) changed their opinion to negative ($p=0.12$, McNemar test).

Conclusion: The proposal of the FtM transgender population as uterus donor is a hypothetical model that has not been experienced before. Nevertheless, our experience revealed that the FtM transgender population would be good candidates socially, legally, and biologically.

Keywords: Uterus, transplantation, live donor, transgender people

Öz

Amaç: Kadından erkeğe cinsiyet değiştiren kişilerin uterus donörü olmaya uygunluklarını histolojik, cerrahi ve sosyal açıdan değerlendirmektir.

Gereç ve Yöntemler: Bu prospektif kohort çalışmada, 31 kişiye kadından erkeğe cinsiyet değişimi için laparoskopik histerektomi ve bilateral salpingo-ooforektomi uygulandı. Bu kişilerin pelvik viserası ve çıkarılan uterusların histolojileri üreme potansiyeli açısından değerlendirildi. Operasyon sonrası uterus donörü olmaya dair tutumlarına dair bir anket uygulandı.

Bulgular: Kişilerin ortalama \pm standart sapma yaşı 28,5 \pm 5 yıldır. Ortalama testosteron desteği alma süresi 2,4 yıl iken destek süresince hastaların tümünün menstrüel periyotları düzensizdi. Herhangi bir kronik hastalık veya geçirilmiş abdominal cerrahileri yoktu. Çıkarılan uterus volümlerinin ortalaması 138 \pm 48 cm³tür. Herhangi bir adenomyozis, endometriozis, polip, adezyon veya uterus anomalisi gözlemlenmedi veya raporlanmadı. Endometrial histolojileri proliferatif (%58), atrofik (%29) ve sekretuar (%13) paternde rapor edildi. Otuz bir kişinin 30'u (%96,7) uterus donörü olma yönünde pozitif bir tutum bildirirken, bir kişi herhangi bir fikri olmadığını söyledi. Nakil için uterusun alınması operasyonu ile ilgili ayrıntılı bilgi verildikten sonra 26 (%84) kişi hala donasyon için gönüllü iken, 4 (%12) kişi kararını değiştirerek negatif tutum beyan etti ($p=0,12$, McNemar testi).

Sonuç: Kadından erkeğe cinsiyet değiştiren kişilerin uterus donörü olması daha önce denenmemiş hipotetik bir modeldir. Bu çalışma ile kadından erkeğe cinsiyet değiştiren kişilerin sosyal, hukuki ve biyolojik açıdan donör olmaya uygun adaylar olduğu düşünülebilir.

Anahtar Kelimeler: Uterus, transplantasyon, canlı donör, transgender

PRECIS: Female to male transgender population would be good for the candidates socially, legally and biologically.

Address for Correspondence/Yazışma Adresi: Ayşen Boza, MD,

American Hospital, Women's Health Centre Assisted Reproduction Unit, İstanbul, Turkey

Phone: +90 530 923 00 46 E-mail: aysenboza@hotmail.com ORCID ID: orcid.org/0000-0002-2019-6798

Received/Geliş Tarihi: 26.05.2017 Accepted/Kabul Tarihi: 05.11.2017

©Copyright 2017 by Turkish Society of Obstetrics and Gynecology

Turkish Journal of Obstetrics and Gynecology published by Galenos Publishing House.

Introduction

Absolute uterine factor infertility (AUF) is characterized by any condition that causes congenital/iatrogenic absence or non-function of uterus, such as severe intrauterine adhesions or multiple leiomyoma, which may destroy the complete architecture of the uterus⁽¹⁻³⁾. Although congenital absence of the uterus Mayer-Rokitansky-Küster-Hausler (MRKH) syndrome was estimated to be present in 1/4500 female births⁽⁴⁾, AUF affects one in every 500 women of reproductive age⁽⁵⁾.

Adoption or gestational surrogacy are the currently available options to overcome childlessness in women with AUF because an artificial uterus to support the embryo and carry the foetus till birth has not yet been invented. However, one or both of the options are forbidden or are not acceptable in several countries due to social, legal or religious reasons. For example, in Turkey surrogacy and in Egypt adoption are not legally approved. Uterus transplantation (UTx), despite it still being at a very experimental stage, is a reasonable option for fertility achievement. It differs from other organ transplantations with its temporary feature that has been kept until the recipient has delivered the desired number of children to limit the immunosuppression period. Therefore, it brings some important clinical and ethical considerations that need to be addressed. The ethical consideration has already been discussed by Farrell and Falcone⁽⁶⁾; therefore, it is beyond the scope of our paper. The clinical issues of this new procedure will be discussed in the context of donor candidates.

The first human UTx was carried out in 2000 in Saudi Arabia⁽⁷⁾, with a uterus from a 46-year-old live donor. It was transplanted into a patient who had undergone emergency peripartum hysterectomy during her first childbirth. This attempt resulted in uterine prolapsus and necrosis followed by removal of the transplanted uterus 3 months after transplantation. The second UTx was reported by Ozkan et al.⁽⁸⁾ from Turkey in 2013 in a recipient with MRKH syndrome who had undergone previous surgery for vaginal reconstruction. The uterus was procured from a brain-dead donor. Eighteen months after the UTx, the patient underwent two embryo transfer cycles⁽⁹⁾. The first cycle resulted in a biochemical pregnancy, and during the second attempt, an intrauterine gestational sac on sonography was confirmed as clinical pregnancy, but it was aborted. In 2014, Brännström et al.⁽¹⁰⁾ initiated the first clinical trial of multiple transplantations, involving nine women who received uteri from live donors. After 6 months, seven uteri remained viable with regular menses and they reported the first successful UTx that resulted in a live birth with a weight of 1775 grams⁽¹¹⁾. As of now, 11 human UTx have been reported and four healthy babies have been born from the aforementioned trial⁽¹²⁾. This report marks an important development to enable live births from women who lack a uterus. In 2009, the International Federation of Obstetrics and Gynecology (FIGO) Committee⁽⁵⁾ reported that it was unethical to remove a uterus for transplantation from young women who had not had the desired number of children. There

seems to be an exception to the FIGO committee opinion. Female-to-male (FtM) transgender people, who voluntarily undergo hysterectomy, can be the most appropriate candidates for donation. The aim of this article was to scrutinize FtM transgender people as to whether they could serve as uterus donors, and to explore their attitude towards uterus donation (UD).

Materials and Methods

From March 2014 to November 2015, 31 FtM transgender people underwent hysterectomy and bilateral salpingo-oophorectomy upon their request after all the legal procedures regarding gender reassignment had been completed. Morphologic and histologic eligibility of the removed uteri were evaluated following surgery. The attitudes of the FtM transgender people towards UD were explored by conducting a survey composed of three choices: positive attitude, negative attitude or no opinion. A senior surgeon (MA) interviewed the transgender people and offered the survey before and after giving detailed information about standard hysterectomy and hysterectomy for procurement. The information about the procedures detailed the type of surgery (i.e. laparotomy/laparoscopy), duration of surgery and hospitalization, and potential complications. Written informed consent was obtained from all patients and the institutional review board approved the study. The McNemar test was used to compare the volunteers before and after giving detailed information about the procedure.

Results

In our cohort of 31 transgender people, the mean \pm standard deviation age was 28.5 \pm 5 years. The patients were on testosterone therapy (Sustanon 250 mg/month, Schering-Plough) for at least two years. The median duration of testosterone supplementation therapy was 2.4 years; therefore, they all had an irregular menstrual history during this period. None had any previous abdominal surgery or additional morbidity. No adenomyosis, endometriosis, polyps, adhesions or uterine anomalies were observed or reported. Histologic examination revealed that the mean uterine volume was 138 \pm 48 cm³. Two patients had intramural myomas with a maximum diameter of 2 cm. Endometrial histology was reported as proliferative (58%), atrophic (29%), and secretory (13%) pattern.

Of the 31-transgender people, 30 (96.7%) had positive attitudes; only one had no opinion at the beginning of the survey. After detailed information about the procedure was given, 26 (84%) still wanted to volunteer for donation, but 4 (12%) changed their opinion to negative ($p=0.12$, McNemar test).

Discussion

Procurement of a uterus from a live transgender person has some advantages; being young and healthy makes them ideal volunteers for donation. According to the evidence from studies on kidney transplantation, compared with recipients

of deceased-donor kidneys, recipients of living-donor kidneys wait less time for transplantation, have a lower risk of rejection, and have better allograft survival and longer life⁽¹³⁾. Moreover, the long-term graft survival of kidneys from live donors is superior to that of kidneys from deceased donors, possibly due to the fact that brain death induces organ injury and associated events. Living donors have to undergo extensive health and psychological assessment. Pre-donation procedures would be more rapid than any other living donors because transgender people have already undergone a two-year psychological and physical assessment for gender reassignment before the operation. Farrell and Falcone⁽¹⁴⁾ commented, “Unlike other living-organ donors, who can expect continued organ system function (e.g., renal or hepatic), the uterus donor loses entirely her ability to have children.” This may trigger some regrets about the donation. FtM transgender people are potential donor candidates who fully volunteer for donation and are more likely to have no regrets concerning this decision.

In the first clinical trial of UTx⁽¹⁰⁾, seven of nine donors were close relatives of the recipients (their mothers or sisters) with a mean age of 53±7 years (Table 1). Unrelated living donors are becoming more common in other organ donations⁽¹⁵⁾. Although living donation in related donors have many advantages for overcoming donor-recipient incompatibility, advances in immunosuppressive therapy make the longevity and function of transplanted organs less dependent on the genetic donor-recipient relationship than in the past⁽¹³⁾. It seems that finding an unrelated donor will not always be easy. Either an unrelated living donor might need the uterus before the end of the reproductive age or the uterus might be useless as a healthy donor organ after the reproductive period because the uterus is a single organ. In the previously mentioned trial, the donors were selected among related postmenopausal women⁽¹⁰⁾. Previously, the effect of uterine aging on age-related decline in female infertility was studied and it was revealed that age-related reproductive failure was attributable to oocyte quality rather than the age of the uterus^(16,17). However, this evidence has come from older but normally menstruating women. Uterine aging may play a role in the reduction of endometrial receptivity, especially in elderly postmenopausal women. This issue needs to be further studied. On the other hand, these donors used combined oral contraceptives for 90 days before procurement to

optimize uterine vasculature. This theoretical approach, which may increase the success of the transplantation, can place the donor in jeopardy of thromboembolism. All of these concerns are far from transgender people who are in their reproductive period. However, we can not obviate the fact that the uterus of transgender people has never harbored a pregnancy or has never been proven functional if it is transplanted. Besides, there is a lack of information as to whether androgen treatment affects the pregnancy potential of the uterus. The transgender patients stated that they had irregular menses under the testosterone supplementation, but when the therapy was suspended, their regular menstrual cycles resumed. It seems that the effect of androgen on the endometrium is transient⁽¹⁸⁾. According to our findings, the uteri of transgender people can be regarded as naïve sources with no morbidity. On this basis, transgender people would be considered as unrelated, readily available, young donors for the future.

Brännström et al.⁽¹¹⁾ developed a national awareness of this new parenthood option UTx in Sweden. In a recent report⁽¹⁹⁾, the public's attitude to UTx was examined and UTx was found to be more acceptable than surrogacy (80% vs. 47%, p<0.001). Surrogacy is not allowed in many countries, and also information on the surrogate mother and their families is scarce. In spite of its potential risk, UTx seems to be more reasonable because it provides intrauterine bonding between the mother and the child. In our study, most of the transgender people accepted the idea of being a uterus donor, but they had some doubts about the uterus procurement surgery. According to the Turkish Lesbian Gay Bisexual Trans-sexual Society records, 1500 FtM transgender individuals (1/25.333 female population) exist. We performed 31 gender reassignment operations over a period of 20 months. It has been estimated that 150 MRKH syndrome cases reach their reproductive ages each year. This rough estimation reveals that if all FtM transgender people agree to donate, this would supply a 10-year demand of UTx for the population with MRKH syndrome in Turkey.

UTx surgery entails isolation of the uterus with bilateral, long venous, and arterial vascular pedicles. The complexity of the surgery is mostly related to the extensive dissection of the pelvic sidewalls, which includes dissection of the ureters from their passages over the iliac vessel bifurcations distally to their inlets into the bladder, and dissection of the uterine veins and uterine

Table 1. Brief characteristics of previous uterus transplantations

Author, year	# cases	Recipient	Donor (age)	Uterus transplantation	Clinical pregnancy (#)	Live birth (#)
Fageeh et al. ⁽⁷⁾	1	Peripartum hysterectomy	Live, unrelated (46)	Uterine prolapsus, necrosis	No	No
Ozkan et al. ⁽⁸⁾	1	MRKH syndrome	Brain dead, unrelated (22)	Successful	Yes	No
Brännström et al. ⁽¹¹⁾	8	MRKH syndrome	Live, related (mean:53)	Successful	Yes (5)	Yes (4)
	1	cervical cancer				

MRKH: Mayer-Rokitansky-Küster-Hauser

arteries from their firm attachments to the ureters. For a living donor, this brings some surgical complications including injury to major pelvic organs, life-threatening bleeding, and infection, amongst other problems. In Saudi Arabia⁽⁷⁾, the donor's left ureter was damaged. Furthermore, in Sweden⁽¹⁰⁾, one of nine donors presented with a utero-vaginal fistula. In addition to extensive dissection of the pelvis, it was reported that the donor surgery lasted 10-13 hours⁽¹⁰⁾.

There is a need for a safe and easy alternative because the duration, complexity, and complications of the operation are unacceptably high for a donor. Transplantation surgery has to be more advanced by using the uterus with short pedicles containing the uterine artery and vein. If this hypothetical short pedicle technique could be achieved, the operations could be risk free and shorter for the donors. Another solution to ease the procedure is the use of other vascular anastomosis rather than uterine vessels. Kisu et al.⁽²⁰⁾ studied experimental surgical technique for UTX for a long time in Japan. Recently, they suggested that the ovarian vein could be used rather than the superficial or deep uterine vein, which were more difficult to dissect⁽²⁰⁾. This proposal can make transplantation surgery less invasive and safe for donors. Long venous ovarian pedicles already exist because FtM transgender surgery encompasses bilateral salpingo-oophorectomy.

In all our case series, every transgender operation was performed via laparoscopy without any complications or conversion to laparotomy. Although laparoscopy has several advantages over laparotomy, by considering laparoscopic uterus procurement surgery, some questions have to be addressed with this specific issue:

1. It is well known that laparoscopy provides better abdominopelvic exploration; with laparoscope magnification, it enables fine dissection of vessels and pneumoperitoneum itself theoretically assists the development of pelvic avascular spaces. Besides these advantages, what are the limitations of laparoscopy in transplant surgery?
2. If an endoscopic approach would be preferred for the donor, could vascular pedicles be damaged during the extraction of the removed uterus through the vagina?
3. Would laparoscopic surgery be more acceptable for donors compared with laparotomy because of its better cosmetic results?

In the near future, UTX will be performed more commonly and the need for donors will be exceedingly debated.

Study Limitations

The results of the study are limited to the patients' characteristics and their attitudes toward UD. There is no information regarding the reasons motivating their decisions. In addition, the cohort is small, which could limit the validity of the study.

Conclusion

The proposal of the FtM transgender population as a uterus donor is a hypothetical model that has not been experienced

before. Nevertheless, our experience has revealed that the FtM transgender population would be ideal candidates socially, legally and biologically.

Acknowledgement

The authors thank Nick Wallcocks for his expert assistance in the English language review as a native speaker.

Ethics

Ethics Committee Approval: The study had been reviewed by the appropriate ethics committee and had been performed in accordance with the ethical standards described in an appropriate version of the 1975 Declaration of Helsinki, as revised in 2000.

Informed Consent: Written informed consent was obtained from all patients and the institutional review board approved the study.

Peer-review: External and internal peer-reviewed.

Authorship Contributions

Surgical and Medical Practices: M.A., A.B., Concept: M.A., Design: M.A., A.B., M.C., Data Collection or Processing: M.A., M.C., Analysis or Interpretation: M.A., A.B., M.C., Literature Search: M.C., Writing: M.A., A.B., M.C.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study received no financial support.

References

1. Al-Inany H. Intrauterine adhesions. An update. *Acta Obstet Gynecol Scand* 2001;80:986-93.
2. Buttram VC Jr RC, Reiter RC. Uterine leiomyomata: etiology, symptomatology, and management. *Fertil Steril* 1981;36:433-45.
3. Grimbizis GF, Gordts S, Di Spiezio Sardo A, Brucker S, De Angelis C, Gergolet M, et al. The ESHRE-ESGE consensus on the classification of female genital tract congenital anomalies. *Gynecol Surg* 2013;10:199-212.
4. Folch M, Pigem I, Konje JC. Mullerian agenesis: etiology, diagnosis, and management. *Obstet Gynecol Surv* 2000;55:644-9.
5. Milliez J. Uterine transplantation FIGO Committee for the Ethical Aspects of Human Reproduction and Women's Health. *Int J Gynaecol Obstet* 2009;106:270.
6. Farrell RM, Falcone T. Uterine transplant: new medical and ethical considerations. *Lancet* 2015;385:581-2.
7. Fageeh W, Raffia H, Jabbad H, Marzouki A. Transplantation of the human uterus. *Int J Gynaecol Obstet* 2002;76:245-51.
8. Ozkan O, Akar ME, Ozkan O, Erdogan O, Hadimioglu N, Yilmaz M, et al. Preliminary results of the first human uterus transplantation from a multiorgan donor. *Fertil Steril* 2013;99:470-6.
9. Erman Akar M, Ozkan O, Aydinuraz B, Dirican K, Cincik M, Mendilcioglu I, et al. Clinical pregnancy after uterus transplantation. *Fertil Steril* 2013;100:1358-63.
10. Brännström M, Johannesson L, Dahm-Kähler P, Enskog A, Mölne J, Kvarnström N, et al. First clinical uterus transplantation trial: a six-month report. *Fertil Steril* 2014;101:1228-36.
11. Brännström M, Johannesson L, Bokström H, Kvarnström N, Mölne J, Dahm-Kähler P, et al. Livebirth after uterus transplantation. *Lancet* 2015;385:607-16.

12. Brannström M. Uterus transplantation. *Curr Opin Organ Transplant* 2015;20:621-8.
13. Reese PP, Boudville N, Garg AX. Living kidney donation: outcomes, ethics, and uncertainty. *Lancet* 2015;385:2003-13.
14. Farrell RM, Falcone T. Uterine transplantation. *Fertil Steril* 2014;101:1244-5.
15. Axelrod DA, McCullough KP, Brewer ED, Becker BN, Segev DL, Rao PS. Kidney and pancreas transplantation in the United States, 1999-2008: the changing face of living donation. *Am J Transplant* 2010;10:987-1002.
16. Navot D, Bergh PA, Williams MA, Garrisi GJ, Guzman I, Sandler B, et al. Poor oocyte quality rather than implantation failure as a cause of age-related decline in female fertility. *Lancet* 1991;337:1375-7.
17. Noci I, Gheri G, Bryk SG, Sgambati E, Moncini D, Paglierani M, et al. Aging of the human endometrium: peri-implantation phase endometrium does not show any age-dependent variation in lectin binding. *Eur J Obstet Gynecol Reprod Biol* 1996;64:11-21.
18. Shufelt CL, Braunstein GD. Safety of testosterone use in women. *Maturitas* 2009;63:63-6.
19. Wennberg AL, Rodriguez-Wallberg KA, Milsom I, Brännström M. Attitudes towards new assisted reproductive technologies in Sweden: a survey in women 30-39 years of age. *Acta Obstet Gynecol Scand* 2016;95:38-44.
20. Kisu I, Banno K, Mihara M, Hara H, Umene K, Adachi M, et al. A surgical technique using the ovarian vein in non-human primate models of potential living-donor surgery of uterus transplantation. *Acta Obstet Gynecol Scand* 2015;94:942-8.



The efficacy of laparoscopic presacral neurectomy in dysmenorrhea: is it related to the amount of excised neural tissue?

Laparoskopik presakral nörektominin etkinliği çıkartılan nöral doku miktarı ile ilişkili midir?

Murat Api¹, Ayşen Boza², Mehmet Ceyhan³, Ecmel Kaygusuz⁴, Hülya Yavuz⁴, Olus Api¹

¹Istanbul Medipol University Faculty of Medicine, Department of Obstetrics and Gynecology, Istanbul, Turkey

²American Hospital, Women's Health Centre and Assited Reproduction Unit, Istanbul, Turkey

³University of Health Sciences, Zeynep Kamil Women and Children Diseases Training and Research Hospital, Clinic of Obstetrics and Gynecology, Istanbul, Turkey

⁴University of Health Sciences, Zeynep Kamil Women and Children Diseases Training and Research Hospital, Clinic of Pathology, Istanbul, Turkey

Abstract

Objective: To assess the correlation between the number of excised neural fibers and degree of pain relief following laparoscopic presacral neurectomy (LPSN).

Materials and Methods: In this before and after study, 20 patients with severe midline dysmenorrhea [Visual Analogue Scale (VAS) >80 mm] unresponsive to medical therapy were consecutively enrolled. All patients underwent LPSN. The superior hypogastric plexus was excised and sent for histologic confirmation. Two pathologists counted the number of neural fibers in the surgically removed tissue. VAS was used for pain assessment before and 2nd, 3rd, 6th, and 12th months after the operations.

Results: Out of the initial 20 patients undergoing LPSN, eight were excluded from the final analysis due to intraoperative diagnosis of endometriosis; therefore, the remaining 12 patients were evaluated. The pain scores significantly decreased at each follow-up visit compared with the preoperative period (p=0.002). The pathologists, who were blinded, reported the median (minimum-maximum) neural fiber count as 46 (20-85) and 47 (18-83). No significant correlation was demonstrated between the number of excised neural fibers and the amount of pain relief following LPSN.

Conclusion: LPSN is an effective surgical procedure to control primary dysmenorrhea. Our preliminary results revealed that the degree of pain relief in cases of severe midline dysmenorrhea was not related to the amount of excised neural tissue in LPSN.

Keywords: Dysmenorrhea, nerve fiber, presacral neurectomy, laparoscopy

Öz

Amaç: Laparoskopik presakral nörektomi (LPSN) sonrası ağrı miktarındaki azalma ile çıkarılan nöral doku miktarı arasındaki korelasyonun değerlendirilmesidir.

Gereç ve Yöntemler: Medikal tedaviye dirençli, şiddetli orta hat dismenoreisi olan [Vizüel Analog Skoru; (VAS) >80 mm] ve LPSN yapılmaya karar verilen 20 ardışık hasta çalışmaya dahil edildi. Operasyonda eksize edilen süperior hipogastrik pleksus histolojik konfirmasyon için patolojiye gönderildi. Cerrahi olarak çıkarılan nöral fibriller iki patoloj tarafından ayrı ayrı sayıldı. Operasyon öncesi ve operasyon sonrası 2., 3., 6. ve 12. aylarda hastaların ağrısı VAS ile değerlendirildi.

Bulgular: LPSN yapılan 20 hastanın 8'i intraoperatif endometriozis tanısı aldığı için analizden çıkarıldı, geriye kalan 12 hasta değerlendirildi. Ağrı skorlarının postoperatif dönemdeki her bir vizitte preoperatif dönem ile kıyaslandığında anlamlı oranda düştüğü izlendi (p=0,002). İki patoloj tarafından rapor edilen medyan (minimum-maksimum) nöral fibril sayısı 46 (20-85) ve 47 (18-83) idi. Eksize edilen nöral fibril sayısı ile LPSN sonrasındaki ağrı azalması arasında anlamlı bir korelasyon bulunmadı.

Sonuç: LPSN primer dismoreyi tedavi etmede etkili bir cerrahi prosedürdür. Elde edilen ön sonuçlara göre ciddi orta hat dismorede LPSN ile eksize edilen nöral doku miktarı ile ağrı iyileşmesi arasında herhangi bir ilişki yoktur.

Anahtar Kelimeler: Dismenore, sinir lifi, presakral nörektomi, laparoskopi

PRECIS: The degree of pain relief after laparoscopic presacral neurectomy is not related to the amount of excised neural tissue.

Address for Correspondence/Yazışma Adresi: Ayşen Boza, MD,

American Hospital, Women's Health Centre and Assited Reproduction Unit, Istanbul, Turkey

Phone: +90 530 923 00 46 E-mail: aysenboza@hotmail.com ORCID ID: orcid.org/0000-0002-2019-6798

Received/Geliş Tarihi: 17.09.2017 Accepted/Kabul Tarihi: 05.11.2017

©Copyright 2017 by Turkish Society of Obstetrics and Gynecology

Turkish Journal of Obstetrics and Gynecology published by Galenos Publishing House.

Introduction

Dysmenorrhea, painful menstrual cramps, is a very common gynecologic problem with a prevalence of 43-90% in women of reproductive age^(1,2). Dysmenorrhea is such a challenge that it interferes with the performance of daily activities, and may even lead to job or school absenteeism. Therefore, the main goal of treatment is to provide pain attenuation sufficient to sustain the woman’s daily performance. Medical therapy is the primary treatment of dysmenorrhea, which includes oral contraceptive pills, systemic or local progestins, non-steroidal anti-inflammatory drugs, danazol and gonadotropin-releasing hormone analogues. Surgical therapies stay as the second line of treatment in refractory cases because medical therapies are associated with a failure rate of 20-25%^(3,4). Surgical intervention includes the interruption of a major group of cervical and uterine sensory nerve fibers, known as pelvic denervation. The presumed mechanism of presacral neurectomy (PSN) for pain relief of dysmenorrhea is primarily based on the anatomy of the sensory pathways from the pelvic viscera through the inferior and superior hypogastric plexus to the spinal column. Excision or incision of the superior hypogastric plexus, located in presacral area and so-called PSN, can disrupt many pain sensory pathways. The surgical technique of PSN was first described by Jaboulay⁽⁵⁾ and Ruggi⁽⁶⁾ as early as 1899. One hundred years after from the first description, Perez⁽⁷⁾ reported the first case of laparoscopic PSN (LPSN).

LPSN is found to be an effective surgical procedure in most cases refractory to medical treatment⁽⁷⁻¹⁰⁾; however, some patients still can not benefit from this approach. This diverse clinical response to LPSN has not yet been elucidated. One explanation may be that other sensory pathways not included in the superior hypogastric plexus may be responsible for cases with partial or no pain attenuation. Another possible mechanism is that the amount of excised neural tissue during LPSN may not be sufficient enough to resolve dysmenorrhea. Factors that determine the degree of response to PSN have yet to be enlightened. We hypothesized that there was an association between the amount of excised neural tissue and the response to therapy. The aim of the present study was to assess the correlation between the number of excised neural fibers and the degree of postoperative pain relief following LPSN.

Materials and Methods

Between July 2013 and August 2015, patients with the sole symptom of dysmenorrhea (pelvic pain during menstrual periods) for more than 6 months were consecutively enrolled in the study. All patients underwent multidisciplinary evaluation by the urology, gastroenterology, physical therapy, and psychiatry departments to exclude other potential causes of pelvic pain. All patients were questioned and physically examined to determine the exact location of their pain. Patients with pelvic pain related to specifiable pathologic conditions such as psychiatric disorder, malignant or infectious disease, previous

pelvic surgery, large uterine leiomyoma, diagnosis of visually or histologically confirmed endometriosis or adenomyosis, and/or patients with lateral pelvic pain were excluded.

The study population consisted of 20 patients, whose most prominent symptoms were severe midline dysmenorrhea [Visual Analogue Scale (VAS) >80 mm] that had been unresponsive to at least two alternate medical therapies for more than 6 months. All patients reported job or school absenteeism in each menstrual period.

Six of the 20 patients reported dyspareunia (painful sexual intercourse) and three had mild chronic pelvic pain (CPP) (pain that occurs below the umbilicus and lasts for at least six months) along with severe midline dysmenorrhea. Patients assessed for LPSN are summarized in a flow chart (Figure 1). Twenty patients underwent LPSN; however, during the laparoscopy, eight patients required additional endometriosis ablation or excision. To rule out the effect of additional procedures on postoperative pain levels, these patients were excluded from the final analysis.

Prior to the operation, all patients gave written informed consent for the details of surgical procedure including the risks, benefits, and recurrence rate of LPSN. A senior surgeon




Figure 1. Flow chart of patients who were assessed for laparoscopic presacral neurectomy

LPSN: Laparoscopic presacral neurectomy

(M.A Massachusetts) performed all LPSN procedures with no intraoperative complications.

The severity of dysmenorrhea was assessed using a 100 mm VAS that ranged from “least possible pain” to “worst possible pain” at the time of hospital admission, and 2, 3, 6, and 12 months following the surgery. At admission, the women were requested to grade the most severe menstrual pain they experienced during the last 6 months using the VAS. The durations of the surgical procedures and hospital stay, blood loss, and intraoperative and postoperative complications were also recorded. All patients were followed up with clinical visits over 12 months to evaluate the degree of pain relief and possible complications. Zeynep Kamil Training and Research Hospital Review Board was approved our study. Written informed consent was provided from all patients to share and publish their medical records.

Surgical procedure

In the steep Trendelenburg position, the small intestines and sigmoid colon over the sacral promontory were pushed out laterally. After identifying the ureter on the right side, the peritoneum overlying the sacral promontory was incised transversally between the sigmoid mesentery on the left side and right ureter on the right side. The tissue on the sacral promontory, presumably the superior hypogastric plexus, was elevated as much to the lateral sides as possible, carefully dissected from the areolar tissue and then, excised approximately 1 cm above and below the L5-S1 disc level using a harmonic scalpel (Ethicon Endo Surgery, Cincinnati, Ohio). The removed plexus segment was sent for histologic evaluation.

Two pathologists (E.K. and H.Y.), who were blinded to the study interest, counted the neural fibers. The nerve specimens, after routine tissue processing, were cut into 3- μ m-thick transverse, oblique, and longitudinal serial sections and deparaffinized in xylol for 10 minutes. They were dehydrated in a graded series of alcohol. The sections were kept in hematoxylin for 5-6 min. and washed with water for 5-10 min. They were then kept in eosin for 3-4 min and cleared in graded series of alcohol. After staining with hematoxylin-eosin, they were left to dry for a few minutes and placed in xylol. The tissues were passed through xylol three times for 10 min. Finally, they were taken out and mounted with a synthetic resin (entella). The sections were examined to determine the most appropriate sample, i.e., the section that included the greatest amount of neural fibers. To prevent repeated counting, the sections were mapped with a pencil (Figure 2).

Statistical Analysis

Statistical analyses were performed using the SPSS software version 20 (SPSS, Inc., Chicago, Illinois, USA). While investigating the associations between non-normally distributed or ordinal variables, the correlation coefficients and their significance were calculated using the Spearman test. Friedman tests were used to compare the difference between the pre- and post-operative pain scores. In the post-

hoc analysis of pairwise comparisons, the Wilcoxon test was performed. The agreement between the two pathologists for the neural fiber count was assessed using Lin's concordance correlation coefficient (ρ_c). A 5% type 1 error level was used to infer statistical significance.

Result

Out of the initial 20 patients undergoing LPSN, eight were excluded from the final analysis due to an intraoperative diagnosis of endometriosis. All of these eight patients had dyspareunia and/or CPP along with dysmenorrhea. The remaining 12 patients were evaluated for the final analysis. The median age was 29 years. All patients had midline dysmenorrhea with a median (minimum-maximum) duration of 11 (7-15) years. The median body mass index was 24.6 kg/m². The median (minimum-maximum) operation time for the LPSN was 32 (21-45) minutes. Blood loss was minimal. There were no minor or major vascular trauma, urinary or gastrointestinal complications related to LPSN. The patients were hospitalized for a maximum of 2 days postoperatively (median 1 day). There was no postoperative voiding dysfunction, constipation or other complications reported during the 12 months of follow-up.

Two pathologists reported the median (minimum-maximum) neural fiber count as 46 (20-85) and 47 (18-83). There was almost perfect agreement between the pathologists for the neural fiber counts [Lin's concordance coefficient (ρ_c)=0.99]. The median pain scores were 9.2, 3.3, 2.6, 1.7, and 1.6 before, and 2, 3, 6, and 12 months following the operation, respectively. Pain scores significantly decreased at each follow-up visit compared with the preoperative period ($p=0.002$). The reduction of pain scores remained stable from 6 to 12 months ($p=0.08$) (Figure 3).




Figure 2. (Stained with hematoxylin and eosin, 40 \times) Neural fibers surrounded by adipose tissue. Neural fibers are indicated by thin arrows; vessels are shown by thick arrows, and the star demonstrates adipose tissue

No statistically significant correlation was found between the neural fiber count and preoperative or postoperative pain scores (Table 1). After the procedure and throughout the follow-up period, all 12 patients reported no pain or mild pain without requiring pain medication.

Discussion

Up to 80% of reproductive aged women are affected by dysmenorrhea, in many cases causing sufficient pain that precludes social and occupational activities. Pain per se is a necessary defense mechanism of the body; however, chronic pain is a disturbing condition that needs to be treated. In persistent pain syndromes, people face distressing situations rather than biologic benefit. The presacral nerve, namely the superior hypogastric plexus, carries pain afferents from the cervix, the body of the uterus, and the proximal fallopian tube, but does not receive fibers from the ovaries and lateral pelvic structures. Therefore, PSN is traditionally performed for midline dysmenorrhea⁽¹¹⁾. At this point, before deciding on surgical treatment, a detailed evaluation of patients to determine the location of pain has paramount importance in order to identify patients who would benefit from the procedure with the highest efficacy. In our study, we excluded subjects who reported lateral pain.

It has been shown that the success rate of PSN in the management of primary dysmenorrhea is 75 to 87%⁽¹²⁻¹⁴⁾. In the study by Jedrzejczak et al.⁽¹³⁾, the efficacy of LPSN was evaluated

in patients with and without endometriosis. Dysmenorrhea decreased at 3 months by 75% in those without endometriosis. Furthermore, these patients reported a significant decline in dyspareunia and pelvic pain unrelated to menses at 3 and 12 months after LPSN. In our cases, the pain scores significantly decreased over months. The median pain scores decreased sharply at the 2nd month, gradually from 2nd to 3rd month and then, remained stable. The patients with dyspareunia and chronic pelvic pain reported substantial pain relief that did not require any analgesic medication. Although the number of our participants is limited to 12 cases, we obtained 100% of efficacy in patients with severe dysmenorrhea and no identifiable pelvic pathology, when nerve bundles were excised.

Previous studies reported that PSN might be ineffective in some cases. There is an on going debate as to whether efficacy could be related to the surgical method used. Some surgeons have asserted that a longer incision should be made on the hypogastric nerve plexus, whereas others claimed that the anatomic variation of nerve fibers at the area below the bifurcation of the aorta caused inconsistency in pain relief⁽¹⁵⁾. Furthermore, because the microscopic anatomy of a nerve plexus can not be differentiated during surgical exploration, surgeons only excise or transect the area where it is presumed to be the possible location of the superior hypogastric plexus. However, the architecture of the presacral area, which consists of fat, connective, vascular, and neural tissue, may mislead adequate excision of neural tissue. To ensure that the neural pathway has been included in the surgical area, histologic confirmation of the excised tissue is needed. On the other hand, the amount of removed neural tissue might be a determinant of surgical success. In our study, the number of neural fibers removed per specimen was counted by the pathologists. We detected that the neural fiber count differed from one patient to another and there was no correlation between the number of fibers removed per tissue and the amount of pain relief. This discrepancy can be explained by individual differences in the number of neural fibers or the complexity of pain perception. Moreover, the neural fiber intensity might not make any difference in pain transmission.

The method for PSN has been described in different approaches (laparotomy, laparoscopy, robotic) with different techniques (only transection or partial excision of nerve bundles) at different levels. Some preferred to excise a segment of 2-3 cm in diameter to prevent re-anastomosis of nerves, but others only transected without excision^(16,17). Chang et al.⁽¹⁵⁾ compared LPSN with modified LPSN by transecting nerve bundles over different




Figure 3. Visual Analogue Scale scores of 12 cases with dysmenorrhea before and 2nd, 3rd, 6th and 12th months after presacral neurectomy

VAS: Visual Analogue Scale

Table 1. Correlation between the number of neural fibers evaluated by two pathologists and the pain scores at each interval

		Preoperative	At 2 nd month	At 3 rd month	At 6 th month	At 12 th month
1 st Pathologist	Correlation coefficient	-0.25	-0.29	-0.17	-0.16	-0.23
	p value	0.42	0.35	0.6	0.6	0.46
2 nd Pathologist	Correlation coefficient	-0.36	-0.6	-0.48	-0.36	-0.02
	p value	0.24	0.04	0.11	0.25	0.95

levels to evaluate long-term effectiveness in pain relief. In traditional LPSN, the presacral nerve bundle is transected over the presacral promontory, whereas in the modified method, it is transected over the aortic bifurcation. Although pain relief was sustained for five years in 90% of patients with both methods, recurrent pain was reported by 82% of the patients in LPSN and 43% in modified LPSN eight years after the operations ($p=0.04$). The authors commented that incomplete resection and re-growth of the nerve fibers might cause this difference. Presacral nerves spread out into a latticework at the level of the first sacral vertebra, where it divides into several branches going to the right and left sides of the pelvis⁽¹⁸⁾. These nerves lie beneath fatty areolar tissue contained in the anterior longitudinal ligament, the middle sacral artery, and the vein plexus, where it is too difficult to distinguish and dissect them completely. In addition, there are individual variations of pelvic anatomy and neurophysiology, intermingling of afferent fibers, intercommunication among nerve plexuses, and cross-talk⁽¹⁹⁾. Excision of the nerves may keep these factors under control and contribute to the long-term effectiveness of the LPSN. We observed a reduction of pain in all subjects supporting the theory that segmental resection might increase the effectiveness of the procedure.

Our study sheds light on the physiology of pain transmission through the superior hypogastric plexus. However, to our knowledge, no studies have identified any association between the efficacy of the procedure and the quantitative or qualitative parameters of excised neural tissue. Inter-observer variability assessment between the pathologists provides the safety of this experimental nerve counting method, which makes it reproducible for further studies.

Study Limitations

Our hypothesis was tested in a small number of cases. Further, the subtypes of the neural fibers were not differentiated.

Conclusion

Our preliminary results revealed that LPSN, if properly performed in selected cases, is an effective surgical procedure to control primary dysmenorrhea. According to the results of our study, the degree of pain relief in severe midline dysmenorrhea is not related to the amount of excised neural tissue in LPSN. The pathophysiology of pain transmission and perception, and the underlying mechanism of the effectiveness of neurectomy need to be further elucidated.

Ethics

Ethics Committee Approval: Zeynep Kamil Training and Research Hospital review board was approved our study.

Informed Consent: Written informed consent was provided from all patients to share and publish their medical records.

Peer-review: External and internal peer-reviewed.

Authorship contributions

Surgical and Medical Practices: M.A., A.B., M.C., Concept: M.A., A.B., Design: M.A., A.B., Data Collection or Processing:

A.B., M.C., Analysis or Interpretation: M.A., A.B., M.C., E.K., H.Y., Literature Search: M.A., O.A., Writing: : M.A., A.B., M.C., E.K., H.Y., O.A.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study received no financial support.

References

- Hurd WW. Criteria that indicate endometriosis is the cause of chronic pelvic pain. *Obstet Gynecol* 1998;92:1029-32.
- Jamieson DJ, Steege JF. The prevalence of dysmenorrhea, dyspareunia, pelvic pain, and irritable bowel syndrome in primary care practices. *Obstet Gynecol* 1996;87:55-8.
- Dawood MY. Premenstrual syndrome and dysmenorrhea. *Urban Schwarzenberg*: 1985.
- Henzl M. Dysmenorrhoea; achievements and challenge. *Sex Med Today* 1985;9:8-12.
- Jaboulay M. Le traitement de la nevralgie pelvienne par la paralysie du sympathique sacre. *Lyon Méd* 1899;90:102-8.
- Ruggi C. La simpatectomia addominale utero-ovarica come mezzo di cura di alcune lesioni interne degli organi genitali della donna. *Bologna: Zanichelli*; 1899.
- Perez JJ. Laparoscopic presacral neurectomy. Results of the first 25 cases. *J Reprod Med* 1990;35:625-30.
- Carter JE. Laparoscopic Treatment for Chronic Pelvic Pain: Results from Three-Year Follow-up. *J Am Assoc Gynecol Laparosc* 1994;1:6-7.
- Proctor ML, Latthe PM, Farquhar CM, Khan KS, Johnson NP. Surgical interruption of pelvic nerve pathways for primary and secondary dysmenorrhoea. *Cochrane Database Syst Rev* 2005:CD001896.
- Tjaden B, Schlaff WD, Kimball A, Rock JA. The efficacy of presacral neurectomy for the relief of midline dysmenorrhea. *Obstet Gynecol* 1990;76:89-91.
- Biggerstaff ED, Foster SN. Laparoscopic presacral neurectomy for treatment of midline pelvic pain. *J Am Assoc Gynecol Laparosc* 1994;2:31-5.
- Chen FP, Chang SD, Chu KK, Soong YK. Comparison of laparoscopic presacral neurectomy and laparoscopic uterine nerve ablation for primary dysmenorrhea. *J Reprod Med* 1996;41:463-6.
- Jedrzejczak P, Sokalska A, Spaczyński RZ, Duleba AJ, Pawelczyk L. Effects of presacral neurectomy on pelvic pain in women with and without endometriosis. *Ginekol Pol* 2009;80:172-8.
- García León F, Oviedo Ortega G, Reyes Cuervo H, Ibarrola Buenabad E, Von der Meden W. [Presacral neurectomy and uterine nerve ablation in chronic pelvic pain. Laparoscopic management. A comparative study]. *Ginecol Obstet Mex* 2003;71:137-42.
- Chang CY, Chang WC, Hung YC, Ho M, Yeh LS, Lin WC. Comparison of a new modified laparoscopic presacral neurectomy and conventional laparoscopic presacral neurectomy in the treatment of midline dysmenorrhea. *Int J Gynaecol Obstet* 2007;99:28-32.
- Chen FP, Soong YK. The efficacy and complications of laparoscopic presacral neurectomy in pelvic pain. *Obstet Gynecol* 1997;90:974-7.
- Kwok A, Lam A, Ford R. Laparoscopic presacral neurectomy: a review. *Obstet Gynecol Surv* 2001;56:99-104.
- Krantz KE. Innervation of the human uterus. *Ann N Y Acad Sci* 1959;75:770-84.
- Rogers RM. Basic neuroanatomy for understanding pelvic pain. *J Am Assoc Gynecol Laparosc* 1999;6:17-25.



Sleep quality of endometrial cancer survivors and the effect of treatments

Endometrium kanseri olan hastalarda uyku kalitesi ve tedavinin etkisi

Tolgay Tuyan İlhan¹, Mustafa Gazi Uçar², Ayhan Gül², Türkan Saymaz İlhan¹, Güler Yavaş³, Çetin Çelik²

¹Mersin Maternity and Children's Diseases Hospital, Clinic of Obstetrics and Gynecology, Mersin, Turkey

²Selçuk University Faculty of Medicine, Department of Obstetrics and Gynecology, Konya, Turkey

³Selçuk University Faculty of Medicine, Department of Radiation Oncology, Konya, Turkey

Abstract

Objective: Sleep disorders affect 54.9% of gynaecologic cancer survivors. The effect of treatment methods on sleep quality is not clear. This study evaluated the sleep quality of survivors of endometrial cancer and compared the effects of different treatments on sleep quality.

Materials and Methods: Patients were categorised as surgery (group 1), surgery + brachytherapy (BRT) (group 2), surgery + external beam radiation therapy (EBRT) (group 3), and surgery + EBRT + BRT + chemotherapy (group 4). Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI) questionnaire. The PSQI was completed by the participants before surgery, 1, 3, and 6 months after each treatment was completed. The PSQI scores were compared between the different measurement times and different study groups.

Results: This study enrolled 114 patients with a mean age of 58.1±11 years. The number of participants in each group was 53 (46.5%), 14 (12.3%), 12 (10.5%), and 35 (30.7%), respectively. At baseline, 28 (24.6%) patients reported poor sleep quality. The mean PSQI score reached the maximum level at the second measurement and decreased slightly during follow-up and the change in the PSQI score was significant (p=0.001). Group 3 and group 4 had significantly higher scores from baseline (p<0.008). At time point 3, the differences between the groups were significant. At time point 4, the most prominent effect of treatment on sleep quality was observed in patients with combined chemo-radiotherapy when compared with the other study groups.

Conclusion: Most survivors of endometrial cancer are affected by poor sleep quality during their treatment. To improve these patients' quality of life, this disorder must be considered at each visit and tailored care plans should be developed to meet the women's needs. Further studies are needed to evaluate the long-term results of sleep quality on patients with endometrial cancer.

Keywords: Endometrial cancer, sleep disorders, sleep quality

Öz

Amaç: Uyku bozuklukları jinekolojik kanserli hastaların %54,9'unu etkilemektedir ve önemli bir sağlık sorunu oluşturmaktadır. Tedavi yöntemlerinin uyku kalitesine olan etkisi net değildir. Bu çalışma endometrium kanseri tedavisi alan hastalarda uyku kalitesinin değerlendirilmesi ve tedavi yöntemlerinin uyku kalitesine etkisini karşılaştırmayı amaçlamaktadır.

Gereç ve Yöntemler: Hastalar farklı tedavi gruplarında değerlendirildi: (grup 1) cerrahi, (grup 2) cerrahi + brakiterapi (BRT), (grup 3) cerrahi + eksternal-ışın radyasyon tedavisi (EBRT) ve (grup 4) cerrahi + EBRT + BRT + kemoterapi. Uyku kalitesi Pittsburgh Uyku Kalitesi İndeksi (PSQI) anket formu kullanılarak değerlendirildi. Bu form katılımcılar tarafında ilk olarak tedavi öncesi dolduruldu. İkinci ölçüm her bir tedavi, yöntemin bitiminde 1 ay sonra ve sonrasında 3. ve 6. aylarda yapıldı. PSQI skorları farklı klinik gruplarda ve farklı ölçüm zamanlarında karşılaştırıldı.

Bulgular: Bu çalışmaya 114 katılımcı dahil olmuştur. Çalışma grubunu ortalama yaşı 58,1±11'dir. Hastaların 53'ü (%46,5) sadece cerrahi, 14'ü (%12,3) cerrahi + BRT, 12'si (%10,5) cerrahi + BRT + eksternal radyoterapi ve 35'i (%30,7) hasta kemoradyoterapi tedavisi aldı. Başlangıçta, 28 (%24,6) hasta düşük uyku kalitesi bildirdi. Ortalama PSQI skoru ikinci ölçümde maksimuma ulaştı ve takipler boyunca azaldı. PSQI skorundaki değişim anlamlı bulundu (p=0,001). Üçüncü ölçümde gruplar arası karşılaştırmada anlamlı farklılık saptandı. Üçüncü ve dördüncü grupların ortalama skorları başlangıç skorlarında anlamlı yüksek saptandı (p<0,008). Dördüncü ölçümde tedavi yöntemleri içerisinde uyku kalitesine en belirgin etki kombine kemoradyoterapi alan hasta grubunda gözlemlendi.

Sonuç: Endometrium kanseri tedavisi alan hastaların birçoğu düşük uyku kalitesi sorunu yaşamaktadır. Hastaların yaşam kalitesini artırmak için bu durum her muayenede sorgulanmalı ve hastanın ihtiyaçlarının karşılayacak kişiye özel tedavi planları yapılmalıdır. Bu durumun uzun dönem sonuçlarının değerlendirilmesi için daha fazla çalışmaya ihtiyaç vardır.

Anahtar Kelimeler: Endometrium kanseri, uyku bozukluğu, uyku kalitesi

Address for Correspondence/Yazışma Adresi: Tolgay Tuyan İlhan, MD,

Mersin Maternity and Children's Diseases Hospital, Clinic of Obstetrics and Gynecology, Mersin, Turkey

Phone: +90 532 786 05 91 E-mail: tolgaytuyan@yahoo.com ORCID ID: orcid.org/0000-0002-2186-441X

Received/Geliş Tarihi: 21.10.2017 Accepted/Kabul Tarihi: 12.11.2017

©Copyright 2017 by Turkish Society of Obstetrics and Gynecology

Turkish Journal of Obstetrics and Gynecology published by Galenos Publishing House.

PRECIS: We determined the effect of treatment on the sleep quality of endometrial cancer survivors by using special questionnaire.

Introduction

Sleep disorders affect an estimated 35% to 40% of adults⁽¹⁾. These disorders affect 54.9% of survivors of gynaecologic cancer and constitute a prevalent health issue⁽²⁾. Sleep disorders have been shown to adversely affect the quality of life (QoL) of patients with ovarian, breast, and lung cancer⁽³⁻⁶⁾. Sleep disorders may arise at any stage of cancer as both cancer itself and therapeutic modalities may lead to sleep disturbance. Several mechanisms have been hypothesized for sleep disturbance in patients with cancer. Some inflammatory signals, tumour necrosis factor and C-reactive protein, as well as the effects of depression and distress are postulated as mechanisms of sleep disorders⁽⁷⁻¹⁰⁾. It was previously shown that radiotherapy affects the QoL of women with endometrial cancer (EC) probably due to radiotherapy-induced urologic symptoms in patients with cervical cancer^(2,11). Moreover, surgery seems to affect sleep quality mainly through surgical stress, pain, and medications. The role of chemotherapy remains controversial so far with few studies reporting inconsistent results. However, the impact of specific types of cancer on sleep still needs to be addressed because several important cofactors for sleep disorders such as age and sex may vary in particular cancer types.

EC is the second most common gynaecologic malignancy worldwide,⁽¹²⁾ with an annual incidence of 300.000⁽¹³⁾. With improvements in diagnostic techniques and novel treatment modalities, most uterine cancers are diagnosed at an early stage, and patients have favourable prognoses⁽¹⁴⁻¹⁶⁾. So far, there are only robust data on the impact of EC on sleep quality. Therefore, the present study evaluated the sleep quality of EC survivors and compared the effects of different treatment modalities on sleep quality. In particular, we sought to determine if chemotherapy, radiotherapy or both as an adjuvant to surgery had any impact on sleep quality in patients with EC.

Materials and Methods

This study enrolled 114 patients with histologically proven EC who had completed treatment in the Selçuk University Faculty of Medicine Department of Gynaecological Oncology from 2012 to 2016. The study was approved by the Research Ethics Committee of Selçuk University (approval number: 2014/135). Written informed consent was obtained from all patients. All patients underwent a hysterectomy, bilateral salpingo-oophorectomy, and lymph node dissection. Debulking was performed as indicated for advanced-stage EC. All patients were staged according to the International Federation of Gynaecology and Obstetrics 2009 staging system for EC. For patients with stage Ia (<50% myometrial invasion) and grade 1 or 2 disease, adjuvant brachytherapy (BRT) was planned based on various risk factors, including patient age, lymphovascular space invasion, tumour size, and the presence of lower uterine

(cervical glandular/stromal) infiltration. For women with grade 1 or 2 cancer and $\geq 50\%$ myometrial invasion or grade 3 cancer and <50% myometrial invasion, vaginal BRT was performed. Patients with grade 3 cancer and $\geq 50\%$ myometrial invasion or cervical stromal invasion were treated with external beam radiotherapy (EBRT). For women with high-risk early-stage disease or advanced disease, we administered EBRT \pm BRT \pm chemotherapy. Patients received concurrent paclitaxel (175 mg/m²) and carboplatin (AUC=5), every 3 weeks for 6 cycles. Patients who received only BRT postoperatively were treated in five fractions at a dose of 5.5 Gy/fraction. Patients with EC who were treated with EBRT received 45.0 to 50.4 gray (Gy) with three-dimensional conformal radiotherapy using 18 mega volt photon beams. When EBRT and BRT were combined, we used the same EBRT dose with three fractions of BRT at a dose of 7 Gy/fraction. The inclusion criteria were histologically proven EC and age of >18 years. The exclusion criteria were recurrent EC, preoperative sleep disorder, the use of antipsychotic or anxiolytic drugs, and loss to follow-up. Demographic data, physical properties, medical comorbidities, and complications were recorded.

Measurement

Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI), which comprises 19 self-rated items and incorporates 7 different components (subjective sleep quality, sleep latency, habitual sleep efficiency, night-time disturbances, sleep duration, use of sleep medications, and daytime dysfunction); the total score is the sum of the component scores. A total score of >5 indicates poor sleep quality. This questionnaire is an effective instrument for assessing the sleep quality of patients with cancer⁽¹⁷⁾. The PSQI was first completed by the participants before surgery (time 1). The time of the second questionnaire differed for each treatment method. Results were obtained after the final pathologic examination, and the patients were assigned to different treatment groups: surgery (group 1), surgery + BRT (group 2), surgery + EBRT (group 3), and surgery + EBRT + BRT + chemotherapy (group 4). The second measurement was made 1 month after each treatment was completed (time 2), and the test was repeated 3 (time 3) and 6 (time 4) months after treatment was completed. The PSQI scores were compared at different measurement times in the different study groups.

Statistical Analysis

Continuous variables were examined for normal distribution using the Kolmogorov-Smirnov test. Data are shown as the median (range) or number of cases and percentages where applicable. The mean values were compared between the groups using Student's t-test, and the Mann-Whitney U test was used to compare median values. Nominal data were analysed using Pearson's chi-square or Fisher's exact test where applicable.

Friedman's test was used to determine the statistical significance of differences among repeated clinical measurements. When the Friedman test yielded a significant p-value, Wilcoxon's 3 was used to identify which parameter was different. Bonferroni correction was applied to control for type 1 errors. Correlation analyses were performed to determine the correlations between sleep quality and variables. In all analyses, $p < 0.05$ was taken to indicate statistical significance. The statistical analyses were performed with SPSS ver. 17.0 (SPSS, Chicago, IL).

Results

This study enrolled 114 patients with a mean age of 58.1 ± 11 years. The final treatment was surgery for 53 (46.5%) patients, surgery + BRT for 14 (12.3%), surgery + EBRT for 12 (10.5%), and surgery + computed tomography + EBRT + BRT for 35 (30.7%). Ninety patients (78.9%) had type 1 EC and 24 (21.1%) had type 2 EC. The patients' characteristics are shown in Table 1.

Pittsburgh Sleep Quality Index scores

At baseline, 28 (24.6%) patients reported poor sleep quality (PSQI score of >5). There were no relationships between sleep quality and age, marital status, education status, economic status or menopausal status. A negative correlation was observed between body mass index and sleep quality ($r = -0.189$; $p = 0.4$). The mean PSQI score at time 1 was 4.59 ± 2.80 . The difference in the baseline PSQI score among the treatment groups was not significant ($p = 0.296$). The score decreased slightly during follow-up. The change in the PSQI score was significant at each time point ($p < 0.05$). Table 2 shows the mean PSQI score and rate of sleep disorders of the patients at the different measurement times.

At time 2, the PSQI score was 8.12 ± 4.30 , which was the maximum score reached. Poor sleep quality was reported by 79 (69.3%) patients. The differences between the study groups were significant ($p < 0.05$). The difference between groups 1 and 2 was not significant. Group 3 had a higher PSQI score, but this was not significant. However, group 4 had a significantly higher score than the other groups ($p < 0.008$) (Table 3). The rate of poor sleep quality was 60.4%, 64.3%, 66.7%, and 85.7% in groups 1 to 4, respectively. Patients in group 4 were more likely to have poor sleep quality than those undergoing other treatments [odds ratio (OR): 3.67; 95% confidence interval (CI): (1.28-10.49); $p = 0.011$]. Subjective sleep quality, habitual sleep efficiency, and sleep duration were the most affected components of the PSQI in group 4.

At time 3, the mean PSQI score was 7.2 ± 3.9 . The differences between the treatment groups were significant ($p = 0.001$). Group 4 had a significantly higher PSQI score than groups 1 and 2 ($p < 0.008$). At time 3, the mean PSQI score in groups 1 and 2 was not significantly different from the baseline score, whereas groups 3 and 4 had higher scores ($p < 0.008$) (Table 3). The rates of poor sleep quality were 22.6%, 35.6%, 66.7%, and 74.3% in groups 1 to 4, respectively. Patients in group 4

were more likely to have poor sleep quality than those receiving other treatments [OR: 6.24; 95% CI: (2.55-15.25); $p \leq 0.001$]. At time 4, the mean PSQI score was 6.67 ± 3.60 . The differences between the treatment groups were significant ($p = 0.012$). Group 4 had a significantly higher PSQI score than groups 1 and 2 ($p < 0.008$), and group 4 had significantly poorer sleep quality (Table 3). Figure 1 shows the component scores and changes at each measurement time.

Table 1. Patient's characteristics

No. of patients	114
Age	58.1 ± 11 (28-82)
Gravida	3.15 ± 1.4
Parity	2.64 ± 1.3
BMI (kg/m ²)	28.5 ± 3.3
Hospital stay (day)	3.9 ± 0.8
Marital status	n (%)
Single	3 (2.6)
Married	97 (85.1)
Divorced/widow	14 (12.3)
Disease characteristics	
Type 1 endometrial cancer	90 (78.9)
Type 2 endometrial cancer	24 (21.1)
Stage	
1A	48 (41.7)
1B	20 (17.5)
2	11 (9.6)
3A	6 (5.2)
3B	5 (4.3)
3C	17 (14.8)
4A	5 (4.3)
4B	2 (1.7)
Comorbidities	n (%)
Diabetes	25 (21.9)
Hypertension	39 (34.2)
Asthma	8 (9.1)
Valvular heart disease	4 (3)
Treatment	
Surgery	53 (46.5%)
Surgery + BRT	14 (12.3%)
Surgery + BRT + EBRT	12 (10.5%)
Surgery + EBRT + CT	35 (30.7%)

BRT: Brachytherapy, EBRT: External beam radiotherapy, CT: Chemotherapy, BMI: Body mass index

Discussion

To our knowledge, this is the first prospective study to evaluate sleep disorders and anxiety in Turkish women with EC. We followed up 114 patients for 6 months after the primary treatment was completed. The main findings of the present study are as follows: patients with EC have similar rates of sleep

disturbance at diagnosis. Overall, sleep quality increases upon the completion of therapy, which then decreases gradually over time. Combined use of chemotherapy and radiotherapy has the greatest impact on sleep quality, but BRT had on adverse effect on sleep quality.

It was suggested in several studies that release of several cytokines such as tumour necrosis factor and C-reactive protein, as well as the effects of depression and distress were the mechanisms of sleep disorders. There is also a relationship between sleep disorders and cancer-related fatigue⁽¹⁸⁾, probably by desynchronisation of the circadian rhythm⁽¹⁹⁾. The relationship between noncancerous gynaecological conditions and poor sleep quality was observed in 33.7% of the participants with benign gynaecologic disease⁽²⁰⁾. The importance of QoL on the prognosis of different cancer types was assessed in a global study and the authors reported that QoL predicted clinical outcomes well⁽²¹⁾. Before surgery, patients with ovarian cancer reported a high sleep disorder rate⁽²²⁾. In ovarian cancer, abdominal discomfort might lead to poor sleep quality. Unlike previous studies, our data suggest that patients with EC had comparable sleep quality before treatment. In our study population, 24.6% of women had poor sleep quality before treatment, similar to that of the healthy population. We believe this difference may




Figure 1. Component scores at each measurement time

Table 2. Comparison of Pittsburgh Sleep Quality Index scores at different measurement times

	Time 1	Time 2	Time 3	Time 4	p
Whole patients					
PSQI score [¥]	4.59±2.80	8.12±4.30 ^a	7.20±3.90 ^{a,b}	6.67±3.60 ^{a,b,c}	0.001*
Poor sleep quality, n (%) ^β	28 (24.6)	79 (69.3)	74 (64.9)	68 (59.6)	<0.001*
Group 1[¥]					
PSQI score [¥]	4.05±2.17	6.86±0.40 ^a	5.79±3.80 ^b	5.90±3.40 ^b	<0.001*
Group 2[¥]					
PSQI score [¥]	4.50±2.70	6.28±2.80 ^a	4.92±1.50	5.42±3.10 ^b	0.001*
Group 3[¥]					
PSQI score [¥]	4.16±2.60	6.58±2.70 ^a	6.62±1.40 ^a	5.25± 3.10 ^{b,c}	0.004*
Group 4[¥]					
PSQI score [¥]	5.62±2.60	11.11±4.90 ^a	9.11±4.70 ^{a,b}	8.42±3.60 ^{a,b,c}	<0.001*

[¥]Friedman test, ^βChi-square test, PSQI: Pittsburgh Sleep Quality Index, *Statistically significant p-value
Significant differences from times ^a1, ^b2, and ^c3 (all p<0.008) after Bonferroni correction
Time 1: Before surgery, Time 2: 1 month after treatment, Time 3: 3 months after treatment, Time 4: 6 months after treatment

Table 3. Comparison of Pittsburgh Sleep Quality Index scores of different treatment groups

	Group 1	Group 2	Group 3	Group 4	p
Time 1	4.05±2.17	4.50±2.70	4.16±2.60	5.62±2.60	0.296
Time 2	6.86±3.40	6.28±2.80	7.02±2.70	11.11±4.90 ^{a,b,c}	≤0.001*
Time 3	5.79±3.80	4.92±1.50	5.58±1.40	9.11±4.70 ^{a,b}	0.001*
Time 4	5.90±3.40	5.42±3.10	6.41±3.30	8.42±3.60 ^{a,b}	0.012*

*Statistically significant p-value
Significant differences from times ^a1, ^b2, and ^c3 (all p<0.008) after Bonferroni correction

be related to the nature of EC which, unlike ovarian cancer, is generally localised at diagnosis and lacks abdominal symptoms. Many studies have suggested an association between surgery and poor sleep quality^(23,24). Sleep fragmentation and reduced sleep time are the primary symptoms observed after surgery. Surgical stress, pain, and medications are suggested causes of poor sleep quality^(23,24). In our study cohort, the mean PSQI score increased significantly compared with the baseline scores and 79 (69.3%) patients had poor sleep quality postoperatively. Subjective sleep quality, sleep disturbances, and daytime dysfunction are the most affected components of the PSQI by surgery. Our data are in keeping with these observations because our cohort had the highest rate of sleep disturbance immediately after surgery (time 2).

Radiotherapy affects the QoL of women with EC, as shown in many studies^(2,11). There is an association between poor sleep quality and radiotherapy in patients with cervical cancer⁽²⁵⁾. The potential mechanisms of the poor sleep quality after radiotherapy could be that the radiotherapy induces urologic symptoms⁽²⁾. Assessment of bladder symptoms in cervical and EC survivors showed that radiotherapy for EC was associated with nocturia, and BRT was associated with the severity of the nocturia⁽²⁶⁾. In the present cohort, patients receiving EBRT alone as an adjuvant therapy had PSQI scores similar to patients receiving BRT or no adjuvant therapy. Daytime dysfunction, sleep latency, and subjective sleep quality were the components most affected after EBRT. Another study showed the impact of radiotherapy on the QoL of patients with cancer and concluded that the negative effect of radiotherapy was temporary and improved 1 month after treatment was completed⁽²⁷⁾. In our study cohort, the PSQI scores were improved slightly at 3 months, but this was not significant. Six months after treatment, the improvement was significant. This result was similar to previous studies. The effect of radiotherapy on sleep quality continues for at least 3 months after radiotherapy is completed.

The effect of chemotherapy on sleep quality is controversial. In breast, prostate, and ovarian cancer, high rates of sleep disorders before treatment and improvement after treatment have been reported^(4,28). Poor sleep quality during chemotherapy for rectal cancer has also been reported⁽²⁹⁾. Palesh et al.⁽³⁰⁾ assessed the association between cancer and sleep quality and concluded that the rate of insomnia was three times higher in patients receiving chemotherapy. Patients receiving combined chemo-radiotherapy are more likely to develop sleep disorders. In our study, The PSQI scores were significantly higher in the chemo-radiotherapy group at all follow-up times. In the chemo-radiotherapy group, subjective sleep quality, habitual sleep efficiency, and sleep duration were the most affected components of the PSQI. We believe the adverse effect profile of the present chemotherapy regimen such as neurotoxicity, emesis, and nephrotoxicity might account for decreased sleep quality in patients who received chemotherapy.

Study Limitation

Our study has some limitations that deserve mention. First, it was conducted at a single centre and the patient group was relatively small and heterogeneous. We did not evaluate symptoms that might affect sleep quality. Moreover, treatments could not be randomly assigned and sleep quality was assessed by only subjective sleep measures. However, this study was a prospective study and allowed for comparison different treatment methods.

Conclusion

Most survivors of EC are affected by poor sleep quality during their treatment. The effects of surgery and BRT on sleep quality appear to be short-term effects. Combined treatment with radiotherapy and chemotherapy seemed to have more severe, long-term effects on sleep quality. This conclusion is based on changes in sleep quality scores at each timeline during treatment. However, we were unable to identify whether the higher rate of sleep disturbance was due to more advanced disease or the therapy itself. Further studies are needed to evaluate the long-term results of sleep quality on patients with EC.

Ethics

Ethics Committee Approval: The study was approved by the Research Ethics Committee of Selçuk University (approval number: 2014/135).

Informed Consent: Written informed consent was obtained from all patients.

Peer-review: Internally peer-reviewed.

Authorship Contributions

Surgical and Medical Practices: Ç.Ç., T.T.İ., A.G., Concept: Ç.Ç., Design: T.T.İ., M.G.U., G.Y., Data Collection or Processing: T.T.İ., A.G., Analysis or Interpretation: T.S.İ., Literature Search: T.T.İ., T.S.İ., Writing: T.T.İ., T.S.İ., A.G.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study received no financial support.

References

1. Hossain JL, Shapiro CM. The prevalence, costimplications, and management of sleep disorders: an overview. *Sleep Breath* 2002;6:85-102.
2. Westin SN, Sun CC, Tung CS, Lacour RA, Meyer LA, Urbauer DL. et al. Survivors of gynecologic malignancies: impact of treatment on health and well-being. *J Cancer Surviv* 2016;10:261-70.
3. Gil KM, Gibbons HE, Jenison EL, Hopkins MP, von Gruenigen VE. Baseline characteristics influencing quality of life in women undergoing gynecologic oncology surgery. *Health Qual Life Outcomes* 2007;1:25.
4. Sandadi S, Frasure HE, Broderick MJ, Waggoner SE, Miller JA, von Gruenigen VE. The effect of sleep disturbance on quality of life in women with ovarian cancer. *Gynecol Oncol* 2011;123:351-5.
5. Fortner BV, Stepanski EJ, Wang SC, Kasprovicz S, Durrence HH. Sleep and quality of life in breast cancer patients. *J Pain Symptom Manage* 2002;24:471-80.

6. Vena C, Parker K, Allen R, Bliwise D, Jain S, Kimble L. Sleep-wake disturbances and quality of life in patients with advanced lung cancer. *Oncol Nurs Forum* 2006;33:761-9.
7. Thomas KS, Motivala S, Olmstead R, Irwin MR. Sleep depth and fatigue: role of cellular inflammatory activation. *Brain Behav Immun* 2011;25:53-8.
8. Medina AB, Lechuga DA, Escandón OS, Moctezuma JV. Update of sleep alterations in depression. *Sleep Sci* 2014;7:165-9.
9. Vgontzas AN, Zoumakis M, Papanicolaou DA, Bixler EO, Prolo P, Lin HM, et al. Chronic insomnia is associated with a shift of interleukin-6 and tumor necrosis factor secretion from nighttime to daytime. *Metabolism* 2002;51:887-92.
10. Meier-Ewert HK, Ridker PM, Rifai N, Regan MM, Price NJ, Dinges DF, et al. Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk. *J Am Coll Cardiol* 2004;43:678-83.
11. Yavas G, Dogan NU, Yavas C, Benzer N, Yuce D, Celik C. Prospective assessment of quality of life and psychological distress in patients with gynecologic malignancy: a 1-year prospective study. *Int J Gynecol Cancer* 2012;22:1096-101.
12. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. *CA Cancer J Clin* 2015;65:87-108.
13. McGuire S. World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. *Adv Nutr* 2016;7:418-9.
14. Lewin SN, Herzog TJ, Barrena Medel NI, Deutsch I, Burke WM, Sun X, et al. Comparative performance of the 2009 international Federation of gynecology and obstetrics' staging system for uterine corpus cancer. *Obstet Gynecol* 2010;116:1141-9.
15. Creutzberg CL, Nout RA, Lybeert ML, Wárlám-Rodenhuis CC, Jobsen JJ, Mens JW, et al. Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. *Int J Radiat Oncol Biol Phys* 2011;81:631-8.
16. Galaal K, Al Moundhri M, Bryant A, Lopes AD, Lawrie TA. Adjuvant chemotherapy for advanced endometrial cancer. *Cochrane Database Syst Rev* 2014:CD010681.
17. Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. *Psychiatry Res* 1989;28:193-213.
18. Goforth HW, Davis MP. Treatment of fatigue and sleep disorders in cancer patients. *Cancer J* 2014;20:306-12.
19. Payne JK. Altered circadian rhythms and cancer-related fatigue outcomes. *Integr Cancer Ther* 2011;10:221-33.
20. Singh JK, Learman LA, Nakagawa S, Gregorich SE, Kuppermann M. Sleep problems among women with noncancerous gynecologic conditions. *J Psychosom Obstet Gynaecol* 2014;35:29-35.
21. Quinten C, Martinelli F, Coens C, Sprangers MA, Ringash J, Gotay C, et al. A global analysis of multivariate data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites. *Cancer* 2014;120:302-11.
22. Clevenger L, Schrepf A, Degeest K, Bender D, Goodheart M, Ahmed A, et al. Sleep disturbance, distress, and quality of life in ovarian cancer patients during the first year after diagnosis. *Cancer* 2013;119:3234-41.
23. Chouchou F, Khoury S, Chauny JM, Denis R, Lavigne GJ. Postoperative sleep disruptions: a potential catalyst of acute pain? *Sleep Med Rev* 2014;18:273-82.
24. Cronin AJ, Keifer JC, Davies MF, King TS, Bixler EO. Postoperative sleep disturbance: influences of opioids and pain in humans. *Sleep* 2001;24:39-44.
25. Tian J, Chen GL, Zhang HR. Sleep status of cervical cancer patients and predictors of poor sleep quality during adjuvant therapy. *Support Care Cancer* 2015;23:1401-8.
26. Donovan KA, Boyington AR, Judson PL, Wyman JF. Bladder and bowel symptoms in cervical and endometrial cancer survivors. *Psychooncology* 2014;23:672-8.
27. Yucel B, Akkaş EA, Okur Y, Eren AA, Eren MF, Karapinar H, et al. The impact of radiotherapy on quality of life for cancer patients: a longitudinal study. *Support Care Cancer* 2014;22:2479-87.
28. Thomas KS, Bower J, Hoyt MA, Sepah S. Disrupted sleep in breast and prostate cancer patients undergoing radiation therapy: the role of coping processes. *Psychooncology* 2010;19:767-76.
29. Berger AM, Grem JL, Visovsky C, Marunda HA, Yurkovich JM. Fatigue and other variables during adjuvant chemotherapy for colon and rectal cancer. *Oncol Nurs Forum* 2010;37:359-69.
30. Palesh OG, Roscoe JA, Mustian KM, Roth T, Savard J, Ancoli-Israel S, et al. Prevalence, demographics, and psychological associations of sleep disruption in patients with cancer: University of Rochester Cancer Center-Community Clinical Oncology Program. *J Clin Oncol* 2010;28:292-8.



Molar pregnancy in cesarean section scar: A case report

Sezaryen skarında molar gebelik: Olgu sunumu

Elif Gülşah Dağdeviren¹, Rıza Dur¹, Erdem Fadiloğlu², Erhan Demirdağ¹, Çağatayhan Öztürk¹, Metin Altay³

¹University of Health Sciences, Etlik Zübeyde Hanım Women's Health Training and Research Hospital, Department of Obstetrics and Gynecology, Ankara, Turkey

²Kilis State Hospital, Clinic of Women's Health, Kilis, Turkey

³TOBB University of Economics and Technology Faculty of Medicine, Department of Obstetrics and Gynecology, Division of Women's Health, Ankara, Turkey

Abstract

Cesarean scar ectopic pregnancies and molar pregnancies are two very rare obstetric pathologies. In both cases, serious morbidities are involved that require careful management. The coexistence of the two clinical conditions is far less common and there are a limited number of cases in the literature. In this case report, a 34-year-old patient with previous cesarean section was diagnosed as having a molar pregnancy in a cesarean scar through ultrasonography. The patient was asymptomatic at that time. Ultrasonography revealed a protruding mass at the cesarean section and her human chorionic gonadotropin level was measured as 59.705 mIU/mL. Due to the risk of severe bleeding, cesarean section scar excision and revision were performed via laparotomy after counselling the patient. Removal of all trophoblastic tissue was observed as a result of the frozen pathology and the operation was terminated. After the definite pathology result came as a complete molar pregnancy, the patient was followed up according to molar pregnancy follow-up protocols and cured completely. Despite the alternative treatment options (methotrexate application, curettage, uterine artery embolization) in such patients, the decision for surgery was made after counselling the patient. In this very rare clinical condition, patients should be closely monitored and the appropriate treatment option should be applied as soon as possible, taking into consideration the bleeding risks of both pathologies.

Keywords: Cesarean scar pregnancy, molar pregnancy, management

Öz

Sezaryen skar ektopik gebelikleri ve molar gebelikler çok nadir görülen iki ayrı obstetrik patolojidir. Her iki durumda da ciddi morbiditeler söz konusudur ve dikkatli bir yönetim gerektirmektedir. İki klinik durumun bir arada görülmesi ise çok daha nadir durumdur ve literatürde sınırlı sayıda olgu vardır. Bu olgu sunumunda 34 yaşında geçirilmiş sezaryen öyküsü olan hasta asemptomatik olarak başvurmuştur ve yapılan ultrasonografi sonucunda sezaryen skarına yerleşmiş molar gebelik ön tanısı oluşmuştur. Ultrasonografide skar üzerinde yerleşen protrude bir kütle izlenmiş ve insan koryonik gonadotropin düzeyi 59,705 mIU/mL olarak tespit edilmiştir. Ciddi kanama riski nedeniyle hastaya operasyon seçeneği sunulmuş ve laparotomi ile sezaryen skar eksizyonu ve revizyonu yapılmıştır. Frozen patoloji sonucunda tüm trofoblastik dokunun çıkarıldığı gözlemlenmiş ve operasyon sonlandırılmıştır. Kesin patoloji sonucunun da komplet molar gebelik olarak gelmesi sonrası hasta molar gebelik takip protokollerine uygun olarak takip edilmiş ve kür sağlanmıştır. Bu tür hastalarda alternatif tedavi seçenekleri (metotreksat uygulanması, küretaj, uterin arter embolizasyonu) olmasına karşın hasta ile tüm riskler konuşularak cerrahi karar verilmiştir. Çok nadir olarak rastlanan bu klinik durumda her iki patolojinin kanama riskleri de göz önünde bulundurularak hastalar yakından takip edilmeli ve uygun tedavi seçeneği en kısa sürede uygulanmalıdır.

Anahtar Kelimeler: Sezaryen skar gebelik, molar gebelik, yönetim

Introduction

Molar pregnancy is mostly seen in the uterine cavity with a frequency of 1/10000. Ectopic pregnancy (EP) is seen more frequently with an overall frequency of 20/1000, and mostly located in the salpinx. Despite the rarity and different clinical spectrum of the diseases, it may be seen together as a very rare entity, which has been reported with a incidence of one per million pregnancies⁽¹⁾.

Here in, we report a case of molar pregnancy in a cesarean section scar that was diagnosed and managed with surgery at our clinic.

Case Report

A woman aged 34 years with a history of one vaginal delivery and one cesarean delivery was hospitalized in our clinic with a diagnosis of cesarean scar EP. The patient had no symptoms at that week of pregnancy. The gestation was calculated as 5 weeks

Address for Correspondence/Yazışma Adresi: Erdem Fadiloğlu, MD,

Kilis State Hospital, Clinic of Women's Health, Kilis, Turkey

Phone: +90 546 475 01 75 E-mail: fadilogluerdem@gmail.com ORCID ID: orcid.org/0000-0001-7953-2517

Received/Geliş Tarihi: 12.10.2017 Accepted/Kabul Tarihi: 05.11.2017

©Copyright 2017 by Turkish Society of Obstetrics and Gynecology

Turkish Journal of Obstetrics and Gynecology published by Galenos Publishing House.

according to the last menstrual period. Transvaginal ultrasound revealed a material in the cesarean scar, which reached the uterine serosa and protruded from anterior uterine wall with dimensions of 28x24 mm. The human chorionic gonadotropin (hCG) level was measured as 59.705 mIU/mL. The patient was suspected as having a molar pregnancy as an initial diagnosis and the possible medical and surgical options were presented to the patient. A surgical approach was chosen as the primary approach and the patient underwent surgery after we acquired informed consent. During the operation, 50x40 mm of pregnancy material was observed in the old cesarean section. After dissecting the bladder from the peritoneum, EP material was seen as a whole reaching the right corner of the old scar (Figure 1).

The old cesarean scar was incised to reveal the extensions of the molar tissue. Whole trophoblastic tissue was excised through a wedge resection reaching the normal tissue both in the upper and lower segments. The incision was repaired using a double-layer suture after ensuring that no trophoblastic tissue remained. The material was evaluated via frozen section because of the suspicion of molar pregnancy. The result was reported as complete molar pregnancy with negative surgical borders (Figure 2).

The hCG level was 7049 mIU/mL on the second postoperative day. The patient was discharged with hCG follow-up according to molar pregnancy follow-up protocols. The hCG level was 3.2



Figure 1. (a) Protruded mass at the cesarean scar (b) Mass reaching the right corner of the cesarean section scar

mIU/mL at the first postoperative month and negative at the first 6-month follow-up. Informed consent was acquired from the patient to publish this case report.

Discussion

EP is a complication of pregnancy in which the embryo attaches to sites beyond the endometrium, mostly the tuba uterina. Patients mostly admit with vaginal bleeding or severe abdominal pain; EP may also be diagnosed in patients who have no symptoms. Beyond some rare forms of EP, cesarean section scar pregnancy is among the rarest form of EP with an incidence of 1:1800 to 1:2216⁽²⁾. Cesarean scar molar pregnancy is even more rare due to the rarity of the coincidence of these 2 rare conditions. According to a literature search, 3 cases of cesarean scar molar pregnancy have been reported. Molar pregnancies with ectopic implantation were mostly seen in the fallopian tubes according to case series of molar EPs⁽³⁾.

The first case was reported by Wu et al.⁽⁴⁾ in 2006. The patient was admitted with vaginal bleeding, which was diagnosed as partial molar pregnancy, and a suction curettage was performed. After on going bleeding after one week, the patient was evaluated again and residual molar tissue was observed in the cesarean scar tissue. Secondary suction curettage was performed with ultrasonographic guidance and treatment was completed.

The second case was reported by Michener and Dickinson⁽⁵⁾ in a case series in 2009. One of 13 cases of cesarean scar EP was reported as a molar pregnancy. After administration of methotrexate systematically and into the gestational sac, the patient was followed up. At the 10th month, the patient was admitted with vaginal bleeding requiring hysterectomy. After pathologic confirmation of molar tissue in the hysterectomy specimen, the patient was evaluated as having molar pregnancy on the cesarean section scar.

The third case was presented by Ko et al.⁽⁶⁾ in 2012. The patient was admitted with suspicion of retained tissue after pregnancy termination at another clinic for a 7-week




Figure 2. Hydropic villi surrounded completely by proliferative trophoblasts. Arrows indicating proliferating trophoblasts and (*) indicating hydropic villi

pregnancy. Transvaginal ultrasound revealed a suspected molar pregnancy in the cesarean section scar and for histopathologic confirmation, suction curettage was performed. Uterine artery embolization was performed for definitive treatment.

Our patient was admitted to our clinic for routine examination and had no symptoms. Cesarean scar EP was the initial diagnosis. Jurkovic et al.⁽⁷⁾ defined the diagnostic criteria for cesarean scar EP as follows: a) Empty uterine cavity and cervix; b) Thinning of the myometrial layer between the bladder and gestational sac; c) Determination of peritrophoblastic perfusion around the gestational sac using Doppler sonography; d) Non-changing position of the gestational sac after gentle pressure from a transvaginal ultrasound probe⁽⁷⁾. Our case was consistent with all these findings and cesarean scar EP was the initial diagnosis for this patient. The reason for our suspicion of molar pregnancy in this case was the absence of a gestational sac, existence of extending tissue beyond the uterus, the incompatible value of hCG with the gestational week, which was calculated according to the last menstrual period.

In the treatment of cesarean scar pregnancies, systemic or direct methotrexate admission, wedge resection by laparotomy or laparoscopy, dilatation and curettage, curettage by hysteroscopy, and uterine artery embolization or a combination of these modalities are used⁽⁸⁾. Ultrasound-guided suction curettage is accepted as a reliable first-line treatment⁽⁹⁾. Suction curettage alone or in combination with other medical interventions has been evaluated as successful according to complications and success rates in case series⁽¹⁰⁾. Cesarean scar pregnancies may also result a high burden of maternal morbidities including severe hemorrhage, early uterine rupture, and hysterectomy with expectant management⁽¹¹⁾. These pregnancies should be diagnosed carefully to manage patients with minimal morbidities. hCG levels, myometrial thickness, and gestational week must be evaluated to determine the proper approach to minimize morbidities⁽¹²⁾.

The decision for laparotomy was made with the suspicion of gestational trophoblastic disease and the high risk of bleeding and perforation. Local methotrexate administration has been reported as a more risky treatment modality for cesarean scar EPs⁽⁵⁾.

Cesarean scar pregnancies are usually identified with ultrasonography and diagnosis maybe delayed. Cesarean section molar pregnancy is a challenging diagnosis and hard to diagnose correctly preoperatively, mostly due to its rarity. Pregnancy localizations should be determined early in pregnancies of patients with past uterine scar or cesarean history and cesarean scar pregnancy should be among our differential diagnoses in such risky pregnancies. The factors mentioned in our case and other cases must be kept in mind so as to acquire the correct diagnosis in these rare cases. Early diagnosis and treatment may be life-saving in such rare cases.

Ethics

Informed Consent: Informed consent was acquired from the patient to publish this case report.

Peer-review: External and internal peer-reviewed.

Authorship Contributions

Surgical and Medical Practices: E.D., M.A., Concept: R.D., Design: E.D., Ç.Ö., Data Collection or Processing: E.F., Analysis or Interpretation: E.F., R.D., Literature Search: E.F., Ç.Ö., Writing: E.F., E.D., E.G.D.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study received no financial support.

References

- Gillespie AM, Lidbury EA, Tidy JA, Honcock BW. The clinical presentation, treatment and outcome of patient diagnosed with possible ectopic molar gestation. *Int J Gynaecol Cancer* 2004;14:366-9.
- Seow KM, Huang LW, Lin YH, Lin MY, Tsai YL, Hwang JL. Cesarean scar pregnancy: issues in management. *Ultrasound Obstet Gynecol* 2004;23:247-53.
- Yamada Y, Ohira S, Yamazaki T, Shiozawa T. Ectopic Molar Pregnancy: Diagnostic Efficacy of Magnetic Resonance Imaging and Review of the Literature. *Case Rep Obstet Gynecol* 2016;2016:7618631.
- Wu CF, Hsu CY, Chen CP. Ectopic molar pregnancy in a cesarean scar. *Taiwan J Obstet Gynecol* 2006;45:343-5.
- Michener C, Dickinson JE. Cesarean scar ectopic pregnancy: a single centre case series. *Aust N Z J Obstet Gynaecol* 2009;49:451-5.
- Ko JK, Wan HL, Ngu SF, Cheung VY, Ng EH. Cesarean scar molar pregnancy. *Obstet Gynecol* 2012;119:449-51.
- Jurkovic D, Hillaby K, Woelfer B, Lawrence A, Salim R, Elson CJ. First-trimester diagnosis and management of pregnancies implanted into the lower uterine segment Cesarean section scar. *Ultrasound Obstet Gynecol* 2003;21:220-7.
- Liu G, Wu J, Cao J, Xue Y, Dai C, Xu J, et al. Comparison of three treatment strategies for cesarean scar pregnancy. *Arch Gynecol Obstet* 2017;296:383-9.
- Özcan HÇ, Uğur MG, Balat Ö, Sucu S, Mustafa A, Bayramoğlu Tepe N, et al. Is ultrasound-guided suction curettage a reliable option for treatment of cesarean scar pregnancy? A cross-sectional retrospective study. *J Matern Fetal Neonatal Med* 2017:1-6.
- Özdamar Ö, Doğer E, Arlier S, Çakıroğlu Y, Ergin RN, Köpük ŞY, et al. Exogenous cesarean scar pregnancies managed by suction curettage alone or in combination with other therapeutic procedures: A series of 33 cases and analysis of complication profile. *J Obstet Gynaecol Res* 2016;42:927-35.
- Calı G, Timor-Trisch IE, Palacios-Jaraquemada J, Monteagudo A, Buca D, Forlani F, et al. Outcome of Cesarean scar pregnancy: a systematic review and meta-analysis. *Ultrasound Obstet Gynecol* 2017.
- Polat I, Ekiz A, Acar DK, Kaya B, Ozkose B, Ozdemir C, et al. Suction curettage as first line treatment in cases with cesarean scar pregnancy: feasibility and effectiveness in early pregnancy. *J Matern Fetal Neonatal Med* 2016;29:1066-71.



Uterine rupture in pregnancy subsequent to hysteroscopic surgery: A case series

Histeroskopi sonrası gebelikte uterin rüptür: Olgu serisi

Şahin Zeteroğlu^{1,2}, Melisa Aslan³, Bertan Akar⁴, Rukiye Ada Bender⁴, Alper Başbuğ⁵, Eray Çalışkan⁶

¹Bursa Acıbadem Hospital, Clinic of Obstetrics and Gynecology, Bursa, Turkey

²Acıbadem University, Vocaitonal High School, İstanbul, Turkey

³Bahçeşehir University Faculty of Medicine, İstanbul, Turkey

⁴Astinye University Faculty of Medicine, Department of Obstetrics and Gynecology, İstanbul, Turkey

⁵Düzce University Faculty of Medicine, Department of Obstetrics and Gynecology, Düzce, Turkey

⁶Bahçeşehir University Faculty of Medicine, Department of Obstetrics and Gynecology, İstanbul, Turkey

Abstract

Uterine rupture during pregnancy is associated with high mortality and morbidity rates in both the fetus and the mother. Hysteroscopic surgeries such as myomectomy and septum resection are known risk factors for uterine rupture in pregnancy following the operation. We present four infertile patients who were admitted to Kocaeli Medical Park Hospital between February 2014 and November 2016. Three of the patients underwent hysteroscopic septum resection without complication and one had hysteroscopic myomectomy and a 7-8 mm sized rupture was detected. All of the patients became pregnant in less than a year after the operations. The first three patients had uterine rupture at 22nd, 38th, and 10th week, which is the earliest rupture in the literature. The last patient had an uneventful pregnancy and the rupture was observed during cesarean section. A short interval between hysteroscopy and pregnancy may increase the risk of rupture. It may be possible to become pregnant despite rupture and not have any problems during the entire pregnancy.

Keywords: Hysteroscopy, uterine rupture, pregnancy

Öz

Gebelik sırasında uterin rüptürü hem anne hem fetus için yüksek mortalite ve morbidite ile ilişkilidir. Miyomektomi ve septum rezeksiyonu gibi histeroskopik operasyonlar, bu operasyonu takip eden gebeliklerde uterin rüptür için bilinen risk faktörleridir. Bu çalışmada Şubat 2014 ve Kasım 2016 arasında Kocaeli Medical Park Hastanesi'ne başvuran dört infertil hasta sunulmaktadır. Üç hastanın histeroskopik septum rezeksiyonu komplikasyonsuz olarak tamamlanmış olup, dördüncü hastada histeroskopik miyomektomi sırasında 7-8 mm boyutunda bir rüptür tespit edilmiştir. Hastaların hepsi histeroskopiden bir yıldan daha az süre sonra gebe kalmışlardır. Uterin rüptürler ilk üç hastada 22., 38. ve 10. haftalarda gerçekleşirken, sonuncu hasta sorunsuz bir gebelik geçirmiş ve rüptür sezaryen sırasında fark edilmiştir. Histeroskopi ve gebelik arasında geçen sürenin kısalığı uterin rüptür riskini artırıyor olabilir. Uterusta bulunan bir rüptüre rağmen gebe kalmak ve tüm gebeliği sorunsuz geçirmek mümkün olabilir.

Anahtar Kelimeler: Histeroskopi, uterin rüptür, gebelik

Introduction

Hysteroscopy is a routinely applied procedure for cervical canal and uterine cavity visualization. It is preferred in diagnosis, sample taking, and also in intrauterine surgeries. In septum resection, synechiolysis, myomectomy of submucosal myomas, and polypectomy, hysteroscopy is accepted as the standard treatment. Although diagnostic hysteroscopy is significantly safe compared with surgical hysteroscopy, there is a rate of 0.95% complications in surgical applications⁽¹⁾. The complications can

be listed in the order of frequency as perforation (instrumental, hysteroscopic) and fluid overload. The rate of complications in different procedures of hysteroscopy differ. Although adhesiolysis has significantly higher incidence of complications, it is followed by endometrial resection, myomectomy, and polypectomy, which are not significantly different from each other^(1,2).

Uterine rupture is both intra-operative and one of the late complications of hysteroscopy. Although it is a rare complication,

Address for Correspondence/Yazışma Adresi: Melisa Aslan, MD,

Bahçeşehir University Faculty of Medicine, İstanbul, Turkey

Phone: +90 505 872 92 43 E-mail: melisaaslan94@gmail.com ORCID ID: orcid.org/0000-0002-7562-7815

Received/Geliş Tarihi: 30.10.2017 Accepted/Kabul Tarihi: 12.11.2017

©Copyright 2017 by Turkish Society of Obstetrics and Gynecology

Turkish Journal of Obstetrics and Gynecology published by Galenos Publishing House.

it can be catastrophic if not managed properly and may result in fetal and maternal death. Uterine perforation and metroplasty (both abdominal and hysteroscopic) are risk factors of uterine rupture in subsequent pregnancies^(3,4). Physiologic distention of the uterus during pregnancy may increase the risk of rupture in scarred uteruses.

The purpose of this study was to present four cases of uterine rupture during pregnancy following a hysteroscopic surgery in 4 infertile patients who were admitted to Kocaeli Medical Park Hospital between February 2014 and November 2016. Approval was obtained from the local ethics committee to perform the study. Written informed consent was obtained from all participants.

Case Reports

Case 1

A 24-year-old nulligravida, nulliparous woman presented with four years of primary infertility. The investigations of hysterosalpingography and 3D ultrasonography (USG) showed uterine septum and later the septum was resected hysteroscopically. During the 6 months of follow-up, the patient could not become pregnant. Despite gonadotropin application for two cycles and insemination because of astenospermia, the infertility of the patient continued. The patient was then treated with short-protocol *in vitro* fertilization (IVF) for one cycle. She had an uneventful pregnancy until she was admitted to hospital with abdominal pain at the 38th week. Despite reactive external fetal tocography without uterine contractions, cesarean section was performed because the patient's pain persisted. A rupture with disruption of all layers measuring 4 cm was observed in the uterine fundus.

There was no accompanying intra-abdominal bleeding, fetus or amniotic sac protrusion. By lower segment transverse incision, a 3150 g male infant with Apgar score of 9-10 was delivered by its foot. The placenta was completely exteriorized from the uterus. Uterine rupture was repaired through a double-layer closure with 1.0 absorbable sutures. The mother and child were discharged two days later without any complications or problems and antibiotic therapy was given. No other problems were observed during the one-month follow-up of the patient.

Case 2

A 39-year-old woman, gravida 6, abortus 5, with no living babies, underwent hysteroscopic surgery because of bicornuate uterus and complete septum. After her septum was resected hysteroscopically, in the laparoscopy a 1.5 cm sized indentation on the fundus was observed, and both tubes were open. No perforation was detected. Six months later, she became pregnant with twins through Klomen (Clomid) induction. The patient had no problems during her pregnancy until she presented to the clinic at the 10th week with periumbilical pain and bleeding. She underwent an emergency operation, and uterine rupture was detected on the fundus and closed. Six months

later, the size of the rupture was measured as 5 mm using USG. She was followed up for three months and could not become pregnant with clomiphene citrate. After IVF treatment for one cycle, she had no results again. Six months after undergoing the Strassman metroplasty, controlled ovarian hyperstimulation IVF was started; follicle growth was not detected and the treatment was cancelled. She was followed up for natural cycles. In the 4th month, human chorionic gonadotropin was applied for one follicle, and she became pregnant. Her pregnancy was uneventful and a 3200 g infant was delivered by elective cesarean section at the 38th week.

Case 3

A 27-year-old woman, gravida 3 (1 ectopic, 1 chemical), parity 1, with no living babies, who had uterine septum with thickness of 2 cm, underwent hysteroscopic septum resection. No complications or uterine rupture were observed in the hysteroscopy. During the 6-month follow-up she could not become pregnant. IVF treatment with 3 embryo transfers was then applied. Her singleton pregnancy was uneventful until the 22nd week, when she was admitted to hospital on foot with persistent right subcostal pain beginning in the night and vaginal spotting. On USG, amniotic membranes protruding from posterior side of the uterus were observed. She was underwent surgery immediately. In the operation, the uterine rupture measured 3 cm and was repaired using double-layer closure with 1.0 absorbable sutures. She was followed up for one year and no extra problems were observed.

Case 4

A 32-year-old nulliparous and nulligravida woman admitted to our clinic after reporting not being able to become pregnant during 2 years of marriage (December, 2014). She had regular but excessive bleeding. A type 3 23x18 mm submucous myoma was detected in the fundal region using transvaginal USG. During the hysteroscopic myomectomy, a 7-8 mm sized rupture near the fundus was observed (Figure 1). After the bleeding was controlled, the operation was ended. The patient was discharged a day after the operation after the vital signs were checked and an abdominal examination was performed.



Figure 1. Perforation of the uterus during hysteroscopic myomectomy

A week after the hysteroscopy, the pelvic examination was normal. Four months after the procedure (April 2015), the patient was readmitted to our clinic with delayed menstruation and spontaneous pregnancy was detected (last menstrual period March 12th, 2015). The patient experienced no problems throughout her pregnancy. On December 12th, 2015, a 3124 g 51 cm male infant with the Apgar score 9/10 was delivered by its head in a planned cesarean section. During the exploration, a rupture involving all layers was observed in the area of the



Figure 2. Full thickness, unhealed or scar dehiscence of previous perforation area noticed during elective cesarean section after the baby is delivered



Figure 3. Uterine repair of the defect with two layer sutures

previous rupture of the hysteroscopic myomectomy (Figure 2). It was repaired using a double-layer closure with 1.0 absorbable sutures (Figure 3).

Discussion

Hysteroscopy is a procedure that is commonly used in daily practice for diagnosis and a variety of operations. It is considered as a safe procedure with a low incidence of adverse effects. The rate of complications was reported as 0.28% among 13.600 operations in the Netherlands by Jansen et al.⁽¹⁾ and by Aydeniz et al.⁽⁵⁾ as 0.22% among 21.676 hysteroscopies in Germany. Operative hysteroscopy is associated with perioperative and late complications⁽²⁾.

Uterine rupture can be observed as a perioperative complication and also late in the course of pregnancy. It is a clinically important situation because it can lead to fetal death and maternal morbidity. Uterine perforation and resection are known causes of uterine rupture. Previously reported cases of uterine rupture subsequent to hysteroscopy occurred between weeks 22 and 41. It is most likely to happen in the last weeks of pregnancy but there are reported cases of uterine rupture in the 22nd(6) and 23rd weeks(7) following hysteroscopic metroplasty and fibroid resection, respectively. All of the patients that we have presented became pregnant in a period of less than a year after hysteroscopy. In case 2, the patient had uterine rupture in the 10th week of her pregnancy. According to our literature search, this is the earliest rupture following hysteroscopic septum resection without a complication. Also, in case 3, the week of rupture was 22. Both are early ruptures compared with similar cases in the literature. The short interval between surgery and conception may have cause the early ruptures because no complications occurred in these cases.

According to Propst et al.⁽⁸⁾, the risks of complications vary according to the type of hysteroscopy. Myomectomy [odds ratio (OR): 7.4] and septum resection (OR: 4.0) had the highest incidence of complications, and diagnostic hysteroscopy (OR: 0.5) and polypectomy (OR: 0.1) had the lowest risks. In case 1, 2, and 3, hysteroscopic septum resection was performed, and in case 4 the hysteroscopic procedure was myomectomy. Both operations are considered as high-risk for complications. Therefore, the type of the hysteroscopy may be a predictive factor. In case 4, the patient underwent myomectomy. During hysteroscopy, a small-sized (7-8 mm) rupture was observed, which was different from the other cases. The patient became pregnant approximately 4 months after surgery, which is a short interval even compared with the patient who had the earliest week of uterine rupture (Case 2). Although she had a previous small rupture, she had no problems during her pregnancy and the rupture was incidentally detected during exploration at cesarean section. This case leads us to two different questions: Did the rupture heal during the four-month-interval and dehiscence occur when the uterus was enlarged because of pregnancy? The second question asks whether it is possible

to become pregnant despite a non-repaired rupture and not experience any complications during pregnancy?

In cases 1 and 4, the uterine rupture was detected late, in the 38th week, and in labor, respectively. The patients delivered healthy babies. The interval was approximately nine months in case 1, and four months in case 4. In cases 2 and 3, the interval was 6 months and the patients experienced uterine rupture early in the course, at the 10th and 22nd weeks.

As a conclusion, the course of uterine rupture in pregnancy after hysteroscopic surgery may depend on many variables, such as the type of surgery, presence or absence of complications such as uterine perforation, the interval between hysteroscopy and pregnancy, and the patient's obstetric history. Uterine rupture may present with abdominal pain and other symptoms, and also can remain silent until delivery when it is detected in exploration. It can happen as late as the last week of pregnancy and as early as the 10th week of pregnancy. Physicians should inform their patients about the possible complications of hysteroscopy and warn them about becoming pregnant in a short time period after surgery because it may increase the risk.

Ethics

Informed Consent: Written informed consent was obtained from all participants.

Peer-review: Externally peer-reviewed.

Authorship Contributions

Surgical and Medical Practices: Ş.Z., E.Ç., B.A., R.A.B., A.B., Concept: E.Ç., Design: E.Ç., Data Collection or Processing: Ş.Z., E.Ç., B.A., R.A.B., A.B., Analysis or Interpretation: Ş.Z.,

E.Ç., B.A., R.A.B., A.B., M.A., Literature Search: E.Ç., M.A., Writing: E.Ç., M.A.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study received no financial support.

References

1. Jansen FW, Vredevoogd CB, Van Hulzen K, Hermans J, Trimbos JB, Trimbos-Kemper TC. Complications of hysteroscopy: a prospective, multicenter study. *Obstet Gynecol* 2000;96:266-70.
2. Munro MG. Complications of hysteroscopic, and uterine resectoscopic surgery. *Obstet Gynecol Clin North Am* 2010;37:399-425.
3. Sentilhes L, Sergent F, Roman H, Verspyck H, Marpeau L. Late complications of operative hysteroscopy: predicting patients at risk of uterine rupture during subsequent pregnancy. *Eur J Obstet Gynecol Reprod Biol* 2005;120:134-8.
4. Bradley LD. Complications in hysteroscopy: prevention, treatment and legal risk. *Curr Opin Obstet Gynecol* 2002;14:409-15.
5. Aydeniz B, Gruber IV, Schauf B, Kurek R, Meyer A, Wallwiener D. A multicenter survey of complications associated with 21,676 operative hysteroscopies. *Eur J Obstet Gynecol Reprod Biol* 2002;104:160-4.
6. Badial G, Fagan PJ, Masood M, Chakravarti S. Spontaneous uterine rupture at 22 weeks' gestation in a multipara with previous hysteroscopic resection of fibroid. *BMJ Case Rep* 2012:2012.
7. Ergenoglu M, Yeniel AO, Yildırım N, Yucebilgin S. Recurrent uterine rupture after hysteroscopic resection of the uterine septum. *Int J Surg Case Rep* 2013;4:182-4.
8. Propst AM, Liberman RF, Harlow BL, Ginsburg ES. Complications of hysteroscopic surgery: predicting patients at risk. *Obstet Gynecol* 2000;96:517-20.



Fertility preservation in male patients subjected to chemotherapy; innovative approaches for further progress

Kemoterapiye maruz kalan erkek hastalarda üretkenliğin korunması ve yenilikçi yaklaşımlar

Mohamed Shehata

University of Cologne Faculty of Medicine, Department of General Medicine, Cologne, Germany

Abstract

About 4% of male patients with cancer are under the age of 35 years. With the current increase in efficacy and safety of therapies, a growing number of young adults can achieve long-term survival. In male patients receiving systemic chemotherapy and or bone marrow transplantation, a permanent loss of fertility is a common adverse effect. The only possibility to preserve the patient's fertility is to spare the gametes or gamete-forming cells from the chemotherapeutic effect. In adults, this can be achieved by the cryopreservation of spermatozoa with the subsequent application of assisted reproductive technology. Sperm cryopreservation is currently performed using slow-rate cryopreservation as a standard method, in which sperm cells are incubated with a cryoprotective medium and slowly subjected to hypothermia in liquid nitrogen (LN) vapor before they are placed in LN. Another technique called vitrification relies on the direct placement of the cells into LN, after being suspended in a vitrification medium. Many studies compared the clinical outcomes of both techniques and revealed equivalent results. This paper sheds light on some innovative approaches for further progress.

Keywords: Fertility preservation, sperm, testicle, cryopreservation

Öz

Erkek kanserli hastaların yaklaşık %4'ü 35 yaşın altındadır. Tedavilerin etkinliği ve güvenirliliği arttıkça artan sayıda genç yetişkinlerin hayatta kalım süresi artmaktadır. Sistemik kemoterapi ve/veya kemik iliği transplantasyonu alan erkek hastalarda doğurganlığın kalıcı olarak kaybı yaygın bir yan etkidir. Hastanın doğurganlığını korumanın tek yolu, kemoterapötik etkiden gametleri veya gamet oluşturan hücreleri korumaktır. Yetişkinlerde, bu, daha sonra yardımcı üreme teknolojisinin uygulanması ile sperm hücrelerinin kriyoprezervasyonu ile elde edilebilir. Sperm kriyoprezervasyonu, şu anda sperm hücrelerinin bir kriyoprotektif ortam ile inkübe edildiği ve yavaşça sıvı azota (LN) yerleştirilmeden önce LN buharında hipotermiye maruz bırakıldığı standart bir yöntem olarak yavaş hızlı kriyoprezervasyon kullanılarak gerçekleştirilir. Vitrifikasyon olarak adlandırılan bir diğer teknik ise, vitrifikasyon ortamına asılarak hücrelerin doğrudan LN'ye yerleştirilmesidir. Pek çok çalışma bu iki tekniğin klinik sonuçlarını karşılaştırmıştır. Bu yazı, yapılacak çalışmalara inovatif notlar bırakarak ışık tutmaktadır.

Anahtar Kelimeler: Doğurganlığın korunması, sperm, testis, kriyoprezervasyon

Introduction

About 4% of male cancer patients are under the age of 35 years⁽¹⁾. With the current increase in efficacy and safety of the therapies, a growing number of young adults can achieve long-term survival⁽²⁾. In male patients receiving systemic chemotherapy and or bone marrow transplantation, a permanent loss of fertility is a common adverse effect. The only possibility to preserve the patient's fertility is to spare the gametes or gamete-forming cells from the chemotherapeutic effect. In adults, this can be achieved by the cryopreservation

of spermatozoa with the subsequent application of assisted reproductive technology⁽³⁾.

Sperm cryopreservation is currently performed using slow-rate cryopreservation as a standard method, in which sperm cells are incubated with a cryoprotective medium and slowly subjected to hypothermia in liquid nitrogen (LN) vapor before they are placed in LN. Another technique called vitrification relies on the direct placement of the cells into LN, after being suspended in a vitrification medium. Many studies compared the clinical outcomes of both techniques and revealed equivalent results^(3,4).

Address for Correspondence/Yazışma Adresi: Mohamed Shehata, MD,

University of Cologne Faculty of Medicine, Department of General Medicine, Cologne, Germany

Phone: +49 162 570 64 93 E-mail: mohammed.shehata1@gmail.com ORCID ID: orcid.org/0000-0002-8922-5243

Received/Geliş Tarihi: 22.07.2017 Accepted/Kabul Tarihi: 12.11.2017

©Copyright 2017 by Turkish Society of Obstetrics and Gynecology

Turkish Journal of Obstetrics and Gynecology published by Galenos Publishing House.

Innovative approaches for further progress

1) The role of molecular biology in the sperm cryopreservation

Although most studies that evaluated the cryopreservation of sperm relied on clinical outcomes and the application of cellular biology techniques, current advances in research have revealed much about the molecular biology of the sperm and its role in sperm physiology and fertile ability. Key proteins that can directly affect sperm physiologic parameters have been identified⁽⁵⁾.

Prohibitin (PHB) is a 30-kilodalton (kDa) protein that consists of two highly homologous subunits, PHB1 and PHB2, which assemble into a ring-like structure in the mitochondrial inner membrane. The absence of PHB in somatic cells was found to be associated with mitochondrial membrane depolarization and increased generation of reactive oxygen species (ROS). Significant positive correlations were found among PHB expression, mitochondrial membrane potential, and sperm motility in normozoospermia, asthenozoospermia, and oligoasthenozoospermia samples⁽⁶⁾. Together, these observations suggest that PHB expression can be an indicator of sperm quality, and that PHB is important for sperm motility and sperm mitochondrial function.

The focal adhesion kinase protein family appears to have a direct role in protein tyrosine phosphorylation of spermatozoa, which may occur via two pathways, the canonical protein-kinase A pathway and a calcium-stimulated pathway. This protein tyrosine phosphorylation activity is a very important step in the sperm capacitation process, which is required to render the sperm competent to fertilize an oocyte⁽⁷⁾. Accordingly, further progress in the clinical practice of sperm cryopreservation could be achieved through the application of molecular biology techniques in future studies to determine the cryopreservation technique of choice.

Although short-term clinical and cellular biology studies revealed no significant differences between slow cryopreservation and vitrification, the effect on the sperm proteome might have another potential. The Zilli et al.⁽⁸⁾ research group used two-dimensional polyacrylamide gel electrophoresis and matrix-associated laser desorption/ionization time-of-flight mass spectrometry to verify whether the protein expression of sea bass sperm was affected by cryopreservation. They stated that the protein profiles differed between fresh and frozen/thawed spermatozoa, as revealed using visual inspection and image analysis software. The group identified 163 spots in fresh sperm; among them, 13 were significantly decreased and 8 were absent in cryopreserved spermatozoa⁽⁸⁾.

In addition, the generation of ROS-associated with cryopreservation could be responsible for mammalian sperm damage and the limited value of stored semen in artificial insemination⁽⁹⁾. Increased ROS generation by itself was found to affect human spermatozoa proteins in terms of expression and degradation⁽¹⁰⁾. A recent study revealed 27 proteins that

differed significantly between control and post-thawing human spermatozoa. These proteins are thought to be involved in various sperm physiologic processes, hence, spermatozoa dysfunction after cryopreservation was suggested to be due to protein degradation and or modification⁽¹¹⁾. Furthermore, the actin band in western blotting differs between fresh and post-thawing sperm,⁽⁶⁾ which might reflect its affection by the process of freezing and thawing, which ultimately affects the functionality and fertilizing ability of the sperm.

Nevertheless, the cryopreservation of swim-up-prepared human spermatozoa with conventional slow freezing and permeating-cryoprotectants-free vitrification showed different degrees of sperm protein affection (Figure 1).

Although no individual proteins were assessed, the application of such a simple molecular biology technique, sSDS-Page (sodium dodecyl sulfate polyacrylamide gel electrophoresis), was able to show significant differences between fresh and post-thawing spermatozoa, as well as between both cryopreservation techniques, regarding the isolated sperm proteins (Figures 1, 2). Of course, further application of mass spectrometry and




Figure 1. Protein extraction and separation in sodium dodecyl sulfate polyacrylamide gel electrophoresis-page showed different band patterns between control non-frozen, slow, and vitrification post-thawing spermatozoa. The most obvious band in all specimens was a protein band between 55-70 kilodalton. This band is denser in the controls than in vitrification, and denser in vitrification than in slow post-thawing spermatozoa protein extracts. The differences were visible by inspection as well as statistically significant after analysis with image-lab analyzer software ($p < 0.05$) (Author's own work)

kDa: Kilodalton

proteomics analysis and or western blotting would provide more precise data about the individual affected proteins and the roles they play in controlling the physiologic parameters and fertilizing ability of sperm. However, such a level of basic and simple investigation was still able to provide reliable evidence that vitrification is superior to conventional slow cryopreservation regarding the degree of affection of sperm proteins, where conventional slow freezing was associated with more significant sperm protein degradation (Figures 1, 2).

Although further progress in this regard is expected soon, sperm cryopreservation can only help post pubertal cancer patients, who are able to provide sperm in one way or another. However, for children exposed to systemic chemotherapy, the cryopreservation of testicular tissue is the only hope for fertility preservation. Established successful cryopreservation of testicular tissue and testicular cell suspensions has been reported with either reimplantation, allowing *in vivo* re-establishment of spermatogenesis, or *in vitro* culture for *ex vivo* spermatogenesis.




Figure 2. Relative band densities before and after cryopreservation. For the protein band detected in Figure 1, the relative density was decreased from ± 1.4 in the controls to ± 0.7 in slow freezing (50% reduction, with a significant difference $p=0.003$), and to ± 0.9 in vitrification (36% reduction, with significant difference $p=0.009$). A significant difference was also found between both cryopreservation techniques ($p=0.042$). Asterisks indicate significant differences between marked columns with each other as well as with the control (Author's own work)

2) *Ex vivo* testicle perfusion and cryopreservation

Though fertility restoration through testicular tissue cryopreservation has been tested and succeeded in animal models as well as in humans, little is known about the safety aspects and quality of the offspring generations⁽⁴⁾. Here, a new strategy for testicular cryopreservation is described, whose expected advantage over the currently applied techniques of testicular tissue or sperm cryopreservation would be the potential for unrestricted preservation of fertility, dual preservation of fertility and endocrine testicular functions (Table 1),⁽¹²⁾ and the preservation of the physiologic route of fertilization, i.e. sexual intercourse, without the application of assisted reproduction technology, which would at least have a significant psychological impact. Moreover, the system allows *ex vivo* testicle perfusion, where high doses of supportive elements and or medications could be supplemented to correct and or improve testicular functions.

The introduced procedure starts with the surgical retrieval of the testicle, where vascular catheterization and immediate perfusion begins. The used perfusates can vary according to the protocol used, for instance, minimal essential medium supplemented with human serum albumen or human tubal fluid medium supplemented with serum substitute supplement (SSS). Further supplementations could be considered according to the protocol used, e.g., ascorbic acid, antioxidants, hormones, growth factors, antibiotics, and heparin.

Immediate and continuous perfusion minimizes the risk of microthrombi formation; however, thrombolytic medications could be supplemented to the perfusates to dissolve any formed microthrombi. At this stage, the testicle has not manifested significant ischemia or oxygen or nutrient deprivation, and the vascular bed is clearly accessible.

Following a short period of *ex vivo* perfusion, the cryopreservation solution (either for slow freezing or for vitrification) can be introduced into the circuit to simultaneously fill the cleaned vascular bed of the testicle and the plastic box around the graft. This ability, together with the presence of temperature adjusters, allow the application of the cryopreservation or vitrification protocol of interest, where at the end, the graft can be stored

Table 1. Hormones produced by the testicles⁽¹²⁾

Hormone	Origin	Regulation	Action
Testosterone	Leydig cells	Gonadotropin-releasing hormone from the hypothalamus causes luteinizing hormone secretion from the pituitary gland, which stimulates the Leydig cells	The control and maintenance of the growth and functions of reproductive organs, libido, and spermatogenesis
Inhibin	Sertoli cells	Gonadotropin-releasing hormone from the hypothalamus causes FSH secretion from the pituitary gland, which stimulates the Sertoli cells	Pituitary feedback inhibition of FSH
Oestradiol	Sertoli cells	Gonadotropin-releasing hormone from the hypothalamus causes FSH secretion from the pituitary gland, which stimulates the Sertoli cells	Produced by testosterone metabolism and may prevent the apoptosis of male germ cells

FSH: Follicle-stimulating hormone

in LN. After the patient's survival, warming protocols could be similarly applied, where the graft can be further perfused till surgical transplantation, minimizing the ischemic reperfusion injury and providing a chance for *ex vivo* testicle reconditioning, using concentrated growth factors and or hormone therapies to omit cryo-injuries before re-implantation (Figure 3).

Materials and methods of author's experimental data

After ethical approval (University of Cologne Nr. 01-106) and patient consents, three semen samples were collected according to the recommendations of the World Health Organization (WHO) from male subjects aged between 25 and 40 years. The samples were collected by masturbation after at least 48 hours of sexual abstinence.

Semen analysis was performed according to the published guidelines of the WHO⁽¹³⁾. Samples were classified according to the following lower reference limits: 15 million spermatozoa/mL, 32% progressive motility, and a minimum of 4% morphologically normal spermatozoa.




Figure 3. (Author's own innovation)

Diagrammatic representation of the *ex vivo* testicle perfusion system (author's invention):

1. A box to enclose the testicle that works as a sealed cryovial
2. Testicular vein stump connected to the circuit using a special cannula or catheter (perfusion output)
3. Testicular artery stump connected to the circuit using a special cannula or catheter (perfusion input)
4. Reservoirs for filling the testicle-containing box with medium, the cryoprotective, vitrification, and warming solutions during cryopreservation
5. The perfusion circuit
6. Perfusate reservoir
7. Centrifugal pump (pulsatile or continuous flow)
8. Set of leukocytic and cytokines filters
9. Temperature adjustor
10. A gas exchanger to remove carbon dioxide and provide oxygen to maintain these gases in the perfusate at physiologic levels
11. The testicle subjected to perfusion and cryopreservation

Each semen sample was diluted 1:2 with pre-warmed (37 °C) Quinn's Sperm Wash Medium (Sage Media, Trumbull, CT, USA) and transferred into a conical centrifuge tube (Becton Dickinson, NJ, USA) and centrifuged at 300 g for 10 minutes. The supernatant was carefully removed and discarded. The sperm pellet was resuspended in 1 mL of the same medium by gentle pipetting, followed by centrifugation again for 10 minutes at 300 g. After removing and discarding the supernatant, 1 mL of pre-warmed (37 °C) human tubal fluid medium +1% SSS was gently placed over the pellet, without disturbing it, followed by incubation for 60 minutes, at 37 °C in a 6% CO₂ atmosphere, in the oblique position (45 °C). After incubation, the tube was handled gently and returned to the up-right position and the uppermost 500 µL medium, where the highly motile sperms are present, was removed into a sterile Eppendorf tube⁽¹³⁾.

Each swim-up preparation was divided into three equal parts; one was the fresh control, one for subsequent conventional slow freezing, and one for subsequent vitrification. Slow freezing and vitrification were performed according to the guidelines⁽¹³⁾.

Protein extraction and SDS polyacrylamide gel electrophoresis

Fresh, slow cryopreserved and vitrified spermatozoa of the same sample and concentration were centrifuged at 300 g for 10 minutes. The supernatant parts were removed and discarded, while the cellular pellets were resuspended in 100 µL radioimmunoprecipitation assay lysis buffer supplemented with a 10% animal component-free protease inhibitor cocktail (Sigma, Munich, Germany), with vigorous shaking, vortex and sonication, when needed, to disrupt the pellet.

The protein concentration and protein amount in each sample were determined using the Bradford method. A standard curve was obtained using blank water and serial protein concentrations of 50-1600 µg/mL of bovine serum albumin. After duplicates of serial dilutions of each sample (6 µL) were equilibrated with color reagent (100 µL) (Bio-Rad Laboratories GmbH, München, Germany) for 10 minutes at room temperature, the absorbance measurements were made using a double-beam ultraviolet-visible spectrophotometer. The standard curve was plotted and the protein concentration in each sample was determined relative to the standard curve.

Equal amounts of protein were subjected to SDS-Page together with 10 µL of pre-stained page ruler protein marker (10-170 kDa) (Thermo Fisher Scientific, Bonn, Germany). The separated protein bands were stained in the gel using Coomassie blue (Thermo Fisher Scientific, Bonn, Germany). The stained gels were then scanned and the densities of the bands were determined using image-lab analyzer software (Life Science Research, Bio-Rad, München, Germany).

The relative band densities were calculated by dividing the actual band density (obtained by the image-lab analyzer) by the average of the three bands of each sample (control and post-thawing bands). The results were detectable visually, as well as with statistical calculations. For statistical analysis, an Excel data

sheet (Microsoft Office 2007) for the calculation of mean and standard deviation was used. A comparison between the three treatments was performed using the Prism 6 Demo program for the determination of significant differences using the non-paired t-test, where p values less than 0.05 were considered significant.

Ethics

Ethics Committee Approval: The study was approved by University of Cologne Ethical Committee (approval number: 01-106).

Informed Consent: Consent was taken by the patients.

Peer-review: External and internal peer-reviewed.

Conflicts of interest: The intellectual properties and the system included in this manuscript belong solely to the author. All rights are preserved solely for the author. Reproduction or use of any of the included intellectual properties requires the written permission of the author.

Financial Disclosure: No funding was provided for the development of this work. The author welcomes funding cooperation for experimental and clinical studies.

References

- Osterberg EC, Ramasamy R, Masson P, Brannigan RE. Current practices in fertility preservation in male cancer patients. *Urol Ann* 2014;6:13-7.
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. *CA Cancer J Clin* 2016;66:7-30.
- Ali Mohamed MS. Slow cryopreservation is not superior to vitrification in human spermatozoa; an experimental controlled study. *Iran J Reprod Med* 2015;13:633-44.
- Onofre J, Baert Y, Faes K, Goossens E. Cryopreservation of testicular tissue or testicular cell suspensions: a pivotal step in fertility preservation. *Hum Reprod Update* 2016;22:744-61.
- Ashrafzadeh A, Karsani SA, Nathan S. Mammalian Sperm Fertility Related Proteins. *Int J Med Sci* 2013;10:1649-57.
- Wang MJ, Ou JX, Chen GW, Wu JP, Shi HJ, O WS, et al. Does prohibitin expression regulate sperm mitochondrial membrane potential, sperm motility, and male fertility? *Antioxid Redox Signal* 2012;17:513-9.
- González-Fernández L, Macías-García B, Loux SC, Varner DD, Hinrichs K. Focal Adhesion Kinases and Calcium/Calmodulin-Dependent Protein Kinases Regulate Protein Tyrosine Phosphorylation in Stallion Sperm. *Biol Reprod* 2013;88:138.
- Zilli L, Schiavone R, Zonno V, Rossano R, Storelli C, Vilella S. Effect of Cryopreservation on Sea Bass Sperm Proteins. *Biol Reprod* 2005;72:1262-7.
- Sharma R, Agarwal A, Mohanty G, Hamada AJ, Gopalan B, Willard B, et al. Proteomic analysis of human spermatozoa proteins with oxidative stress. *Reprod Biol Endocrinol* 2013;11:48.
- Wang S, Wang W, Xu Y, Tang M, Fang J, Sun Y, et al. Proteomic characteristics of human sperm cryopreservation. *Proteomics* 2014;14:298-310.
- Felipe-Pérez YE, Valencia J, Juárez-Mosqueda Mde L, Pescador N, Roa-Espitia AL, Hernández-González EO. Cytoskeletal proteins F-actin and α -dystrobrevin are altered by the cryopreservation process in bull sperm. *Cryobiology* 2012;64:103-9.
- Huhtaniemi I. Testicular hormones. Oxford university press; 2011. ISBN-13: 9780199235292.
- World Health Organization. WHO laboratory manual for the examination and processing of human semen. 5th ed. WHO Press; 2010.

ERRATUM

Turk J Obstet Gynecol 2017;14:23-7
DOI: 10.4274/tjod.61482

The significance of reverse flow in ductus venosus between sixteen and twenty weeks' gestation

On altıncı ve yirminci gebelik haftaları arasında değerlendirilen duktus venozus ters akımının önemi

Gökhan Karakoç¹, And Yavuz², Serenat Eriş Yalçın², Mehmet Özgür Akkurt², Nuri Danışman³

¹University of Health Sciences, Etlik Zübeyde Hanım Women's Health Training and Research Hospital, Clinic of Perinatology, Ankara, Turkey

²Süleyman Demirel University Faculty of Medicine, Department of Perinatology, Isparta, Turkey

³Zekai Tahir Burak Women's Health Training and Research Hospital, Clinic of Perinatology, Ankara, Turkey

Nuri Danışman'ın yazar kurum bilgilerinin düzeltilmiş hali aşağıdaki gibidir;

Gökhan Karakoç¹, And Yavuz², Serenat Eriş Yalçın², Mehmet Özgür Akkurt², Nuri Danışman³

¹University of Health Sciences, Etlik Zübeyde Hanım Women's Health Training and Research Hospital, Clinic of Perinatology, Ankara, Turkey

²Süleyman Demirel University Faculty of Medicine, Department of Perinatology, Isparta, Turkey

³Acıbadem University, Altunizade Hospital, Clinic of Perinatology, İstanbul, Turkey

2017 Referee Index

A. Akın Sivashiođlu	Enis Özkaya	Murat Api
Abdulkadir Turgut	Eralp Baser	Murat Bozkurt
Abdullah Karaer	Eray Çalıřkan (E)	Murat Yassa
Ahmet Zeki Iřık	Erbil Karaman	Naci Cine
Alper Bařbuđ	Ercan Bařtu	Numan Çim
Ařkı Ellibeř Kaya	Esra Esim Büyükbayrak	Olus Api
Ayřen Telce Boza	Evrin Erdemođlu	Orkun Çetin
Aysun Altınok Karabulut	Eyüp Yayı	Ozan Dođan
Banu Dane	Fatma Ferda Verit	Ömer Lütü Tapısız
Banu Kumbak Aygun	Filiz Çayan	Önder Çelik
Barıř Ata	Filiz Fatma Yanık	Özkan Özdamar
Barıř Boza	Gökçe Anık İlhan	Pelin Cořtur Filiz
Bařak Baksu	Gürkan Bozdađ	Polat Dursun
Begum Yıldızhan	H. Güler řahin	Rahime Nida Ergin
Berna Halilođlu Peker	Halil Gürsoy Pala	Recep Yıldızhan
Buđra Cořkun	Harika Bodur Öztürk	Remzi Abalı
Bülent Berker	Hasan Onur Topçu	Sabiha Özdemir Özkan
Bülent Ergun	Hasan Yüksel	Sabri Cavkaytar
Bülent Haydardedeođlu	Hüseyin Mete Tanır	Selçuk Özden
Cem Çelik	Hüseyin Yurdakul	Serdar Filiz
Cem Dane	Hüsnü Çelik	Sertaç Esin
Cenk N. Sayın	İlgın Türkçüođlu	Servet Özden Haciveliöđlu
Çađrı Gülümser	İlker Selçuk	Sunullah Soysal
Çetin Çelik	İlter Yenidede	řule Yıldırım Köpük
Deniz Cemgil Arkan	İncim Bezirciođlu	Talat Umut Kutlu Dilek
Egemen Harun Tolunay	Kemal Güngördük	Taylan Senol
Ekrem Tok	Kemal Özerkan	Tevfik Yoldemir
Emek Dođer	Mehmet Küçükbař	Tolga Güler
Emin Üstünyurt	Mehmet Parlak	Utku Nasuh Dođan
Emre Ekmekçi	Mehmet Sıddık Evsen	Ünal İsaöđlu
Emre Karařahin	Melike Dođanay	Veysel řal
Emre Özgü	Mete Gürol Uđur	Yasemin Dođan
Emre Zafer	Muhammet Erdal Sak	Yiđit Çakırođlu

2017 Author Index

Abdulkadir Turgut	64	Elif Yılmaz	1
Adnan Kaynak	37	Emre Kardeşahin	176
Ahmet Eser	128, 128	Enis Özkaya	58, 128, 181
Ahmet Zeki Işık	199	Eray Çalışkan	100, 252
Ahter Tanay Tayyar	89	Ercan Baştu	145
Ali Ünlü	18	Erdem Fadiloğlu	187, 249
Amita Pandey	106	Eren Pek	74
And Yavuz	23, 170	Erhan Demirdağ	187, 249
Anita Dalal	138	Eser Çolak	214
Anjoo Agarwal	106	Esra Bulgan Kılıçdağ	76, 94
Anwar M. Batieha	28	Evren Akgöl	18
Ateş Karateke	58, 64, 181	Evrin Bostancı Ergen	160
Ayhan Gül	243	Evrin Erdemoğlu	45, 203
Aynur Acar	151	Fahri Bayram	89
Aynur Mustafa	67, 114, 141	Fahri Fıratlıgil	176
Ayşe Gül Zamani	151	Faik Deniz Gün	18
Ayşen Boza	191, 233, 238	Faruk Buyru	145
Ayşen Gürbüz	128	Fatih Sağ	145
Aytekin Aydın	176	Fatma Beyazıt	74
B.R. Nilgar	138	Fatma Doğa Öcal	1
Bahadır Saatli	195	Fatma Selcen Cebe	45
Barış Boza	191	Feride Söylemez	166
Batuhan Turgay	133, 166	Fikriye Karanfil	151
Belgin Devranoğlu	58	Fisun Vural	160
Belide Shruthi	138	Funda Gode	199
Bertan Akar	252	Gizem Güneş	10
Beyhan Sağlam	58	Gökhan Açmaz	89
Bircan Yıldırım	166	Gökhan Karakoç	23, 170
Bora Çoşkun	214	Gönül Erkan	89
Bülent Haydardedeoğlu	76, 94	Gülden Başkol	89
Bülent Kars	100	Güler Yavaş	243
Burak Tatar	45, 203	Günay Başar	145
Can Ateş	166	Habibe Ayyacı	58
Cengiz Kadiyoran	37	Hakan Aylanç	74
Charu Tiwari	70	Hakan Kalaycı	94
Cihan Kaya	210	Halis Özdemir	76
Çağatayhan Öztürk	187, 249	Harika Yumru	145
Çağlar Helvacıoğlu	210	Hatice Çankaya	121
Çetin Çelik	243	Hatice Yılmaz Dođru	228
Çetin Kılıççı	160, 181	Hediye Dağdeviren	210
Çiğdem Yayla Abide	160	Hemanshi Shah	70
Deniz Can Öztekin	100	Hülya Yavuz	238
Derya Akdağ Cırnk	214	Hüseyin Ataseven	37
Didem Alkaş	94	Hüseyin Çağlayan Özcan	67, 114, 141
Dirk Wildemeersch	64	Hüseyin Cengiz	210
Döndü Arslan Kurnaz	10	İper Başbuğ	252
Ebru Erdemoğlu	203	İlhan Sanverdi	58, 181
Ebru Tuncez	151	İlter Yenidede	160
Ecmel Kaygusuz	238	İptisam İpek Müderris	89
Elif Duygu	121	İsmail Benli	228
Elif Gülşah Dağdeviren	249	Kazibe Koyuncu	133, 166

2017 Author Index

Kazım Gezginç	151	Sami Çifçi.....	37
Kenan Sofuoğlu.....	100	Sami Gökhan Kılıç.....	181
Kiran Khedkar.....	70	Seda Çakır.....	100
M. Selman Yıldırım.....	151	Seda Yüksel Şimşek	94
Mehmet Ceyhan	233, 238	Sedat Abuşoğlu.....	18
Mehmet Metin Altay.....	214	Sedat Soyupek.....	45
Mehmet Özgür Akkurt	23,170	Sefa Arlier.....	220
Melisa Aslan	252	Selçuk Yetkinel.....	94
Meral Koyuncuoğlu.....	195	Sema Soysal.....	151
Merve Dizdar.....	181	Semra Kayataş	128, 191
Meryem Ceyhan	1	Serenat Eriş Yalçın.....	23, 170
Mesut Polat.....	181	Serkan Bodur	176
Mete Gürol Uğur.....	114, 141, 156	Serkan Doğru	228
Metin Altay.....	249	Sevim Süreyya Çerçi.....	203
Metin Kaplan.....	187	Seyhan Çıkman	128
Mine Kanat Pektaş.....	82	Seyhun Sucu	67, 114, 141, 156
Mohamed Shehata	256	Sibel Bulgurcuoğlu	145
Müfit Yenen.....	176	Sibel Demir	199
Muhammet Fatih Uysal	121	Smriti Agrawal.....	106
Mukta Waghmare.....	70	Süleyman Akarsu.....	199
Murat Api.....	128, 191, 233, 238	Süleyman Kargın	37
Murat Çakır.....	37	Şafak Hatunaz	82
Murat Ekin.....	210	Şahin Zeteroğlu.....	252
Mustafa Gazi Uçar	243	Şeyda Karaveli	52
Mustafa Öztürk	176	Şeyma Fadiloğlu	187
Mustafa Ulubay	176	Şükrü Gündüz.....	170
Nadin M. Abdel Razeq.....	28	Taner Özgürtaş.....	176
Namrata Kumar.....	106	Tayfun Kutlu	58
Nehaben Limbani.....	138	Tayfun Toptaş.....	52
Neslihan Bayramoğlu Tepe	114	Taylan Oksay.....	45
Nima Bavili.....	145	Tayup Şimşek.....	52
Nuri Danışman.....	23	Tolgay Tuyan İlhan.....	243
Nuri Yıldırım.....	195	Tuncay Küçüközkan.....	1
Nuriye Özenin.....	121	Türkan Saymaz İlhan.....	243
Olus Api.....	238	Uğur Fırat Ortaç	133
Orhan Gelişen	214	Uğur Parlatan	145
Osman Fadıl Kara.....	1	Ulkar Heydarova	210
Oya Pekin.....	160	Vinita Das.....	106
Ömer Lütfi Tapısız	187	Yakup Yalçın.....	170, 203
Özcan Balat	67, 114, 141, 156	Yavuz Emre Şükür.....	166
Özge Kömürcü Karuserci	156	Yavuz Şahin.....	58
Özkan Özdamar	64	Yeşim Bakar.....	121
Özlem Öztürk	176	Yousef S. Khader.....	28
Pınar Çağlar Aytaç	76, 94	Yusuf Aytaç Tohma.....	214
Pınar Kumru	58	Yusuf Topalahmetoğlu.....	214
Rahime Nida Ergin	100	Zehra Bozdağ.....	67, 141
Rengin Karataylı	151	Zehra Vural Yılmaz.....	1
Rıza Dur	187, 249	Zekiye Karaçam.....	10
Rukiye Ada Bender.....	252		
Salih Taşkın.....	133		

2017 Subject Index

- Abdominal fistula repair / *Abdominal fistül onarımı* 45
- Adenosine triphosphate binding cassette A12 / *Adenozin trifosfat bağlayıcı kaset A12* 138
- Adiponectin / *Adiponektin* 89
- Amniocentesis / *Amniyosentez* 114
- Anemia / *Anemi* 166, 176
- Anxiety disorder / *Anksiyete bozukluğu* 214
- Arizona Sexual Experiences Scale / *Arizona Seksüel Deneyimler Ölçeği* 128
- Ascites / *Asit* 94
- Assisted reproduction / *Yardımla üreme* 58
- Atypical / *Atipik* 70
- Autosomal recessive / *Otozomal resesif* 138
- Bladder pressure / *Mesane basıncı* 210
- Blastocyst / *Blastokist* 82
- Bologna score / *Bologna skoru* 10
- Breastfeeding initiation / *Emzirmeye başlama* 1
- Brenner tumor / *Brenner tümörü* 133
- Bupivacaine / *Bupivakain* 170
- Care / *Bakım* 10
- Case series / *Olgu serisi* 187
- Cervical smears / *Servikal yaymalar* 151
- Cervix / *Serviks* 195
- Cesarean scar pregnancy / *Sezaryen skar gebelik* 249
- Cholestasis / *Kolestaz* 160
- Chondrosarcoma / *Kondrosarkom* 67
- Chorionic villus sampling / *Koryon villus örnekleme* 114
- Complementary feeding / *Tamamlayıcı besleme* 1
- Complication / *Komplikasyon* 191
- Cordocenteses / *Kordosentez* 114
- Corifollitropin alfa / *Korifollitropin alfa* 199
- Cryopreservation / *Kriyoprezervasyon* 256
- Depression / *Depresyon* 214
- Diagnosis / *Tanı* 203
- Diagnostic criteria / *Tanı kriteri* 18
- Diagnostic errors / *Tanısal hatalar* 67
- Diminished ovarian reserve / *Yumurtalık rezervinin azalması* 199
- Ductus venosus Doppler / *Duktus venozus Doppler* 23
- Dysmenorrhea / *Dismenore* 238
- Ectopic pregnancy / *Ektopik gebelik* 156
- Embryo culture media / *Embriyo kültür medyası* 145
- Embryo transfer / *Embriyo transferi* 76, 82
- Encephalopathy / *Ansefalopati* 106
- Endometrial cancer / *Endometriyal kanser* 203, 243
- Endometrium cancer / *Endometrium kanseri* 52
- Endothelial cell / *Endotelial hücre* 220
- Epidural / *Epidural* 170
- Exclusive breastfeeding / *Sadece anne sütü ile besleme* 1
- Fecal incontinence / *Fekal inkontinans* 37
- Female / *Kadın* 100
- Female Sexual Function Index / *Kadın Seksüel Fonksiyon İndeksi* 128
- Fentanyl / *Fentanil* 170
- Fertility preservation / *Doğurganlığın korunması* 256
- Fertilization rate / *Fertilizasyon oranı* 58
- Frameless intrauterine devices / *Çerçevesiz rahim içi araçlar* 64
- Free fetal DNA / *Serbest fetal DNA* 156
- Genotoxicity tests / *Genotoksitesite testleri* 151
- Gestational diabetes mellitus / *Gestasyonel diabetes mellitus* 18, 23
- Gestational hypertension / *Gestasyonel hipertansiyon* 23
- Gonadotropin-releasing hormone antagonist / *Gonadotropin salgılatıcı hormon antagonisti* 58, 76, 199
- Gynecologic oncology / *Jinekolojik onkoloji* 133
- Gynecologic surgery / *Jinekolojik cerrahi* 45
- Harlequin ichthyosis / *Harlequin iktiyozis* 138
- Hepatitis B / *Hepatit B* 106
- Hepatitis E / *Hepatit E* 106
- Hospitalization / *Hastanede kalış süresi* 166
- Hyperemesis gravidarum / *Hiperemesis gravidarum* 214
- Hypospadias / *Hypospadias* 74
- Hysterectomy / *Histerektomi* 128
- Hysteroscopy / *Histeroskopi* 252
- Immediate contraception / *Acil kontrasepsiyon* 64
- In vitro fertilization / *İn vitro fertilizasyonu* 76, 82, 94, 145, 199
- Infant / *İnfant* 28
- Infertility / *İnfertilite* 100
- Inflammation / *Enflamasyon* 160
- Injury / *Yaralanma* 191
- Insulin resistance / *İnsülin direnci* 89
- Interleukin-8 / *İnterlökin-8* 220
- Intracytoplasmic sperm injection / *Intrasitoplazmik sperm enjeksiyonu* 82, 100
- Intrapartum / *İntrapartum* 10
- Intrauterine device / *Rahim içi araç* 64
- Isolated tubal torsion / *İzole tubal torsiyon* 187
- Jaundice / *Sarılık* 106
- Labor / *Doğum* 170
- Laparoscopy / *Laparoskopi* 181, 191, 238
- Leptin / *Leptin* 220
- Leptin receptor / *Leptin reseptörü* 220

2017 Subject Index

- Libido / *Libido*..... 128
Live donor / *Canlı donör*..... 233
Lymph node dissection / *Lenf nodu diseksiyonu*..... 52
Lymphocytes / *Lenfositler*..... 151
Malondialdehyde / *Malondialdehit*..... 228
Management / *Yönetim*..... 249
Maximum standardized uptake value / *Maksimum standart uptake değeri*..... 20
Mayer-Rokitansky-Kuster-Hauser syndrome / *Mayer-Rokitansky-Kuster-Hauser sendromu*..... 70
Mean platelet volume / *Ortalama platelet hacmi*..... 160
Micronucleus tests / *Mikronükleus testleri*..... 151
Molar pregnancy / *Molar gebelik*..... 249
Morphology / *Morfoloji*..... 145
Müllerian adenosarcoma / *Müllerian adenosarkom*..... 195
Muscle strength / *Kas kuvveti*..... 121
Nerve fiber / *Sinir lifi*..... 238
Neutrophil-to-lymphocyte ratio / *Nötrofil-lenfosit oranı*..... 160
Newborn / *Yenidoğan*..... 74
Nitric oxide / *Nitrik oksit*..... 228
Obstetric / *Obstetrik*..... 28
Obstetric sphincter injury / *Obstetrik sfinkter yaralanması*..... 37
Oral glucose tolerance test / *Oral glukoz tolerans testi*..... 18
Osteocalcin / *Osteokalsin*..... 89
Ovarian hyperstimulation syndrome / *Ovaryan hiperstimülasyon sendromu*..... 94
Ovarian mass / *Ovaryan kitleleri*..... 67
Ovarian metastasis / *Over metastazı*..... 195
Ovarian neoplasm / *Ovaryan neoplasm*..... 133
Oxidative stress / *Oksidatif stress*..... 228
Pelvic floor symptoms / *Pelvik taban semptomu*..... 121
Pelvic organ prolapses / *Pelvik organ prolapsusu*..... 121
Penoscrotal transposition / *Penoskrotal transpozisyon*..... 74
Pigtail catheter / *Pigtail kateter*..... 94
Platelet-to-lymphocyte ratio / *Platelet-lenfosit oranı*..... 160
Polycystic ovarian syndrome / *Polikistik over sendromu*..... 151
Polycystic ovary syndrome / *Polikistik over sendromu*..... 89
Poor responder / *Düşük over yanıtı*..... 199
Poor responders / *Zayıf cevaplı hasta*..... 58
Positron emission tomography / *Pozitron emisyon tomografi*..... 203
Postmenopausal stage / *Postmenapozal durum*..... 37
Preeclampsia / *Preeklampsi*..... 220
Pregnancy / *Gebelik*..... 106, 176, 214
Pregnancy rate / *Gebelik oranı*..... 100
Premature birth / *Prematüre doğum*..... 28
Prematurity / *Prematürite*..... 28
Prenatal genetic diagnostic testing / *Prenatal genetik diagnostik test*..... 114
Presacral neurectomy / *Presakral nörektomi*..... 238
Preterm / *Preterm*..... 28
Prevalence / *Prevalans*..... 18, 176
Prognostic factors / *Prognostik faktörler*..... 203
Quality of health care / *Sağlık bakım kalitesi*..... 10
Raman spectroscopy / *Raman spektroskopisi*..... 145
Rectovestibular fistula / *Rektovestibüler fistül*..... 70
Regnancy / *Gebelik*..... 252
Reproductive system / *Üreme sistemi*..... 228
Residue urine / *Rezidü idrar*..... 210
Risk factors / *Risk faktörleri*..... 52
Ropivacaine / *Ropivakain*..... 170
Sacrohysteropexy / *Sakrohisteropeksi*..... 181
Second trimester / *İkinci trimester*..... 23
Sexual function / *Seksüel fonksiyon*..... 121, 128
Sleep disorders / *Uyku bozukluğu*..... 243
Sleep quality / *Uyku kalitesi*..... 243
Spectrophotometry / *Spektrofotometre*..... 156
Sperm / *Sperm*..... 256
Squamous cell cervical cancer / *Skvamöz hücreli serviks kanseri*..... 141
Subclinical hypothyroidism / *Subklinik hipotiroidi*..... 100
Testicle / *Testis*..... 256
Third trimester / *Üçüncü trimester*..... 166
Transgender people / *Transgender*..... 233
Transplantation / *Transplantasyon*..... 233
Transvaginal fistula repair / *Transvajinal fistül onarımı*..... 45
Trisomy / *Trizomi*..... 23
Tumor necrosis factor-alpha / *Tümör nekroz faktörü-alfa*..... 89
Ultrasonography / *Ultrasonografi*..... 187
Umbilical cord / *Umbilikal kord*..... 220
Umbilical metastasis / *Umbilikal metastaz*..... 141
Ureter / *Üreter*..... 191
Urodynamics / *Ürodinami*..... 210
Uterine cavity / *Uterin kavite*..... 76
Uterine rupture / *Uterin rüptür*..... 252
Uterus / *Uterus*..... 233
Vaginally-assisted laparoscopic sacrohysteropexy / *Vajinal asiste laparoskopik sakrohisteropeksi*..... 181
Vesicovaginal fistula / *Vezikovajinal fistül*..... 45
Voiding / *İşeme*..... 210
Vulvar metastasis / *Vulvar metastaz*..... 141
Whirlpool sign / *Burgaç bulgusu*..... 187